Multi-specific binding molecules having specificity for myodiopharman and laminin-2

By developing multispecific binding molecules that combine dystrophin glycan and laminin-2, the problem of treating α-dystrophin glycan in the prior art is solved, and the recovery of sarcoplasmic connections and improvement of clinical practice is achieved. Effect of symptoms.

CN118955707APending Publication Date: 2024-11-15SANOFI SA(FR)
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410485938.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-02-17
Filing Date
2018-02-16
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat α-dystrophinoglycan disease, especially because recombinant α-dystrophinoglycans are difficult to reach the sarcosmembrane, resulting in poor treatment effect.

Method used

Develop multispecific binding molecules that contain domains that bind dystrophin glycan and laminin-2 for binding to dystrophin glycan on the sarcoma and laminin-2 in the basement membrane , restore missing connections.

Benefits of technology

By multispecific binding molecules, improving the symptoms of α-dystrophinoglycan disease in the body and prolonging pharmacokinetics, providing a new method for the treatment of α-dystrophinoglycan disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to a multispecific binding molecule having specificity for myodystrophin and laminin-2, and specifically provides a multispecific (e.g., bispecific) binding molecule, the present invention relates to a fusion protein comprising a first binding domain that binds to an extracellular portion of myodystrophin and a second binding domain that binds to laminin-2. Also provided herein are methods of making such binding molecules and the use of such binding molecules for the treatment and / or prophylaxis of alpha-myodystrophan disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention application is a divisional application based on an invention patent application filed on February 16, 2018, with application number 201880013751.3 (international application number PCT / US2018 / 000056) and entitled “Multispecific binding molecules specific for dystrophin and laminin-2”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Application Serial No. 62 / 460,663, filed on February 17, 2017, and European Application No. EP18305168.9, filed on February 16, 2018, each of which is incorporated herein by reference in its entirety.

[0004] Sequence Listing Submitted as ASCII Text File The contents of the ASCII text file submitted below are incorporated herein by reference in their entirety: Sequence Listing in Computer Readable Form (CRF) (File Name: 183952028140SEQLIST.txt, Record Date: February 16, 2018, Size: 315KB). Technical Field

[0005] The present disclosure relates to multispecific (e.g., multispecific and trivalent, or bispecific and bivalent, or tetravalent) binding molecules comprising a first binding domain that binds to the extracellular portion of dystroglycan and a second binding domain that binds laminin-2. The present disclosure also relates to methods of making such binding molecules and the use of such binding molecules for treating and / or preventing alpha-dystroglycan disease. Background Art

[0006] Alpha-dystroglycanopathy is a subtype of congenital muscular dystrophy (CMD) characterized by reduced or absent O-glycosylation in the mucin-like domain of alpha-dystroglycan (α-DG) (Muntoni, F. (2004) Acta. Myol. 23(2), 79-84; Toda, T. (2005) Rinsho Shinkeigaku 45(11), 932-934; Muntoni, F. et al., (2007) Acta. Myol. 26(3), 129-135; Hewitt, JE (2009). Biochim. Biophys. Acta. 1792(9), 853-861; Godfrey, C. et al., (2011) Curr. Opin. Genet. Dev. 21(3), 278-285). The absence or hypoglycosylation of α-dystroglycan results in loss or reduction of its ligand binding, including laminin-2, agrin, and perlecan in skeletal muscle, neurite in the brain, and picococcin in the eye. α-dystroglycan is a dystrophin-glycoprotein complex (DGC) common to all muscles and the heart ( Figure 1A ) (Matsumura, K. et al., (1993) Neuromuscul. Disord. 3(5-6), 533-535). In these tissues, the role of the DGC complex is to connect the filamentous actin (F-actin)-related cytoskeleton of the muscle fiber to the extracellular matrix (ECM, also known as the basement membrane) via laminin-2 through dystrophin ( Figure 1B ).

[0007] In alpha-dystroglycanopathy, mutations in at least 18 genes identified to date are associated with aberrant processing of O-glycosylation on α-DG and deficient binding to its ligands, leading to disease. See, e.g., Hara, Y. et al., (2011) N. Engl. J. Med. 364(10), 939-946; Kim, DS et al., (2004) Neurology 62(6), 1009-1011; van Reeuwijk, J. et al., (2005) J. Med. Genet. 42(12), 907-912; Murakami, T. et al., (2009) Brain Dev. 31(6), 465-468; Yanagisawa, A. et al., (2009) Eur. J. Med. Genet. 52(4), 201-206; Clement, EM et al., (2008) Arch. Neurol. 65(1), 137-141; Endo, T. et al., (2010) Methods Enzymol. 479, 343-352; Saredi, S. et al., (2012) J. Neurol. Sci. 318(1-2), 45-50; Longman, C. et al., (2003) Hum. Mol. Genet. 12(21), 2853-2861; Lefeber, DJ et al., (2009) Am. J. Hum. Genet. 85(1), 76-86; Barone, R. et al., (2012) Ann. Neurol. 72(4), 550-558; Toda, T. et al., (2003) Congenit. Anom. (Kyoto) 43(2), 97-104; Toda, T. (2007) Rinsho Shinkeigaku 47(11),743-748; Puckett, RL et al., (2009) Neuromuscul. Disord. 19(5),352-356; Toda, T. (2009) Rinsho Shinkeigaku 49(11),859-862; Yamamoto, T. et al., (2010) Cent. Nerv. Syst. Agents. Med. Chem. 10(2),169-179; Kanagawa, M. et al., (2016) Cell. Rep. 14(9),2209-2223; Yoshida-Moriguchi, T. et al., (2013) Science 341(6148),896-899).These genes include, for example, many glycosyltransferases, such as LARGE, which encodes a xylosyl and glucuronyl-ditransferase responsible for the repeated addition of xylose-glucuronic acid to glycans to facilitate ligand binding (Inamori, K. et al., (2012) Science 335(6064), 93-96; Longman, C. et al., (2003) Hum. Mol. Genet. 12(21), 2853-2861). The main biological function of glycosyltransferases (e.g., LARGE) in this pathway is the proper O-glycosylation of the mucin-like domain assembled in α-DG, which is essential for tight binding to laminin-2 in the muscle basement membrane, agrin and perlecan in the neuromuscular junction, axonin in the central nervous system, and picococcin in the eye (Michele, DE et al., (2002) Nature 418(6896), 417-422; Muntoni, F. et al., (2002) Lancet 360(9343), 1419-1421). In the absence of proper O-glycosylation due to defects in any of the above genes, α-DG binding to laminin-2 in the extracellular matrix (ECM) is impaired or lost (. Figure 1C ), which leads to the destruction of the mechanical connections necessary for the integrity of the sarcolemma. This makes the muscle susceptible to contraction-induced damage, leading to sarcolemmal damage of the myofiber and subsequent muscular dystrophy (Barresi, R. and Campbell. KP (2006) J. Cell. Sci. 119, 199-207).

[0008] Due to genetic heterogeneity, α-dystrophy protein glycan disease includes many disease subtypes, which show diverse and overlapping clinical manifestations ranging from very severe muscular dystrophy with central nervous system (CNS) and eye abnormalities to relatively mild muscular dystrophy phenotypes without CNS manifestations or eye problems. There is no strict genetic and phenotypic correlation between different subtypes of α-dystrophy protein glycan disease. Mutations in one gene may cause different disease subtypes with overlapping clinical manifestations, and mutations in different genes can lead to the same or similar diseases (Godfrey, C. et al., (2007) Brain 130, 2725-2735). Due to this heterogeneity, treatment strategies for individual α-dystrophy protein glycan diseases caused by mutations in individual genes are not attractive for drug development because of their low cost-effectiveness.

[0009] Alpha-dystroglycan and beta-dystroglycan are encoded by the same gene, DAG1, and are translated from a single mRNA as an intact type 1 transmembrane protein (i.e., dystroglycan). On its way to the cell surface, dystroglycan is proteolytically cleaved to produce the transmembrane skeleton (stud) beta-dystroglycan and non-covalently bound alpha-dystroglycan (Holt, KH et al., (2000) FEBS Lett. 468(1), 79-83). Recombinant alpha-dystroglycan with appropriate O-glycosylation has been theoretically proposed as a protein replacement therapy for alpha-dystroglycan disease. However, systemic delivery of recombinant alpha-dystroglycan showed that this protein failed to reach the interstitial space for incorporation into the sarcolemma (Han, R. et al., (2009) PNAS 106(31), 12573-12579). Therefore, the use of recombinant α-dystroglycan as a protein replacement therapy for α-dystroglycanopathy is considered technically impractical.

[0010] Therefore, there is a need for therapeutic molecules for the prevention and / or treatment of alpha-dystroglycanopathy and its associated conditions.

[0011] All references, including patent applications, patent publications, and UniProtKB / Swiss-Prot accession numbers, cited herein are hereby incorporated by reference in their entirety to the same extent as if each individual reference were specifically and individually indicated to be incorporated by reference. Summary of the Invention

[0012] To address this and other needs, multispecific and bispecific binding molecules (e.g., bispecific antibodies) and bifunctional biologics that can simultaneously bind to laminin-2 and one or more dystroglycans are provided herein. When such multispecific / bispecific antibodies or bifunctional biologics are administered to patients with α-dystroglycanopathy, their simultaneous binding to laminin-2 in the basement membrane and dystroglycans (α- or β-) on the sarcolemma can restore the missing connections ( Figure 1D and 1E ). The present disclosure demonstrates that this approach can ameliorate the characteristic symptoms of α-dystroglycanosis in an in vivo animal model system. Specifically, known antibodies have prolonged circulating half-lives (long pharmacokinetics) in vivo due to their binding to neonatal Fc receptors, which mediate antibody recycling. Therefore, this multispecific / bispecific antibody strategy (or alternatively, a bifunctional biologic strategy) represents a novel therapeutic approach for treating α-dystroglycanosis.

[0013] In some embodiments, the present disclosure provides a multispecific binding molecule comprising at least one first binding domain that binds to the extracellular portion of dystroglycan and at least one second binding domain that binds laminin-2. In some embodiments, the multispecific binding molecule is a multispecific binding protein comprising one or more polypeptide chains.

[0014] In some embodiments, the multispecific binding molecule is a multispecific trivalent binding protein comprising three antigen binding sites. In some embodiments, the binding protein comprises four polypeptide chains, wherein the first polypeptide chain comprises a structure represented by the following formula:

[0015] V L2 -L1-V L1 -L2-C L [I]

[0016] And the second polypeptide chain comprises a structure represented by the following formula:

[0017] V H1 -L3-V H2 -L4-C H1 -Hinge-C H2 -C H3 [II]

[0018] And the third polypeptide chain comprises a structure represented by the following formula:

[0019] V H3 -C H1 -Hinge-C H2 -C H3 [III]

[0020] And the fourth polypeptide chain comprises a structure represented by the following formula:

[0021] V L3 -C L [IV]

[0022] in:

[0023] V L1 is the first immunoglobulin light chain variable domain;

[0024] V L2 is the second immunoglobulin light chain variable domain;

[0025] V L3 is the third immunoglobulin light chain variable domain;

[0026] V H1 is the first immunoglobulin heavy chain variable domain;

[0027] V H2is a second immunoglobulin heavy chain variable domain;

[0028] V H3 is the third immunoglobulin heavy chain variable domain;

[0029] C L is the immunoglobulin light chain constant domain;

[0030] C H1 Immunoglobulin C H1 heavy chain constant domain;

[0031] C H2 Immunoglobulin C H2 heavy chain constant domain;

[0032] C H3 Immunoglobulin C H3 heavy chain constant domain;

[0033] The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and

[0034] L1, L2, L3, and L4 are amino acid linkers;

[0035] wherein the polypeptide of Formula I and the polypeptide of Formula II form a crossover light chain-heavy chain pair; and wherein V H1 and V L1 Form an antigen binding site where V H2 and V L2 forms an antigen binding site, and wherein V H3 and V L3 One antigen binding site is formed, a total of three antigen binding sites are formed, and wherein the three antigen binding sites include at least one antigen binding site that binds to the extracellular portion of dystroglycan and at least one antigen binding site that binds to laminin-2.

[0036] In some embodiments, the multispecific binding molecule comprises one antigen binding site that binds to the extracellular portion of dystroglycan and two antigen binding sites that bind to laminin-2. In some embodiments, the two antigen binding sites that bind to laminin-2 bind to different epitopes of laminin-2. In some embodiments, the two antigen binding sites that bind to laminin-2 bind to the same epitope of laminin-2. In some embodiments, V H1 and V L1 Forms the first antigen binding site for laminin-2, V H2 and V L2 Forms a second antigen binding site that binds laminin-2, and VH3 and V L3 Forms a third antigen binding site that binds to the extracellular portion of dystroglycan.

[0037] In some embodiments, the multispecific binding molecule comprises two antigen binding sites that bind to the extracellular portion of dystroglycan and one antigen binding site that binds to laminin-2. In some embodiments, the two antigen binding sites that bind to the extracellular portion of dystroglycan bind to different epitopes of the extracellular portion of dystroglycan. In some embodiments, the two antigen binding sites that bind to the extracellular portion of dystroglycan bind to the same epitope of the extracellular portion of dystroglycan. In some embodiments, V H1 and V L1 Forms the first antigen binding site that binds to the extracellular portion of dystroglycan, V H2 and V L2 Forms a second antigen binding site that binds to the extracellular portion of dystroglycan, and V H3 and V L3 Forms a third antigen binding site that binds laminin-2.

[0038] In some embodiments, at least one antigen binding site binds the extracellular portion of dystroglycan with an equilibrium dissociation constant (K) of less than about 1 μM when assayed as part of a multispecific binding protein. D) binds to the extracellular portion of dystroglycan. In some embodiments, at least one antigen binding site that binds to the extracellular portion of dystroglycan binds to the extracellular portion of human and mouse dystroglycan. In some embodiments, at least one antigen binding site that binds to the extracellular portion of dystroglycan binds to β-dystroglycan. In some embodiments, at least one antigen binding site that binds to the extracellular portion of dystroglycan binds to a polypeptide comprising the sequence SIVVEWTNN TLPLEPCPKE QIIGLSRRIA DENGKPRPAF SNALEPDFKALSIAVTGSGS CRHLQFIPVA PPSPGSSAAP ATEVPDRDPE KSSEDD (SEQ ID NO: 290). In some embodiments, at least one antigen binding site that binds to the extracellular portion of dystroglycan binds a polypeptide comprising the sequence SIVVEWT NNTLPLEPCP KEQIAGLSRR IAEDDGKPRP AFSNALEPDF KATSITVTGS GSCRHLQFIPVVPPRRVPSE APPTEVPDRD PEKSSEDDV (SEQ ID NO: 291). In some embodiments, at least one antigen binding site that binds to the extracellular portion of dystroglycan binds alpha-dystroglycan. In some embodiments, at least one antigen binding site that binds to the extracellular portion of dystroglycan binds a polypeptide comprising the sequence SIVVEWT NNTLPLEPCP KEQIAGLSRR IAEDDGKPRP AFSNALEPDF KATSITVTGSGSCRHLQFIP VVPPRRVPSE APPTEVPDRD PEKSSEDDV (SEQ ID NO: 291).

[0039] In some embodiments, at least one antigen binding site that binds laminin-2 binds human laminin-2. In some embodiments, at least one antigen binding site that binds laminin-2 binds human laminin-2 with an equilibrium dissociation constant (K) of less than about 1 μM when assayed as part of a multispecific binding protein. D) binds to human laminin-2. In some embodiments, at least one antigen binding site that binds to laminin-2 binds to both mouse and human laminin-2. In some embodiments, at least one antigen binding site that binds to laminin-2 binds to a polypeptide comprising the laminin G-like (LG) domain 4 of laminin-2, the laminin G-like (LG) domain 5 of laminin-2, or both. In some embodiments, at least one antigen binding site that binds to laminin-2 binds to a polypeptide comprising the laminin G-like (LG) domain 4 and the laminin G-like (LG) domain 5 of laminin-2. In some embodiments, at least one antigen binding site that binds to laminin-2 binds to a protein comprising the sequence VQPQPV PTPAFPFPAP TMVHGPCVAESEPALLTGSK QFGLSRNSHI AIAFDDTKVK NRLTIELEVR TEAESGLLFY MARINHADFA TVQLRNGFPYFSYDLGSGDT STMIPTKIND GQWHKIKIVR VKQEGILYVD DASSQTISPK KADILDVVGI LYVGGLPINYTTRRIGPVTY SLDGCVRNLH MEQAPVDLDQ PTSSFHVGTC FANAESGTYFDGTGFAKAVG GFKVGLDLLVEFEFRTTRPT GVLLGVSSQKMDGMGIEMID EKLMFHVDNG AGRFTAIYDA GIPGHMCNGQ WHKVTAKKIKNRLELVVDGN QVDAQSPNSA STSADTNDPV FVGGFPGGLN QFGLTTNIRF A polypeptide of RGCIRSLKLT KGTGKPLEVNFAKALELRGV QPVSCPTT (SEQ ID NO: 300).In some embodiments, at least one antigen binding site that binds to laminin-2 binds to a protein comprising the sequence Q PEPVPTPAFP TPTPVLTHGP CAAESEPALL IGSKQFGLSRNSHIAIAFDD TKVKNRLTIELEVRTEAESG LLFYMARINH ADFATVQLRN GLPYFSYDLGSGDTHTMIPTKINDGQWHKI KIMRSKQEGI LYVDGASNRTISPKKADILD VVGMLYVGGL PINYTTRRIGPVTYSIDGCVRNLHMAEAPA DLEQPTSSFH VGTCFANAQR GTYFDGTGFA KAVGGFKVGL DLLVEFEFRTTTTTGVLLGI SSQKMDGMGI EMIDEKLMFH VDNGAGRFTA VYDAGVPGHL CDGQWHKVTA NKIKHRIELTVDGNQVEAQS PNPASTSADT NDPVFVGGFP DDLKQFGLTT SIPFRGCIRS In some embodiments, at least one antigen binding site that binds to laminin-2 binds a polypeptide comprising the laminin G-like (LG) domain 5 of laminin-2. In some embodiments, at least one antigen binding site that binds to laminin-2 binds a polypeptide comprising the sequence ANAESGTYF DGTGFAKAVGGFKVGLDLLV EFEFRTTRPTGVLLGVSSQK MDGMGIEMID EKLMFHVDNG AGRFTAIYDAGIPGHMCNGQWHKVTAKKIK NRLELVVDGN QVDAQSPNSASTSADTNDPV FVGGFPGGLN QFGLTTNIRFRGCIRSLKLTKGTGKPLEVN FAKALELRGV QPVSCPTT (SEQ ID NO: 292).In some embodiments, at least one antigen binding site that binds laminin-2 binds a polypeptide comprising the sequence ANAQR GTYFDGTGFAKAVGGFKVGL DLLVEFEFRT TTTTGVLLGI SSQKMDGMGI EMIDEKLMFH VDNGAGRFTA VYDAGVPGHLCDGQWHKVTA NKIKHRIELT VDGNQVEAQS PNPASTSADT NDPVFVGGFP DDLKQFGLTT SIPFRGCIRSLKLTKGTGKP LEVNFAKALE LRGVQPVSCP AN (SEQ ID NO: 293).

[0040] In some embodiments, at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises: (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-17, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-27; and (b) a light chain variable domain (VL) comprising a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-37, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-42, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-50. In some embodiments, the VH domain that binds at least one antigen binding site of the extracellular portion of dystroglycan comprises a sequence selected from the group consisting of SEQ ID NOs: 170, 172, 174, 176, 178, 180, 182, 184, 186, and 188; and the VL domain that binds at least one antigen binding site of the extracellular portion of dystroglycan comprises a sequence selected from the group consisting of SEQ ID NOs: 171, 173, 175, 177, 179, 181, 183, 185, 187, and 189. In some embodiments, the at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises: (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320; and (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, the at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises a humanized VH domain and a humanized VL domain. In some embodiments, the VH domain that binds to at least one antigen binding site of the extracellular portion of dystroglycan comprises the sequence of SEQ ID NO: 314; and the VL domain that binds to at least one antigen binding site of the extracellular portion of dystroglycan comprises the sequence of SEQ ID NO: 330. In some embodiments, the VH domain that binds to at least one antigen binding site of the extracellular portion of dystroglycan comprises the sequence of SEQ ID NO: 346; and the VL domain that binds to at least one antigen binding site of the extracellular portion of dystroglycan comprises the sequence of SEQ ID NO: 362.In some embodiments, at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises: (a) a heavy chain variable domain (VH) comprising CDR-H1, CDR-H2, and CDR-H3 of AS30SS_Hu6 or AS30SS_Hu9 shown in Table A2, D2, or I4; and (b) a light chain variable domain (VL) comprising CDR-L1, CDR-L2, and CDR-L3 of AS30SS_Hu6 or AS30SS_Hu9 shown in Table A2, D2, or I4. In some embodiments, the VH domain that binds to at least one antigen binding site of the extracellular portion of dystroglycan comprises the sequence of an AS30SS_Hu6 or AS30SS_Hu9 VH domain shown in Table D2 or I4; and the VL domain that binds to at least one antigen binding site of the extracellular portion of dystroglycan comprises the sequence of an AS30SS_Hu6 or AS30SS_Hu9 VL domain shown in Table D2 or I4.

[0041] In some embodiments, at least one antigen binding site that binds laminin-2 comprises: (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-55 and 81-95, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-60 and 96-110, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-65 and 111-125; and (b) a light chain variable domain (VL) comprising a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-70 and 126-140, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 71-75 and 141-154, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-80 and 155-169. In some embodiments, the VH domain that binds at least one antigen binding site of laminin-2 comprises a sequence selected from the group consisting of SEQ ID NOs: 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228; and the VL domain that binds at least one antigen binding site of laminin-2 comprises a sequence selected from the group consisting of SEQ ID NOs: 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, and 229. In some embodiments, at least one antigen binding site that binds to laminin-2 comprises: (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384; and (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400. In some embodiments, at least one antigen binding site that binds to laminin-2 comprises a humanized VH domain and a humanized VL domain. In some embodiments, the VH domain of at least one antigen binding site that binds to laminin-2 comprises the sequence of SEQ ID NO: 378; and the VL domain of at least one antigen binding site that binds to laminin-2 comprises the sequence of SEQ ID NO: 394.In some embodiments, at least one antigen binding site that binds to laminin-2 comprises: (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384; and (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400. In some embodiments, at least one antigen binding site that binds to laminin-2 comprises a humanized VH domain and a humanized VL domain. In some embodiments, the VH domain of at least one antigen binding site that binds to laminin-2 comprises the sequence of SEQ ID NO: 410; and the VL domain of at least one antigen binding site that binds to laminin-2 comprises the sequence of SEQ ID NO: 426. In some embodiments, at least one antigen binding site that binds to laminin-2 comprises: (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 446, and a CDR-H3 comprising the sequence of SEQ ID NO: 448; and (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464. In some embodiments, at least one antigen binding site that binds to laminin-2 comprises a humanized VH domain and a humanized VL domain. In some embodiments, the VH domain of at least one antigen binding site that binds to laminin-2 comprises the sequence of SEQ ID NO: 442; and the VL domain of at least one antigen binding site that binds to laminin-2 comprises the sequence of SEQ ID NO: 458. In some embodiments, at least one antigen binding site that binds laminin-2 comprises: (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 478, and a CDR-H3 comprising the sequence of SEQ ID NO: 448; and (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464. In some embodiments, at least one antigen binding site that binds laminin-2 comprises a humanized VH domain and a humanized VL domain.In some embodiments, the VH domain of at least one antigen binding site that binds laminin-2 comprises the sequence of SEQ ID NO: 474; and the VL domain of at least one antigen binding site that binds laminin-2 comprises the sequence of SEQ ID NO: 490. In some embodiments, at least one antigen binding site that binds laminin-2 comprises: (a) a heavy chain variable domain (VH) comprising CDR-H1, CDR-H2, and CDR-H3 of C3_Hu10, C3_Hu11, C21_Hu11, or C21_Hu21 as shown in Table A2, D2, or I4; and (b) a light chain variable domain (VL) comprising CDR-L1, CDR-L2, and CDR-L3 of C3_Hu10, C3_Hu11, C21_Hu11, or C21_Hu21 as shown in Table A2, D2, or I4. In some embodiments, the VH domain that binds to at least one antigen binding site of laminin-2 comprises the sequence of a C3_Hu10, C3_Hu11, C21_Hu11, or C21_Hu21 VH domain shown in Table D2 or I4; and the VL domain that binds to at least one antigen binding site of laminin-2 comprises the sequence of a C3_Hu10, C3_Hu11, C21_Hu11, or C21_Hu21 VL domain shown in Table D2 or I4.

[0042] In some embodiments, V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Contains the sequence SEQ ID NO: 378, V L1 Containing the sequence SEQ ID NO: 394; V H2 Containing the sequence SEQ ID NO: 378, V L2 comprising the sequence SEQ ID NO: 394; and V H3 Containing the sequence SEQ ID NO: 314, V L3 Contains the sequence SEQ ID NO: 330. In some embodiments, V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 446, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Containing the sequence SEQ ID NO: 378, V L1 Containing the sequence SEQ ID NO: 394; V H2 Containing the sequence SEQ ID NO:442, V L2 comprising the sequence SEQ ID NO: 458; and V H3Containing the sequence SEQ ID NO: 314, V L3 Contains the sequence SEQ ID NO: 330. In some embodiments, V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 478, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Contains the sequence SEQ ID NO:410, V L1 Containing the sequence SEQ ID NO:426; V H2 Containing the sequence SEQ ID NO: 474, V L2 comprising the sequence SEQ ID NO: 490; and V H3 Containing the sequence SEQ ID NO: 314, V L3 Contains the sequence SEQ ID NO: 330. In some embodiments, V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 446, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L1comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Containing the sequence SEQ ID NO:442, V L1 Containing the sequence SEQ ID NO: 458; V H2 Contains the sequence SEQ ID NO:410, V L2 comprising the sequence SEQ ID NO: 426; and V H3 Containing the sequence SEQ ID NO: 314, V L3 Contains the sequence SEQ ID NO: 330. In some embodiments, V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 478, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L2comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Containing the sequence SEQ ID NO: 474, V L1 Containing the sequence SEQ ID NO: 490; V H2 Containing the sequence SEQ ID NO: 378, V L2 comprising the sequence SEQ ID NO: 394; and V H3 Containing the sequence SEQ ID NO: 314, V L3 Comprising the sequence SEQ ID NO:330.

[0043] In some embodiments of any of the above embodiments, L1 and L2 comprise the sequence DKTHT (SEQ ID NO: 534). In some embodiments, L3 and L4 comprise the sequence DKTHT (SEQ ID NO: 534). In some embodiments, L1, L2, L3, and L4 comprise the sequence DKTHT (SEQ ID NO: 534).

[0044] In some embodiments of any of the above embodiments, C of the second polypeptide chain H3 The domain comprises an amino acid substitution at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are S354C and T366W; and wherein C of the third polypeptide chain H3 The domain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, C of the second polypeptide chain H3 The domain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein C of the third polypeptide chain H3The domain comprises an amino acid substitution at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the C of the second and third polypeptide chains H3 The domain is human IgG1 or IgG4 C H3 domain, and wherein said C H3 In some embodiments, only one of the C436A and C436B domains comprises an amino acid substitution at positions corresponding to positions 435 and 436 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are H435R and Y436F. H2 The domain is human IgG1 or IgG4 C H2 A domain comprising an asparagine residue at position 297, an asparagine residue at position 298, an alanine residue at position 299, and a serine or threonine residue at position 300, numbered according to the EU index. In some embodiments, the C residues of the second and third polypeptide chains are H2 The domain is human IgG1 or IgG4 C H2 A domain comprising a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256, numbered according to the EU index.

[0045] In some embodiments, the first polypeptide chain comprises the sequence of SEQ ID NO: 500, the second polypeptide chain comprises the sequence of SEQ ID NO: 498, the third polypeptide chain comprises the sequence of SEQ ID NO: 499, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 501. In some embodiments, the first polypeptide chain comprises the sequence of SEQ ID NO: 504, the second polypeptide chain comprises the sequence of SEQ ID NO: 502, the third polypeptide chain comprises the sequence of SEQ ID NO: 503, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 505. In some embodiments, the first polypeptide chain comprises the sequence of SEQ ID NO: 508, the second polypeptide chain comprises the sequence of SEQ ID NO: 506, the third polypeptide chain comprises the sequence of SEQ ID NO: 507, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 509. In some embodiments, the first polypeptide chain comprises the sequence of SEQ ID NO: 512, the second polypeptide chain comprises the sequence of SEQ ID NO: 510, the third polypeptide chain comprises the sequence of SEQ ID NO: 511, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 513. In some embodiments, the first polypeptide chain comprises the sequence of SEQ ID NO: 516, the second polypeptide chain comprises the sequence of SEQ ID NO: 514, the third polypeptide chain comprises the sequence of SEQ ID NO: 515, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 517. In some embodiments, the binding protein comprises 1, 2, 3, or 4 polypeptides of triAb 3407, 3423, 3429, 3437, or 3439 as shown in Tables 12 or 14.

[0046] In some embodiments, the binding protein comprises (a) a first antibody heavy chain comprising a first heavy chain variable (VH) domain and a first antibody light chain comprising a first C H3 The present invention relates to a first antibody heavy chain comprising a first Fc region of an immunoglobulin having a first Fc region, said first antibody light chain comprising a first light chain variable (VL) domain, wherein said first VH and VL domains form a first antigen binding domain that binds to the extracellular portion of dystroglycan, and (b) a second antibody heavy chain comprising a second heavy chain variable (VH) domain and a second antibody light chain, said second antibody heavy chain comprising a second heavy chain variable (VH) domain and a second antibody light chain comprising a second C H3 The second antibody light chain comprises a second Fc region of an immunoglobulin having a first antigen binding domain and a second light chain variable (VL) domain, wherein the second VH and VL domains form a second antigen binding domain that binds laminin-2; wherein the first and second C H3 The sequences of the regions are different, and the first and second C H3 The heterodimer interaction between the first and second C H3The homodimers of the first and second homodimers are more strongly interacting with each other, and wherein the first homodimer protein has an amino acid other than Lys, Leu or Met at position 409, and the second homodimer protein has an amino acid substitution at a position selected from 366, 368, 370, 399, 405 and 407, and / or wherein the first and second C H3 The sequence of the region is such that the C H3 The dissociation constant of the homodimer interaction between the respective regions is between 0.01 and 10 micromolar. In some embodiments, the first antibody heavy chain comprises the sequence of SEQ ID NO: 518, wherein the second antibody heavy chain comprises the sequence of SEQ ID NO: 519, wherein the first antibody light chain comprises the sequence of SEQ ID NO: 520, and wherein the second antibody light chain comprises the sequence of SEQ ID NO: 521. In some embodiments, the binding protein comprises 1, 2, 3 or 4 polypeptides of AS30_Hu6 x C3_Hu10 Duobody, AS30_Hu6 xC21_Hu11Duetmab, AS30_Hu6 x C3_Hu10 TBTI, AS30_Hu6 x C21_Hu11 TBTI, AS30_Hu9 xC3_Hu11 CODV or AS30_Hu9 x C21_Hu21 CODV as shown in Tables I3 or I4.

[0047] Further provided herein are isolated nucleic acid molecules comprising a nucleotide sequence encoding a multispecific binding molecule of any of the above embodiments. Also provided are isolated nucleic acid molecules comprising the nucleotide sequence of Table G2 or I4. Also provided are expression vectors comprising the nucleic acid molecules of any of the above embodiments. Also provided are host cells (e.g., isolated host cells) comprising the nucleic acid molecules or expression vectors of any of the above embodiments. Also provided are vector systems comprising one or more vectors encoding the first, second, third, and fourth polypeptide chains of the multispecific binding molecule of any of the above embodiments. Also provided are host cells (e.g., isolated host cells) comprising the vector systems of any of the above embodiments. Also provided are methods for producing multispecific binding molecules, the methods comprising: culturing the host cells of any of the above embodiments under conditions such that the host cells express the multispecific binding molecules; and isolating the multispecific binding molecules from the host cells.

[0048] Further provided herein are methods for treating or preventing alpha-dystroglycan disease in an individual, the methods comprising administering to the individual a multispecific binding molecule of any of the above embodiments. Also provided herein are methods for providing a connection between laminin-2 and the extracellular portion of dystroglycan in an individual, the methods comprising administering to the individual a multispecific binding molecule of any of the above embodiments. Also provided herein are uses of the multispecific binding molecules of any of the above embodiments for treating or preventing alpha-dystroglycan disease in an individual. Also provided herein are uses of the multispecific binding molecules of any of the above embodiments for providing a connection between laminin-2 and the extracellular portion of dystroglycan in an individual. Also provided herein are uses of the multispecific binding molecules of any of the above embodiments in the preparation of a medicament for treating or preventing alpha-dystroglycan disease in an individual. Also provided herein are uses of the multispecific binding molecules of any of the above embodiments in the preparation of a medicament for providing a connection between laminin-2 and the extracellular portion of dystroglycan in an individual.

[0049] In some embodiments of any of the above embodiments, the individual has reduced expression of alpha-dystroglycan. In some embodiments, the alpha-dystroglycan expressed in the individual has impaired or abnormal O-glycosylation. In some embodiments, the individual has a mutation in a gene selected from the group consisting of dystroglycan (DAG1), protein O-mannosyltransferase-1 (POMT1), protein O-mannosyltransferase-2 (POMT2), protein O-linked mannose beta 1,2-N-acetylglucosaminyltransferase subunit 1 (POMGNT1), protein O-linked mannose beta 1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), xylosyl and glucuronyltransferase 1 (LARGE1), xylosyl and glucuronyltransferase 2 (LARGE2), phosphomannose mannose kinase (PMT1), phosphomannose kinase 2 (PMT2), phosphomannose kinase 2 (PMT3), phosphomannose kinase 3 (PMT4), phosphomannose kinase 4 (PMT5), phosphomannose kinase 5 (PMT6), phosphomannose kinase 6 (PMT7), phosphomannose kinase 7 (PMT8), phosphomannose kinase 8 (PMT9), phosphomannose kinase 9 (PMT10), phosphomannose kinase 10 (PMT11), phosphomannose kinase 11 (PMT12), phosphomannose kinase 12 (PMT13), phosphomannose kinase 13 (PMT14), phosphomannose kinase 14 (PMT15), phosphomannose kinase 15 (PMT16), phosphomannose kinase In some embodiments, the multispecific binding molecule is administered by intravenous infusion. In some embodiments, the multispecific binding molecule is administered by intramuscular, intraperitoneal, or subcutaneous injection. In some embodiments, the subject is a human.

[0050] Further provided herein are pharmaceutical compositions comprising the multispecific binding molecules of any of the above embodiments and a pharmaceutically acceptable carrier. Also provided are kits comprising the multispecific binding molecules of any of the above embodiments and instructions for treating or preventing alpha-dystroglycan disease in an individual. In some embodiments, the individual has reduced expression of alpha-dystroglycan. In some embodiments, the alpha-dystroglycan expressed in the individual has impaired or abnormal O-glycosylation. In some embodiments, the individual has a mutation in a gene selected from the group consisting of dystroglycan (DAG1), protein O-mannosyltransferase-1 (POMT1), protein O-mannosyltransferase-2 (POMT2), protein O-linked mannose β1,2-N-acetylglucosaminyltransferase subunit 1 (POMGNT1), protein O-linked mannose β1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), xylosyl and glucuronosyltransferase 1 (LARGE1), xylosyl and glucuronosyltransferase 2 (LARGE2), phosphomannose mannose In some embodiments, the subject is a human.

[0051] Further provided herein are antibodies that bind to the extracellular portion of dystroglycan, wherein the antibody comprises: (a) an antibody heavy chain comprising a heavy chain variable domain (VH) comprising a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-17, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-27; and (b) an antibody light chain comprising a light chain variable domain (VL) comprising a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-37, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-42, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-50. In some embodiments, the VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 170, 172, 174, 176, 178, 180, 182, 184, 186, and 188; and the VL domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 171, 173, 175, 177, 179, 181, 183, 185, 187, and 189. In some embodiments, the antibody comprises 1, 2, 3, 4, 5, or 6 CDR sequences of a binding domain shown in Table A2, D2, or I4, or a VH and / or VL domain sequence of a binding domain shown in Table D2 or I4, or encoded by a polynucleotide sequence shown in Table G2.

[0052] Further provided herein are antibodies that bind to the extracellular portion of dystroglycan, wherein the antibody comprises: (a) an antibody heavy chain comprising a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320; and (b) an antibody light chain comprising a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 314, and the VL domain comprises the amino acid sequence of SEQ ID NO: 330; or the VH domain comprises the amino acid sequence of SEQ ID NO: 346, and the VL domain comprises the amino acid sequence of SEQ ID NO: 362. In some embodiments, the antibody comprises 1, 2, 3, 4, 5, or 6 CDR sequences of a binding domain shown in Table A2, D2, or I4, or a VH and / or VL domain sequence of a binding domain shown in Table D2 or I4, or encoded by a polynucleotide sequence shown in Table G2.

[0053] Further provided herein are antibodies that bind laminin-2, wherein the antibody comprises: (a) an antibody heavy chain comprising a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-55 and 81-95, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-60 and 96-110, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-65 and 111-125; and (b) an antibody light chain comprising a light chain variable domain (VL) comprising a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-70 and 126-140, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 71-75 and 141-154, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-80 and 155-169. In some embodiments, the VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228; and the VL domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, and 229. In some embodiments, the antibody comprises 1, 2, 3, 4, 5, or 6 CDR sequences of a binding domain shown in Table A2, D2, or I4, or a VH and / or VL domain sequence of a binding domain shown in Table D2 or I4, or encoded by a polynucleotide sequence shown in Table G2.

[0054] Further provided herein are antibodies that bind laminin-2, wherein the antibody comprises: (a) an antibody heavy chain comprising a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and an antibody light chain comprising a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; (b) an antibody heavy chain comprising a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384. NO: 384, and an antibody light chain comprising a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; (c) an antibody heavy chain comprising a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 446, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and an antibody light chain comprising a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: NO:464; or (d) an antibody heavy chain comprising a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO:444, a CDR-H2 comprising the sequence of SEQ ID NO:478, and a CDR-H3 comprising the sequence of SEQ ID NO:448, and an antibody light chain comprising a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO:460, a CDR-L2 comprising the sequence of SEQ ID NO:462, and a CDR-L3 comprising the sequence of SEQ ID NO:464.In some embodiments, (a) the VH domain comprises the amino acid sequence of SEQ ID NO: 378, and the VL domain comprises the amino acid sequence of SEQ ID NO: 394; (b) the VH domain comprises the amino acid sequence of SEQ ID NO: 410, and the VL domain comprises the amino acid sequence of SEQ ID NO: 426; (c) the VH domain comprises the amino acid sequence of SEQ ID NO: 442, and the VL domain comprises the amino acid sequence of SEQ ID NO: 458; or (d) the VH domain comprises the amino acid sequence of SEQ ID NO: 474, and the VL domain comprises the amino acid sequence of SEQ ID NO: 490. In some embodiments, the antibody comprises 1, 2, 3, 4, 5, or 6 CDR sequences of a binding domain shown in Table A2, D2, or I4, or a VH and / or VL domain sequence of a binding domain shown in Table D2 or I4, or encoded by a polynucleotide sequence shown in Table G2.

[0055] Further provided herein are isolated nucleic acid molecules comprising a nucleotide sequence encoding an antibody according to any of the above embodiments. Also provided are expression vectors comprising the nucleic acid molecules according to any of the above embodiments. Also provided are host cells (e.g., isolated host cells) comprising the nucleic acid molecules or expression vectors according to any of the above embodiments. Also provided are methods for producing antibodies, comprising: culturing the host cells according to any of the above embodiments under conditions such that the host cells express the antibodies; and isolating the antibodies from the host cells.

[0056] In one embodiment, the present disclosure provides a bispecific binding molecule comprising a first binding domain that binds to the extracellular portion of dystroglycan and a second binding domain that binds laminin-2. In some embodiments, the bispecific binding molecule is a bispecific binding protein comprising one or more polypeptide chains.

[0057] In some embodiments, the bispecific binding molecule is a bispecific, bivalent, or tetravalent binding protein comprising two or four antigen binding sites. In some embodiments, the bispecific binding protein comprises a first binding domain that binds to the extracellular portion of dystroglycan and a second binding domain that binds laminin-2, wherein the first binding domain comprises a first immunoglobulin heavy chain variable domain (V H1 ) and the first immunoglobulin light chain variable domain (V L1 ), wherein the second binding domain comprises a second immunoglobulin heavy chain variable domain (V H2 ) and a second immunoglobulin light chain variable domain (V L2 ). In some embodiments, V H1The domain comprises at least one, at least two, at least three, at least four, at least five or six CDR sequences and / or V domains of the antibodies shown in Table A. L1 The domain comprises at least one, at least two, at least three, at least four, at least five, or six CDR sequences of the antibodies shown in Table A. In some embodiments, V H2 The domain comprises at least one, at least two, at least three, at least four, at least five or six CDR sequences and / or V domains of an antibody shown in Table B or Table C. L2 The domain comprises at least one, at least two, at least three, at least four, at least five or six CDR sequences of an antibody shown in Table B or Table C.

[0058] In some embodiments, the bispecific binding molecule comprises four polypeptide chains that form four antigen binding sites, wherein two of the polypeptide chains comprise a structure represented by the following formula:

[0059] V L1 -L1-V L2 -L2-C L [I]

[0060] And the two polypeptide chains contain the structure represented by the following formula:

[0061] V H2 -L3-V H1 -L4-C H1 -Hinge-C H2 -C H3 [II]

[0062] in:

[0063] V L1 is the first immunoglobulin light chain variable domain;

[0064] V L2 is the second immunoglobulin light chain variable domain;

[0065] V H1 is the first immunoglobulin heavy chain variable domain;

[0066] V H2 is a second immunoglobulin heavy chain variable domain;

[0067] C L is the immunoglobulin light chain constant domain;

[0068] C H1 Immunoglobulin C H1 heavy chain constant domain;

[0069] C H2 Immunoglobulin C H2heavy chain constant domain;

[0070] C H3 Immunoglobulin C H3 heavy chain constant domain;

[0071] The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and

[0072] L1, L2, L3 and L4 are amino acid linkers; wherein V H1 and V L1 Domain formation V H1 / V L1 Combining pairs, and where V H2 and V L2 Domain formation V H2 / V L2 Combined pair.

[0073] In some embodiments, V H1 and V L1 Domains intersect to form V H1 / V L1 In some embodiments, V H2 and V L2 Domains intersect to form V H2 / V L2Binding pair. In some embodiments, L1, L2, L3, and L4 are each 0 to 50 amino acid residues in length. In some embodiments, L1, L2, L3, and L4 are each 0 to 25 amino acid residues in length. In some embodiments, L1, L2, L3, and L4 are each 0 to 14 amino acid residues in length. In some embodiments, L1 is 5 amino acid residues in length; L2 is 5 amino acid residues in length; L3 is 5 amino acid residues in length; and L4 is 5 amino acid residues in length. In some embodiments, L1 is 14 amino acid residues in length; L2 is 2 amino acid residues in length; L3 is 14 amino acid residues in length; and L4 is 2 amino acid residues in length. In some embodiments, L1 and L3 each comprise the sequence EPKSDKTHTSPPSP (SEQ ID NO: 296), and wherein L2 and L4 each comprise the sequence GG. In some embodiments, L1 is 7 amino acid residues in length; L2 is 5 amino acid residues in length; L3 is 1 amino acid residue in length; and L4 is 2 amino acid residues in length. In some embodiments, L1 comprises the sequence GQPKAAP (SEQ ID NO: 297); L2 comprises the sequence TKGPS (SEQ ID NO: 298); L3 comprises a serine residue; and L4 comprises the sequence RT. In some embodiments, L1 is 10 amino acid residues in length; L2 is 10 amino acid residues in length; L3 is 0 amino acid residues in length; and L4 is 0 amino acid residues in length. In some embodiments, L1 and L2 each comprise the sequence GGSGSSGSGG (SEQ ID NO: 299). In some embodiments, one or both of the two variable domains of the polypeptide of Formula I and / or Formula II are human, humanized, or mouse variable domains.

[0074] In some embodiments, the bispecific binding molecule comprises two light chains comprising a structure represented by the following formula:

[0075] V L1 -L5-V L2 -L6-C L [III]

[0076] and two heavy chains comprising the structure represented by the following formula:

[0077] V H1 -L7-V H2 -L8-C H1 -Hinge-C H2 -C H3 [IV]

[0078] in:

[0079] VL1 is the first immunoglobulin light chain variable domain;

[0080] V L2 is the second immunoglobulin light chain variable domain;

[0081] V H1 is the first immunoglobulin heavy chain variable domain;

[0082] V H2 is a second immunoglobulin heavy chain variable domain;

[0083] C L is the immunoglobulin light chain constant domain;

[0084] C H1 Immunoglobulin C H1 heavy chain constant domain;

[0085] C H2 Immunoglobulin C H2 heavy chain constant domain;

[0086] C H3 Immunoglobulin C H3 heavy chain constant domain;

[0087] The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and

[0088] L5, L6, L7 and L8 are amino acid linkers; wherein V H1 and V L1 Domain formation V H1 / V L1 Combining pairs, and where V H2 and V L2 Domain formation V H2 / V L2 Combined pair.

[0089] In some embodiments, the length of L5, L6, L7 and L8 is 0 to 50 amino acid residues. In some embodiments, the length of L5, L6, L7 and L8 is 0 to 25 amino acid residues. In some embodiments, the length of L5, L6, L7 and L8 is 0 to 14 amino acid residues. In some embodiments, L5 and L7 linkers comprise the amino acid sequence GGGGSGGGGS (SEQ ID NO: 294), and wherein the length of L6 and L8 linkers is 0 amino acid residues. In some embodiments, one or both of the two variable domains of the polypeptide of Formula III and / or Formula IV are human, humanized or mouse variable domains.

[0090] In some embodiments of any of the above embodiments, V H1 / V L1 The binding pair binds to the extracellular portion of dystroglycan, and wherein V H2 / V L2 In some embodiments, V H1 / V L1 The binding pair binds to the extracellular portion of human dystroglycan. In some embodiments, V H1 / V L1 The binding pair has an equilibrium dissociation constant (K) of less than about 1 μM. D ) binds to the extracellular portion of human dystroglycan. In some embodiments, V H1 / V L1 The binding pair binds to the extracellular portion of human and mouse dystroglycan. In some embodiments, V H1 / V L1 The binding pair binds to beta-dystroglycan. In some embodiments, V H1 / V L1 The binding pair binds to a polypeptide comprising the sequence SIVVEWTNN TLPLEPCPKE QIIGLSRRIA DENGKPRPAF SNALEPDFKA LSIAVTGSGS CRHLQFIPVAPPSPGSSAAP ATEVPDRDPE KSSEDD (SEQ ID NO: 290). H1 / V L1 The binding pair binds to a polypeptide comprising the sequence SIVVEWT NNTLPLEPCP KEQIAGLSRR IAEDDGKPRP AFSNALEPDF KATSITVTGSGSCRHLQFIP VVPPRRVPSE APPTEVPDRD PEKSSEDDV (SEQ ID NO: 291). In some embodiments, V H1 / V L1 The binding pair binds to α-dystroglycan. In some embodiments, V H2 / V L2 The binding pair binds to human laminin-2. In some embodiments, V H2 / V L2 The binding pair has an equilibrium dissociation constant (K) of less than about 1 μM. D ) binds to human laminin-2. In some embodiments, V H2 / V L2 The binding pair binds to mouse and human laminin-2. In some embodiments, V H2 / V L2The binding pair binds to a polypeptide comprising laminin G-like (LG) domain 4 of laminin-2, laminin G-like (LG) domain 5 of laminin-2, or both. H2 / V L2 The binding pair binds to a polypeptide comprising laminin G-like (LG) domain 4 and laminin G-like (LG) domain 5 of laminin-2. In some embodiments, V H2 / V L2 The binding pair contains the sequence VQPQPV PTPAFPFPAP TMVHGPCVAE SEPALLTGSKQFGLSRNSHI AIAFDDTKVK NRLTIELEVR TEAESGLLFY MARINHADFA TVQLRNGFPY FSYDLGSGDTSTMIPTKIND GQWHKIKIVR VKQEGILYVD DASSQTISPK KADILDVVGI LYVGGLPINY TTRRIGPVTYSLDGCVRNLH MEQAPVDLDQ PTSSFHVGTC FANAESGTYF DGTGFAKAVG GFKVGLDLLV EFEFRTTRPTGVLLGVSSQK MDGMGIEMID EKLMFHVDNG AGRFTAIYDA GIPGHMCNGQ WHKVTAKKIK NRLELVVDGNQVDAQSPNSA STSADTNDPV FVGGFPGGLN QFGLTTNIRFRGCIRSLKLT KGTGKPLEVN FAKALELRGVQPVSCPTT (SEQ ID NO: 300). In some embodiments, V H2 / V L2The binding pair contains the sequence QPEPVPTPAFP TPTPVLTHGP CAAESEPALL IGSKQFGLSR NSHIAIAFDD TKVKNRLTIE LEVRTEAESGLLFYMARINH ADFATVQLRN GLPYFSYDLG SGDTHTMIPT KINDGQWHKI KIMRSKQEGI LYVDGASNRTISPKKADILD VVGMLYVGGL PINYTTRRIG PVTYSIDGCV RNLHMAEAPA DLEQPTSSFH VGTCFANAQRGTYFDGTGFA KAVGGFKVGL DLLVEFEFRT TTTTGVLLGI SSQKMDGMGI EMIDEKLMFH VDNGAGRFTAVYDAGVPGHL CDGQWHKVTA NKIKHRIELT VDGNQVEAQS PNPASTSADT NDPVFVGGFP DDLKQFGLTTSIPFRGCIRS LKLTKGTGKP LEVNFAKALE LRGVQPVSCP AN (SEQ ID NO: 301). In some embodiments, V H2 / V L2 The binding pair binds to a polypeptide comprising laminin G-like (LG) domain 5 of laminin-2. In some embodiments, V H2 / V L2 The binding pair binds to a polypeptide comprising the sequence ANAESGTYF DGTGFAKAVG GFKVGLDLLVEFEFRTTRPT GVLLGVSSQK MDGMGIEMID EKLMFHVDNG AGRFTAIYDA GIPGHMCNGQ WHKVTAKKIKNRLELVVDGN QVDAQSPNSA STSADTNDPV FVGGFPGGLN QFGLTTNIRF RGCIRSLKLT KGTGKPLEVNFAKALELRGV QPVSCPTT (SEQ ID NO: 292). In some embodiments, V H2 / V L2The binding pair binds to a polypeptide comprising the sequence ANAQR GTYFDGTGFA KAVGGFKVGL DLLVEFEFRT TTTTGVLLGI SSQKMDGMGI EMIDEKLMFHVDNGAGRFTA VYDAGVPGHL CDGQWHKVTA NKIKHRIELT VDGNQVEAQS PNPASTSADT NDPVFVGGFPDDLKQFGLTT SIPFRGCIRS LKLTKGTGKP LEVNFAKALE LRGVQPVSCP AN (SEQ ID NO: 293).

[0091] In some embodiments, V H1 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-17, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-27; and / or wherein V L1 The V domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-37, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-42, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-50. In some embodiments, V H1 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 170, 172, 174, 176, 178, 180, 182, 184, 186, and 188. In some embodiments, V L1 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 171, 173, 175, 177, 179, 181, 183, 185, 187, and 189. In some embodiments, V H1 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 230, 232, 234, 236, 238, 240, 242, 244, 246, and 248. In some embodiments, the V L1 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 231, 233, 235, 237, 239, 241, 243, 245, 247, and 249. In some embodiments, the V H2The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-55 and 81-95, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-60 and 96-110, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-65 and 111-125; and / or wherein V L2 The domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-70 and 126-140, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 71-75 and 141-154, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-80 and 155-169. In some embodiments, V H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228. In some embodiments, V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, and 229. In some embodiments, V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, and 288. In some embodiments, V L2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287 and 289.

[0092] In some embodiments of any of the above embodiments, V H1 / V L1 Binding pair binds to laminin-2, and wherein V H2 / V L2 The binding pair binds to the extracellular portion of dystroglycan. In some embodiments, V H2 / V L2 The binding pair binds to the extracellular portion of human dystroglycan. In some embodiments, V H2 / V L2 The binding pair has an equilibrium dissociation constant (K) of less than about 1 μM. D ) binds to the extracellular portion of human dystroglycan. In some embodiments, V H2 / V L2 The binding pair binds to the extracellular portion of human and mouse dystroglycan. In some embodiments, V H2 / V L2 The binding pair binds to beta-dystroglycan. In some embodiments, V H2 / V L2 The binding pair binds to a polypeptide comprising the sequence SIVVEWTNN TLPLEPCPKE QIIGLSRRIA DENGKPRPAF SNALEPDFKA LSIAVTGSGS CRHLQFIPVAPPSPGSSAAP ATEVPDRDPE KSSEDD (SEQ ID NO: 290). H2 / V L2 The binding pair binds to a polypeptide comprising the sequence SIVVEWT NNTLPLEPCP KEQIAGLSRR IAEDDGKPRP AFSNALEPDF KATSITVTGSGSCRHLQFIP VVPPRRVPSE APPTEVPDRD PEKSSEDDV (SEQ ID NO: 291). In some embodiments, V H2 / V L2 The binding pair binds to α-dystroglycan. In some embodiments, V H1 / V L1 The binding pair binds to human laminin-2. In some embodiments, V H1 / V L1 The binding pair has an equilibrium dissociation constant (K) of less than about 1 μM. D ) binds to human laminin-2. In some embodiments, V H1 / V L1 The binding pair binds to mouse and human laminin-2. In some embodiments, V H1 / V L1 The binding pair binds to a polypeptide comprising laminin G-like (LG) domain 4 of laminin-2, laminin G-like (LG) domain 5 of laminin-2, or both. H1 / V L1 The binding pair binds to a polypeptide comprising laminin G-like (LG) domain 4 and laminin G-like (LG) domain 5 of laminin-2. In some embodiments, V H1 / V L1The binding pair contains the sequence VQPQPV PTPAFPFPAP TMVHGPCVAE SEPALLTGSKQFGLSRNSHI AIAFDDTKVK NRLTIELEVR TEAESGLLFY MARINHADFA TVQLRNGFPY FSYDLGSGDTSTMIPTKIND GQWHKIKIVR VKQEGILYVD DASSQTISPK KADILDVVGI LYVGGLPINY TTRRIGPVTYSLDGCVRNLH MEQAPVDLDQ PTSSFHVGTC FANAESGTYF DGTGFAKAVG GFKVGLDLLV EFEFRTTRPTGVLLGVSSQK MDGMGIEMID EKLMFHVDNG AGRFTAIYDA GIPGHMCNGQ WHKVTAKKIK NRLELVVDGNQVDAQSPNSA STSADTNDPV FVGGFPGGLN QFGLTTNIRFRGCIRSLKLT KGTGKPLEVN FAKALELRGVQPVSCPTT (SEQ ID NO: 300). In some embodiments, V H1 / V L1 The binding pair contains the sequence QPEPVPTPAFP TPTPVLTHGP CAAESEPALL IGSKQFGLSR NSHIAIAFDD TKVKNRLTIE LEVRTEAESGLLFYMARINH ADFATVQLRN GLPYFSYDLG SGDTHTMIPT KINDGQWHKI KIMRSKQEGI LYVDGASNRTISPKKADILD VVGMLYVGGL PINYTTRRIG PVTYSIDGCV RNLHMAEAPA DLEQPTSSFH VGTCFANAQRGTYFDGTGFA KAVGGFKVGL DLLVEFEFRT TTTTGVLLGI SSQKMDGMGI EMIDEKLMFH VDNGAGRFTAVYDAGVPGHL CDGQWHKVTA NKIKHRIELT VDGNQVEAQS PNPASTSADT NDPVFVGGFP DDLKQFGLTTSIPFRGCIRS LKLTKGTGKP LEVNFAKALE LRGVQPVSCP AN (SEQ ID NO: 301). In some embodiments, V H1 / V L1The binding pair binds to a polypeptide comprising laminin G-like (LG) domain 5 of laminin-2. In some embodiments, V H1 / V L1 The binding pair binds to a polypeptide comprising the sequence ANAESGTYF DGTGFAKAVG GFKVGLDLLVEFEFRTTRPT GVLLGVSSQK MDGMGIEMID EKLMFHVDNG AGRFTAIYDA GIPGHMCNGQ WHKVTAKKIKNRLELVVDGN QVDAQSPNSA STSADTNDPV FVGGFPGGLN QFGLTTNIRF RGCIRSLKLTKGTGKPLEVNFAKALELRGV QPVSCPTT (SEQ ID NO: 292). In some embodiments, V H1 / V L1 The binding pair binds to a polypeptide comprising the sequence ANAQR GTYFDGTGFA KAVGGFKVGL DLLVEFEFRT TTTTGVLLGI SSQKMDGMGI EMIDEKLMFHVDNGAGRFTA VYDAGVPGHL CDGQWHKVTA NKIKHRIELT VDGNQVEAQS PNPASTSADT NDPVFVGGFPDDLKQFGLTT SIPFRGCIRS LKLTKGTGKP LEVNFAKALE LRGVQPVSCP AN (SEQ ID NO: 293).

[0093] In some embodiments, V H2 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-17, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-27; and / or wherein V L2 The V domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-37, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-42, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-50. In some embodiments, V H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 170, 172, 174, 176, 178, 180, 182, 184, 186, and 188. In some embodiments, V L2The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 171, 173, 175, 177, 179, 181, 183, 185, 187, and 189. In some embodiments, V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 230, 232, 234, 236, 238, 240, 242, 244, 246, and 248. In some embodiments, the V L2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 231, 233, 235, 237, 239, 241, 243, 245, 247, and 249. In some embodiments, the V H1 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-55 and 81-95, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-60 and 96-110, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-65 and 111-125; and / or wherein V L1 The domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-70 and 126-140, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 71-75 and 141-154, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-80 and 155-169. In some embodiments, V H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228. In some embodiments, V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, and 229. In some embodiments, V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, and 288. In some embodiments, V L2The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287 and 289.

[0094] In one embodiment, the present disclosure provides an isolated nucleic acid molecule comprising the nucleotide sequence encoding the bispecific binding molecule according to any of the above-mentioned embodiments. In one embodiment, the present disclosure provides an expression vector comprising the nucleotide sequence encoding the bispecific binding molecule according to any of the above-mentioned embodiments. In one embodiment, the present disclosure provides an isolated host cell comprising the nucleotide sequence encoding the bispecific binding molecule according to any of the above-mentioned embodiments or comprising an expression vector comprising the nucleotide sequence encoding the bispecific binding molecule according to any of the above-mentioned embodiments. In one embodiment, the present disclosure provides a vector system comprising one or more vectors encoding the first, second, third and fourth polypeptide chains of the bispecific binding molecule according to any of the above-mentioned embodiments. In one embodiment, the present disclosure provides a vector system comprising one or more vectors encoding two light chains and two heavy chains of the bispecific binding molecule according to any of the above-mentioned embodiments. In one embodiment, the present disclosure provides an isolated host cell comprising a vector system according to any of the above-mentioned embodiments.

[0095] In one embodiment, the present disclosure provides a method of producing a bispecific binding molecule, the method comprising: a) culturing a host cell according to any of the above embodiments under conditions such that the host cell expresses the bispecific binding molecule; and b) isolating the bispecific binding molecule from the host cell. In one embodiment, the present disclosure provides a method for producing a bispecific binding protein comprising a first binding domain that binds to an extracellular portion of dystroglycan and a second binding domain that binds laminin-2, the method comprising: a) culturing a first host cell comprising a nucleic acid molecule encoding a first polypeptide chain comprising the first binding domain under conditions such that the host cell expresses the first polypeptide chain as part of a first monospecific binding protein having a first CH3 domain; b) culturing a second host cell comprising a nucleic acid molecule encoding a second polypeptide chain comprising the second binding domain under conditions such that the host cell expresses the second polypeptide chain as part of a second monospecific binding protein having a second CH3 domain; c) isolating the first monospecific binding protein from the first host cell; d) isolating the second monospecific binding protein from the second host cell; e) incubating the isolated first and second monospecific binding proteins under reducing conditions sufficient to isomerize disulfide bonds of cysteines in the hinge region; and f) obtaining the bispecific binding protein, wherein the first and second CH3 domains are different and such that heterodimeric interactions between the first and second CH3 domains are stronger than homodimeric interactions between each of the first and second CH3 domains.

[0096] In one embodiment, the present disclosure provides a method for treating or preventing alpha-dystroglycan disease in an individual, the method comprising administering to the individual a bispecific binding molecule according to any of the above embodiments. In one embodiment, the present disclosure provides a method for providing a connection between laminin-2 and the extracellular portion of dystroglycan in an individual, the method comprising administering to the individual a bispecific binding molecule according to any of the above embodiments. In some embodiments, the individual has reduced expression of alpha-dystroglycan. In some embodiments, the alpha-dystroglycan expressed in the individual has impaired or abnormal O-glycosylation. In some embodiments, the individual has a mutation in a gene selected from the group consisting of dystroglycan (DAG1), protein O-mannosyltransferase-1 (POMT1), protein O-mannosyltransferase-2 (POMT2), protein O-linked mannose β1,2-N-acetylglucosaminyltransferase subunit 1 (POMGNT1), protein O-linked mannose β1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), xylosyl and glucuronosyltransferase 1 (LARGE1), xylosyl and glucuronosyltransferase 2 (LARGE2), phosphomannose mannose In some embodiments, the bispecific binding molecules are administered by intravenous infusion. In some embodiments, the bispecific binding molecules are administered by intramuscular, intraperitoneal, or subcutaneous injection. In some embodiments, the subject is a human.

[0097] In one embodiment, the present disclosure provides a pharmaceutical composition comprising a bispecific binding molecule according to any of the above embodiments and a pharmaceutically acceptable carrier. In one embodiment, the present disclosure provides a kit comprising a bispecific binding molecule according to any of the above embodiments and instructions for use in treating or preventing alpha-dystroglycan disease in an individual. In some embodiments, the individual has reduced expression of alpha-dystroglycan. In some embodiments, the alpha-dystroglycan expressed in the individual has impaired or abnormal O-glycosylation. In some embodiments, the individual has a mutation in a gene selected from the group consisting of dystroglycan (DAG1), protein O-mannosyltransferase-1 (POMT1), protein O-mannosyltransferase-2 (POMT2), protein O-linked mannose β1,2-N-acetylglucosaminyltransferase subunit 1 (POMGNT1), protein O-linked mannose β1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), xylosyl and glucuronosyltransferase 1 (LARGE1), xylosyl and glucuronosyltransferase 2 (LARGE2), phosphomannose mannose In some embodiments, the subject is a human.

[0098] Specific embodiments of the invention will become apparent from the following more detailed description of certain embodiments and the claims.

[0099] It should be understood that one, some or all of the features of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the present invention will become apparent to those skilled in the art.

[0100] Specifically, the present invention includes but is not limited to the following:

[0101] 1. A multispecific binding molecule comprising at least one first binding domain that binds to the extracellular portion of dystroglycan and at least one second binding domain that binds to laminin-2.

[0102] 2. The multispecific binding molecule of claim 1 , wherein the multispecific binding molecule is a multispecific binding protein comprising one or more polypeptide chains.

[0103] 3. The multispecific binding molecule of claim 2, wherein the binding protein comprises four polypeptide chains, wherein the first polypeptide chain comprises a structure represented by the following formula:

[0104] V L2 -L1-V L1 -L2-C L [I]

[0105] And the second polypeptide chain comprises a structure represented by the following formula:

[0106] V H1 -L3-V H2 -L4-C H1 -Hinge-C H2 -C H3 [II]

[0107] And the third polypeptide chain comprises a structure represented by the following formula:

[0108] V H3 -C H1 -Hinge-C H2 -C H3 [III]

[0109] And the fourth polypeptide chain comprises a structure represented by the following formula:

[0110] V L3 -C L [IV]

[0111] in:

[0112] V L1 is the first immunoglobulin light chain variable domain;

[0113] V L2 is the second immunoglobulin light chain variable domain;

[0114] V L3 is the third immunoglobulin light chain variable domain;

[0115] V H1 is the first immunoglobulin heavy chain variable domain;

[0116] V H2 is a second immunoglobulin heavy chain variable domain;

[0117] V H3 is the third immunoglobulin heavy chain variable domain;

[0118] CL is the immunoglobulin light chain constant domain;

[0119] C H1 Immunoglobulin C H1 heavy chain constant domain;

[0120] C H2 Immunoglobulin C H2 heavy chain constant domain;

[0121] C H3 Immunoglobulin C H3 heavy chain constant domain;

[0122] The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and

[0123] L1, L2, L3, and L4 are amino acid linkers;

[0124] wherein the polypeptide of Formula I and the polypeptide of Formula II form a crossover light chain-heavy chain pair; and

[0125] Where V H1 and V L1 Form an antigen binding site, where V H2 and V L2 forms an antigen binding site, and wherein V H3 and V L3 Antigen binding sites are formed, three antigen binding sites in total, and wherein the three antigen binding sites comprise at least one antigen binding site that binds to the extracellular portion of dystroglycan and at least one antigen binding site that binds to laminin-2.

[0126] 4. The multispecific binding molecule of item 3, comprising one antigen binding site that binds to the extracellular portion of dystroglycan and two antigen binding sites that bind to laminin-2.

[0127] 5. The multispecific binding molecule of item 4, wherein the two laminin-2 binding antigen binding sites bind to different epitopes of laminin-2.

[0128] 6. The multispecific binding molecule of item 4, wherein the two laminin-2 binding antigen binding sites bind to the same epitope of laminin-2.

[0129] 7. The multispecific binding molecule of any one of items 4-6, wherein V H1 and V L1 Forms the first antigen binding site for laminin-2, V H2 and VL2 Forms a second antigen binding site that binds laminin-2, and V H3 and V L3 Forms a third antigen binding site that binds to the extracellular portion of dystroglycan.

[0130] 8. The multispecific binding molecule of item 3, comprising two antigen binding sites that bind to the extracellular portion of dystroglycan and one antigen binding site that binds to laminin-2.

[0131] 9. The multispecific binding molecule of item 8, wherein the two antigen binding sites that bind to the extracellular portion of dystroglycan bind to different epitopes of the extracellular portion of dystroglycan.

[0132] 10. The multispecific binding molecule of item 8, wherein the two antigen binding sites that bind to the extracellular portion of dystroglycan bind to the same epitope of the extracellular portion of dystroglycan.

[0133] 11. The multispecific binding molecule of any one of items 8-10, wherein V H1 and V L1 Forms the first antigen binding site that binds to the extracellular portion of dystroglycan, V H2 and V L2 Forms a second antigen binding site that binds to the extracellular portion of dystroglycan, and V H3 and V L3 Forms a third antigen binding site that binds laminin-2.

[0134] 12. The multispecific binding molecule of any one of items 3-11, wherein the at least one antigen binding site that binds the extracellular portion of dystroglycan has an equilibrium dissociation constant (K) of less than about 1 μM when measured as part of a multispecific binding protein. D ) binds to the extracellular portion of dystroglycan.

[0135] 13. The multispecific binding molecule of any one of items 3-12, wherein the at least one antigen binding site that binds to the extracellular portion of dystroglycan binds to the extracellular portion of human and mouse dystroglycan.

[0136] 14. The multispecific binding molecule of any one of items 3 to 13, wherein the at least one antigen binding site that binds to the extracellular portion of dystroglycan binds β-dystroglycan.

[0137] 15. The multispecific binding molecule of claim 14, wherein the at least one antigen binding site that binds to the extracellular portion of dystroglycan binds a polypeptide comprising the sequence SIVVEWTNN TLPLEPCPKE QIIGLSRRIADENGKPRPAF SNALEPDFKA LSIAVTGSGS CRHLQFIPVA PPSPGSSAAP ATEVPDRDPE KSSEDD (SEQ ID NO: 290).

[0138] 16. The multispecific binding molecule of item 14 or 15, wherein the at least one antigen binding site that binds to the extracellular portion of dystroglycan binds a polypeptide comprising the sequence SIVVEWT NNTLPLEPCP KEQIAGLSRRIAEDDGKPRP AFSNALEPDF KATSITVTGS GSCRHLQFIP VVPPRRVPSE APPTEVPDRD PEKSSEDDV (SEQ ID NO: 291).

[0139] 17. The multispecific binding molecule of any one of items 3-13, wherein the at least one antigen binding site that binds to the extracellular portion of dystroglycan binds alpha-dystroglycan.

[0140] 18. The multispecific binding molecule of claim 17, wherein the at least one antigen binding site that binds to the extracellular portion of dystroglycan binds a polypeptide comprising the sequence SIVVEWT NNTLPLEPCP KEQIAGLSRRIAEDDGKPRP AFSNALEPDF KATSITVTGS GSCRHLQFIP VVPPRRVPSE APPTEVPDRD PEKSSEDDV (SEQ ID NO: 291).

[0141] 19. The multispecific binding molecule of any one of items 3 to 18, wherein the at least one laminin-2 binding antigen binding site binds human laminin-2.

[0142] 20. The multispecific binding molecule of item 19, wherein the at least one antigen binding site that binds laminin-2 has an equilibrium dissociation constant (K) of less than about 1 μM when assayed as part of a multispecific binding protein. D ) binds to human laminin-2.

[0143] 21. The multispecific binding molecule of any one of items 3-20, wherein the at least one antigen binding site that binds laminin-2 binds both mouse and human laminin-2.

[0144] 22. A multispecific binding molecule according to any one of items 3-21, wherein at least one of the antigen binding sites that binds to laminin-2 binds to a polypeptide comprising the laminin G-like (LG) domain 4 of laminin-2, the laminin G-like (LG) domain 5 of laminin-2, or both.

[0145] 23. A multispecific binding molecule according to claim 22, wherein the at least one antigen binding site that binds laminin-2 binds to a polypeptide comprising the laminin G-like (LG) domain 4 and the laminin G-like (LG) domain 5 of laminin-2.

[0146] 24. The multispecific binding molecule of item 23, wherein the at least one antigen binding site that binds laminin-2 binds a protein comprising the sequence VQPQPV PTPAFPFPAP TMVHGPCVAE SEPALLTGSK QFGLSRNSHIAIAFDDTKVK NRLTIELEVR TEAESGLLFY MARINHADFA TVQLRNGFPY FSYDLGSGDT STMIPTKINDGQWHKIKIVR VKQEGILYVD DASSQTISPK KADILDVVGI LYVGGLPINY TTRRIGPVTY SLDGCVRNLHMEQAPVDLDQ PTSSFHVGTC FANAESGTYF DGTGFAKAVG GFKVGLDLLV EFEFRTTRPT GVLLGVSSQKMDGMGIEMID EKLMFHVDNG AGRFTAIYDA GIPGHMCNGQ WHKVTAKKIK NRLELVVDGN QVDAQSPNSASTSADTNDPV The polypeptide of FVGGFPGGLN QFGLTTNIRF RGCIRSLKLT KGTGKPLEVN FAKALELRGV QPVSCPTT (SEQ ID NO: 300).

[0147] 25. The multispecific binding molecule of item 23 or 24, wherein the at least one antigen binding site that binds laminin-2 binds a protein comprising the sequence Q PEPVPTPAFP TPTPVLTHGP CAAESEPALL IGSKQFGLSRNSHIAIAFDD TKVKNRLTIE LEVRTEAESG LLFYMARINH ADFATVQLRN GLPYFSYDLG SGDTHTMIPTKINDGQWHKI KIMRSKQEGI LYVDGASNRT ISPKKADILD VVGMLYVGGL PINYTTRRIG PVTYSIDGCVRNLHMAEAPA DLEQPTSSFH VGTCFANAQR GTYFDGTGFA KAVGGFKVGL DLLVEFEFRT TTTTGVLLGISSQKMDGMGI EMIDEKLMFH VDNGAGRFTA VYDAGVPGHL CDGQWHKVTA NKIKHRIELT VDGNQVEAQSPNPASTSADT The polypeptide of NDPVFVGGFP DDLKQFGLTT SIPFRGCIRS LKLTKGTGKP LEVNFAKALE LRGVQPVSCPAN (SEQ ID NO: 301).

[0148] 26. The multispecific binding molecule of claim 22, wherein the at least one antigen binding site that binds laminin-2 binds a polypeptide comprising the laminin G-like (LG) domain 5 of laminin-2.

[0149] 27. The multispecific binding molecule of claim 26, wherein the at least one antigen binding site that binds laminin-2 binds a polypeptide comprising the sequence ANAESGTYF DGTGFAKAVG GFKVGLDLLV EFEFRTTRPT GVLLGVSSQKMDGMGIEMID EKLMFHVDNG AGRFTAIYDA GIPGHMCNGQ WHKVTAKKIK NRLELVVDGN QVDAQSPNSASTSADTNDPV FVGGFPGGLN QFGLTTNIRF RGCIRSLKLT KGTGKPLEVN FAKALELRGV QPVSCPTT (SEQ ID NO: 292).

[0150] 28. The multispecific binding molecule of item 26 or 27, wherein the at least one antigen binding site that binds laminin-2 binds a polypeptide comprising the sequence ANAQR GTYFDGTGFA KAVGGFKVGL DLLVEFEFRT TTTTGVLLGISSQKMDGMGI EMIDEKLMFH VDNGAGRFTA VYDAGVPGHL CDGQWHKVTA NKIKHRIELT VDGNQVEAQSPNPASTSADT NDPVFVGGFP DDLKQFGLTT SIPFRGCIRS LKLTKGTGKP LEVNFAKALE LRGVQPVSCPAN (SEQ ID NO: 293).

[0151] 29. The multispecific binding molecule of any one of items 3-11, wherein the at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises:

[0152] (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-17, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-27; and

[0153] (b) a light chain variable domain (VL), comprising a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-37, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-42, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-50.

[0154] 30. The multispecific binding molecule of item 29, wherein:

[0155] (a) the at least one VH domain that binds to an antigen binding site of the extracellular portion of dystroglycan comprises a sequence selected from the group consisting of SEQ ID NOs: 170, 172, 174, 176, 178, 180, 182, 184, 186, and 188; and

[0156] (b) the VL domain of the at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises a sequence selected from the group consisting of SEQ ID NO: 171, 173, 175, 177, 179, 181, 183, 185, 187 and 189.

[0157] 31. The multispecific binding molecule of any one of items 3-11, wherein the at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises:

[0158] (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320; and

[0159] (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336.

[0160] 32. The multispecific binding molecule of claim 31 , wherein the at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises a humanized VH domain and a humanized VL domain.

[0161] 33. The multispecific binding molecule of item 31 or 32, wherein:

[0162] (a) the at least one VH domain that binds to the antigen binding site of the extracellular portion of dystroglycan comprises the sequence of SEQ ID NO: 314; and

[0163] (b) the VL domain of the at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises the sequence of SEQ ID NO: 330.

[0164] 34. The multispecific binding molecule of item 31 or 32, wherein:

[0165] (a) the at least one VH domain that binds to the antigen binding site of the extracellular portion of dystroglycan comprises the sequence of SEQ ID NO: 346; and

[0166] (b) the VL domain of the at least one antigen binding site that binds to the extracellular portion of dystroglycan comprises the sequence of SEQ ID NO: 362.

[0167] 35. The multispecific binding molecule of any one of items 3-11 and 29-34, wherein the at least one antigen binding site that binds laminin-2 comprises:

[0168] (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-55 and 81-95, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-60 and 96-110, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-65 and 111-125; and

[0169] (b) a light chain variable domain (VL), comprising a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-70 and 126-140, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 71-75 and 141-154, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-80 and 155-169.

[0170] 36. The multispecific binding protein of item 35, wherein:

[0171] (a) the at least one VH domain that binds to an antigen binding site of laminin-2 comprises a sequence selected from the group consisting of SEQ ID NOs: 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228; and

[0172] (b) the VL domain of the at least one antigen binding site that binds laminin-2 comprises a sequence selected from the group consisting of SEQ ID NO: 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227 and 229.

[0173] 37. The multispecific binding molecule of any one of items 3-11 and 29-34, wherein the at least one antigen binding site that binds laminin-2 comprises:

[0174] (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384; and

[0175] (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400.

[0176] 38. The multispecific binding molecule of claim 37, wherein the at least one antigen binding site that binds laminin-2 comprises a humanized VH domain and a humanized VL domain.

[0177] 39. The multispecific binding molecule of item 37 or 38, wherein:

[0178] (a) the at least one VH domain that binds to the laminin-2 antigen binding site comprises the sequence of SEQ ID NO: 378; and

[0179] (b) the VL domain of the at least one antigen binding site that binds laminin-2 comprises the sequence of SEQ ID NO: 394.

[0180] 40. The multispecific binding molecule of any one of items 3-11 and 29-34, wherein the at least one antigen binding site that binds laminin-2 comprises:

[0181] (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384; and

[0182] (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400.

[0183] 41. The multispecific binding molecule of claim 40, wherein the at least one antigen binding site that binds laminin-2 comprises a humanized VH domain and a humanized VL domain.

[0184] 42. The multispecific binding molecule of claim 40 or 41, wherein:

[0185] (a) the at least one VH domain that binds to the laminin-2 antigen binding site comprises the sequence of SEQ ID NO: 410; and

[0186] (b) the VL domain of the at least one antigen binding site that binds laminin-2 comprises the sequence of SEQ ID NO: 426.

[0187] 43. The multispecific binding molecule of any one of items 3-11 and 29-34, wherein the at least one antigen binding site that binds laminin-2 comprises:

[0188] (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 446, and a CDR-H3 comprising the sequence of SEQ ID NO: 448; and

[0189] (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464.

[0190] 44. The multispecific binding molecule of item 43, wherein the at least one antigen binding site that binds laminin-2 comprises a humanized VH domain and a humanized VL domain.

[0191] 45. The multispecific binding molecule of item 43 or 44, wherein:

[0192] (a) the at least one VH domain that binds to the laminin-2 antigen binding site comprises the sequence of SEQ ID NO: 442; and

[0193] (b) the VL domain of the at least one antigen binding site that binds laminin-2 comprises the sequence of SEQ ID NO: 458.

[0194] 46. ​​The multispecific binding molecule of any one of items 3-11 and 29-34, wherein the at least one antigen binding site that binds laminin-2 comprises:

[0195] (a) a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 478, and a CDR-H3 comprising the sequence of SEQ ID NO: 448; and

[0196] (b) a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464.

[0197] 47. The multispecific binding molecule of item 46, wherein the at least one antigen binding site that binds laminin-2 comprises a humanized VH domain and a humanized VL domain.

[0198] 48. The multispecific binding molecule of item 46 or 47, wherein:

[0199] (a) the at least one VH domain that binds to the laminin-2 antigen binding site comprises the sequence of SEQ ID NO: 474; and

[0200] (b) the VL domain of the at least one antigen binding site that binds laminin-2 comprises the sequence of SEQ ID NO: 490.

[0201] 49. The multispecific binding molecule of item 3, wherein:

[0202] V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400;

[0203] V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; and

[0204] V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3It comprises a CDR-L1 comprising the sequence of SEQ ID NO:332, a CDR-L2 comprising the sequence of SEQ ID NO:334, and a CDR-L3 comprising the sequence of SEQ ID NO:336.

[0205] 50. The multispecific binding molecule of item 49, wherein:

[0206] V H1 Contains the sequence SEQ ID NO: 378, and V L1 comprising the sequence SEQ ID NO: 394;

[0207] V H2 Contains the sequence SEQ ID NO: 378, and V L2 comprising the sequence SEQ ID NO: 394; and

[0208] V H3 Contains the sequence SEQ ID NO: 314, and V L3 Comprising the sequence SEQ ID NO:330.

[0209] 51. The multispecific binding molecule of item 3, wherein:

[0210] V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400;

[0211] V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 446, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; and

[0212] V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and VL3 It comprises a CDR-L1 comprising the sequence of SEQ ID NO:332, a CDR-L2 comprising the sequence of SEQ ID NO:334, and a CDR-L3 comprising the sequence of SEQ ID NO:336.

[0213] 52. The multispecific binding molecule of item 51, wherein:

[0214] V H1 Contains the sequence SEQ ID NO: 378, and V L1 comprising the sequence SEQ ID NO: 394;

[0215] V H2 Contains the sequence SEQ ID NO: 442, and V L2 comprising the sequence SEQ ID NO:458; and

[0216] V H3 Contains the sequence SEQ ID NO: 314, and V L3 Comprising the sequence SEQ ID NO:330.

[0217] 53. The multispecific binding molecule of claim 3, wherein:

[0218] V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400;

[0219] V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 478, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; and

[0220] V H3comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 It comprises a CDR-L1 comprising the sequence of SEQ ID NO:332, a CDR-L2 comprising the sequence of SEQ ID NO:334, and a CDR-L3 comprising the sequence of SEQ ID NO:336.

[0221] 54. The multispecific binding molecule of item 53, wherein:

[0222] V H1 Contains the sequence SEQ ID NO: 410, and V L1 comprising the sequence SEQ ID NO:426;

[0223] V H2 Contains the sequence SEQ ID NO: 474, and V L2 comprising the sequence SEQ ID NO: 490; and

[0224] V H3 Contains the sequence SEQ ID NO: 314, and V L3 Comprising the sequence SEQ ID NO:330.

[0225] 55. The multispecific binding molecule of item 3, wherein:

[0226] V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 446, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464;

[0227] V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; and

[0228] VH3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 It comprises a CDR-L1 comprising the sequence of SEQ ID NO:332, a CDR-L2 comprising the sequence of SEQ ID NO:334, and a CDR-L3 comprising the sequence of SEQ ID NO:336.

[0229] 56. The multispecific binding molecule of item 55, wherein:

[0230] V H1 Contains the sequence SEQ ID NO: 442, and V L1 comprising the sequence SEQ ID NO:458;

[0231] V H2 Contains the sequence SEQ ID NO: 410, and V L2 comprising the sequence SEQ ID NO:426; and

[0232] V H3 Contains the sequence SEQ ID NO: 314, and V L3 Comprising the sequence SEQ ID NO:330.

[0233] 57. The multispecific binding molecule of item 3, wherein:

[0234] V H1 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 478, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464;

[0235] V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; and

[0236] V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 It comprises a CDR-L1 comprising the sequence of SEQ ID NO:332, a CDR-L2 comprising the sequence of SEQ ID NO:334, and a CDR-L3 comprising the sequence of SEQ ID NO:336.

[0237] 58. The multispecific binding molecule of item 57, wherein:

[0238] V H1 Contains the sequence SEQ ID NO: 474, and V L1 comprising the sequence SEQ ID NO: 490;

[0239] V H2 Contains the sequence SEQ ID NO: 378, and V L2 comprising the sequence SEQ ID NO: 394; and

[0240] V H3 Contains the sequence SEQ ID NO: 314, and V L3 Comprising the sequence SEQ ID NO:330.

[0241] 59. The multispecific binding molecule of any one of items 3-58, wherein L1 and L2 comprise the sequence DKTHT (SEQ ID NO: 534).

[0242] 60. The multispecific binding molecule of any one of items 3-58, wherein L3 and L4 comprise the sequence DKTHT (SEQ ID NO: 534).

[0243] 61. A multispecific binding molecule as described in any one of items 3-58, wherein L1, L2, L3 and L4 comprise the sequence DKTHT (SEQ ID NO: 534).

[0244] 62. The multispecific binding molecule of any one of items 3-61, wherein C of the second polypeptide chain H3 The domain comprises an amino acid substitution at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are S354C and T366W; and wherein C of the third polypeptide chain H3The domain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

[0245] 63. The multispecific binding molecule of any one of items 3-61, wherein C of the second polypeptide chain H3 The domain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein C of the third polypeptide chain H3 The domain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are S354C and T366W.

[0246] 64. The multispecific binding molecule of any one of items 3-63, wherein the C of the second and third polypeptide chains H3 The domain is human IgG1 or IgG4 C H3 domain, and wherein said C H3 Only one of the domains comprises amino acid substitutions at positions corresponding to positions 435 and 436 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitutions are H435R and Y436F.

[0247] 65. The multispecific binding molecule of any one of claims 3-64, wherein the C of the second and third polypeptide chains H2 The domain is human IgG1 or IgG4 C H2 A domain comprising an asparagine residue at position 297, an asparagine residue at position 298, an alanine residue at position 299, and a serine or threonine residue at position 300, numbered according to the EU index.

[0248] 66. The multispecific binding molecule of any one of items 3-65, wherein the C of the second and third polypeptide chains H2 The domain is human IgG1 or IgG4 C H2 A domain comprising a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256, numbered according to the EU index.

[0249] 67. The multispecific binding molecule of claim 3, wherein the first polypeptide chain comprises the sequence of SEQ ID NO: 500, the second polypeptide chain comprises the sequence of SEQ ID NO: 498, the third polypeptide chain comprises the sequence of SEQ ID NO: 499, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 501.

[0250] 68. The multispecific binding molecule of claim 3, wherein the first polypeptide chain comprises the sequence of SEQ ID NO: 504, the second polypeptide chain comprises the sequence of SEQ ID NO: 502, the third polypeptide chain comprises the sequence of SEQ ID NO: 503, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 505.

[0251] 69. The multispecific binding molecule of claim 3, wherein the first polypeptide chain comprises the sequence of SEQ ID NO: 508, the second polypeptide chain comprises the sequence of SEQ ID NO: 506, the third polypeptide chain comprises the sequence of SEQ ID NO: 507, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 509.

[0252] 70. The multispecific binding molecule of claim 3, wherein the first polypeptide chain comprises the sequence of SEQ ID NO: 512, the second polypeptide chain comprises the sequence of SEQ ID NO: 510, the third polypeptide chain comprises the sequence of SEQ ID NO: 511, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 513.

[0253] 71. The multispecific binding molecule of claim 3, wherein the first polypeptide chain comprises the sequence of SEQ ID NO: 516, the second polypeptide chain comprises the sequence of SEQ ID NO: 514, the third polypeptide chain comprises the sequence of SEQ ID NO: 515, and the fourth polypeptide chain comprises the sequence of SEQ ID NO: 517.

[0254] 72. The multispecific binding molecule of item 1 or item 2, comprising:

[0255] (a) comprising a first heavy chain variable (VH) domain and a first C H3 a first antibody heavy chain comprising a first Fc region of an immunoglobulin containing a first VH region, and a first antibody light chain comprising a first light chain variable (VL) domain, wherein the first VH and VL domains form a first antigen binding domain that binds to the extracellular portion of dystroglycan, and

[0256] (b) comprising a second heavy chain variable (VH) domain and a second C H3a second antibody heavy chain comprising a second Fc region of an immunoglobulin containing a region of interest, and a second antibody light chain comprising a second light chain variable (VL) domain, wherein the second VH and VL domains form a second antigen binding domain that binds laminin-2;

[0257] wherein the first and second C H3 The sequences of the regions are different, and the first and second C H3 The heterodimer interaction between the first and second C H3 The homodimers of the first and second homodimers are more strongly interacting with each other, and wherein the first homodimer protein has an amino acid other than Lys, Leu or Met at position 409, and the second homodimer protein has an amino acid substitution at a position selected from the group consisting of 366, 368, 370, 399, 405 and 407 and / or wherein the first and second C H3 The sequence of the region is such that the C H3 The dissociation constants for the respective homodimeric interactions are between 0.01 and 10 micromolar.

[0258] 73. A multispecific binding molecule according to claim 72, wherein the first antibody heavy chain comprises the sequence of SEQ ID NO:518, wherein the second antibody heavy chain comprises the sequence of SEQ ID NO:519, wherein the first antibody light chain comprises the sequence of SEQ ID NO:520, and wherein the second antibody light chain comprises the sequence of SEQ ID NO:521.

[0259] 74. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a multispecific binding molecule according to any one of items 1-73.

[0260] 75. An expression vector comprising a nucleic acid molecule according to item 74.

[0261] 76. An isolated host cell comprising a nucleic acid molecule according to item 74.

[0262] 77. An isolated host cell comprising an expression vector according to item 75.

[0263] 78. A vector system comprising one or more vectors encoding the first, second, third and fourth polypeptide chains of the multispecific binding molecule according to item 3.

[0264] 79. An isolated host cell comprising the vector system according to item 78.

[0265] 80. A method of producing a multispecific binding molecule, the method comprising:

[0266] a) culturing the host cell according to any one of items 76, 77 and 79 under conditions such that the host cell expresses the multispecific binding molecule; and

[0267] b) isolating the multispecific binding molecule from the host cell.

[0268] 81. A method for treating or preventing alpha-dystroglycanopathy in an individual, said method comprising administering to said individual a multispecific binding molecule according to any one of items 1-73.

[0269] 82. A method for providing a linkage between laminin-2 and the extracellular portion of dystroglycan in an individual, said method comprising administering to said individual a multispecific binding molecule according to any one of items 1-73.

[0270] 83. The method of item 81 or item 82, wherein the individual has reduced expression of alpha-dystroglycan.

[0271] 84. The method of item 81 or item 82, wherein the alpha-dystroglycan expressed in the individual has impaired or abnormal O-glycosylation.

[0272] 85. The method of claim 81 or 82, wherein the individual has an enzyme selected from the group consisting of dystroglycan (DAG1), protein O-mannosyltransferase-1 (POMT1), protein O-mannosyltransferase-2 (POMT2), protein O-linked mannose β1,2-N-acetylglucosaminyltransferase subunit 1 (POMGNT1), protein O-linked mannose β1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), xylosyl and glucuronosyltransferase 1 (LARGE1), xylosyl and glucuronosyltransferase 2 (LARGE2), phosphodelmannosyltransferase subunit 1 (PS1), and phosphodelmannosyltransferase subunit 2 (PS2). Mutations in genes of a group consisting of dolichol kinase (DOLK), transmembrane protein 5 (TMEM5), fukutin, fukutin-related protein (FKRP), isoprenoid synthase domain-containing protein (ISPD), protein O-mannose kinase (POMK), β-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2), β-1,4-glucuronosyltransferase 1 (B4GAT1), dolichol kinase (DOLK), transmembrane protein 5 (TMEM5), and GDP-mannose pyrophosphorylase B (GMPPB) were detected.

[0273] 86. The method of any one of items 81-85, wherein the multispecific binding molecule is administered by intravenous infusion.

[0274] 87. The method of any one of items 81-85, wherein the multispecific binding molecule is administered by intramuscular, intraperitoneal or subcutaneous injection.

[0275] 88. The method of any one of items 81-87, wherein the individual is a human.

[0276] 89. A pharmaceutical composition comprising the multispecific binding molecule of any one of items 1-73 and a pharmaceutically acceptable carrier.

[0277] 90. A kit comprising the multispecific binding molecule of any one of items 1-73 and instructions for use in treating or preventing alpha-dystroglycanopathy in an individual.

[0278] 91. The kit of item 90, wherein the subject has reduced expression of alpha-dystroglycan.

[0279] 92. The kit of item 90, wherein the alpha-dystroglycan expressed in the individual has impaired or abnormal O-glycosylation.

[0280] 93. The kit of claim 90, wherein the individual has an enzyme selected from the group consisting of dystroglycan (DAG1), protein O-mannosyltransferase-1 (POMT1), protein O-mannosyltransferase-2 (POMT2), protein O-linked mannose β1,2-N-acetylglucosaminyltransferase subunit 1 (POMGNT1), protein O-linked mannose β1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), xylosyl and glucuronosyltransferase 1 (LARGE1), xylosyl and glucuronosyltransferase 2 (LARGE2), phosphodelphinol mannos ...2-N-acetylglucosaminyltransferase subunit 1 (POMGNT2), protein O-linked mannose β1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), Mutations in a group of genes consisting of phosphodol mannosyltransferase subunit 2 (DPM1), phosphodol mannosyltransferase subunit 2 (DPM2), phosphodol mannosyltransferase subunit 3 (DPM3), Fukutin, Fukutin-related protein (FKRP), isoprenoid synthase domain-containing protein (ISPD), protein O-mannokinase (POMK), β-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2), β-1,4-glucuronosyltransferase 1 (B4GAT1), dolichol kinase (DOLK), transmembrane protein 5 (TMEM5), and GDP-mannose pyrophosphorylase B (GMPPB).

[0281] 94. The kit of any one of items 90-93, wherein the individual is a human.

[0282] 95. A bispecific binding molecule comprising a first binding domain that binds to the extracellular portion of dystroglycan and a second binding domain that binds laminin-2, wherein the bispecific binding molecule is a bispecific binding protein comprising one or more polypeptide chains, and wherein the bispecific binding molecule comprises four polypeptide chains forming four antigen binding sites, wherein two polypeptide chains comprise a structure represented by the following formula:

[0283] V L1 -L1-V L2 -L2-C L [I]

[0284] And the two polypeptide chains contain the structure represented by the following formula:

[0285] V H2 -L3-V H1 -L4-C H1 -Hinge-C H2 -C H3 [II]

[0286] in:

[0287] V L1 is the first immunoglobulin light chain variable domain;

[0288] V L2 is the second immunoglobulin light chain variable domain;

[0289] V H1 is the first immunoglobulin heavy chain variable domain;

[0290] V H2 is a second immunoglobulin heavy chain variable domain;

[0291] C L is the immunoglobulin light chain constant domain;

[0292] C H1 Immunoglobulin C H1 heavy chain constant domain;

[0293] C H2 Immunoglobulin C H2 heavy chain constant domain;

[0294] C H3 Immunoglobulin C H3 heavy chain constant domain;

[0295] The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and

[0296] L1, L2, L3, and L4 are amino acid linkers;

[0297] Where V H1 and V L1 Domain formation V H1 / V L1 Combining pairs, and where V H2 and V L2 Domain formation V H2 / V L2 Combined pair.

[0298] 96. A bispecific binding molecule according to item 95, wherein V H1 and V L1 Domains intersect to form V H1 / V L1 Combined pair.

[0299] 97. The bispecific binding molecule of item 95, wherein V H2 and V L2 Domains intersect to form V H2 / V L2 Combined pair.

[0300] 98. A bispecific binding molecule according to any one of items 95-97, wherein the length of L1, L2, L3 and L4 is each 0 to 50 amino acid residues.

[0301] 99. A bispecific binding molecule according to claim 98, wherein the length of L1, L2, L3 and L4 is each 0 to 25 amino acid residues.

[0302] 100. The bispecific binding molecule of item 98 or 99, wherein L1, L2, L3 and L4 are each 0 to 14 amino acid residues in length.

[0303] 101. The bispecific binding molecule of any one of items 98-100, wherein:

[0304] L1 is 5 amino acid residues in length;

[0305] L2 is 5 amino acid residues in length;

[0306] L3 is 5 amino acid residues in length; and

[0307] L4 is 5 amino acid residues in length.

[0308] 102. The bispecific binding molecule of any one of items 98 to 100, wherein:

[0309] L1 is 14 amino acid residues in length;

[0310] L2 is 2 amino acid residues in length;

[0311] L3 is 14 amino acid residues in length; and

[0312] L4 is 2 amino acid residues in length.

[0313] 103. A bispecific binding molecule according to item 102, wherein L1 and L3 each comprise the sequence EPKSDKTHTSPPSP (SEQ ID NO: 296), and wherein L2 and L4 each comprise the sequence GG.

[0314] 104. The bispecific binding molecule of any one of items 98 to 100, wherein:

[0315] L1 is 7 amino acid residues in length;

[0316] L2 is 5 amino acid residues in length;

[0317] L3 is 1 amino acid residue in length; and

[0318] L4 is 2 amino acid residues in length.

[0319] 105. The bispecific binding molecule of item 104, wherein:

[0320] L1 comprises the sequence GQPKAAP (SEQ ID NO: 297);

[0321] L2 comprises the sequence TKGPS (SEQ ID NO: 298);

[0322] L3 contains a serine residue; and

[0323] L4 contains the sequence RT.

[0324] 106. The bispecific binding molecule of any one of items 98-100, wherein:

[0325] L1 is 10 amino acid residues in length;

[0326] L2 is 10 amino acid residues in length;

[0327] L3 is 0 amino acid residues in length; and

[0328] L4 is 0 amino acid residues in length.

[0329] 107. The bispecific binding molecule of item 106, wherein L1 and L2 each comprise the sequence GGSGSSGSGG (SEQ ID NO: 299).

[0330] 108. The bispecific binding molecule of any one of items 95-107, wherein one or both of the two variable domains of the polypeptide of Formula I and / or Formula II are human, humanized or mouse variable domains.

[0331] 109. A bispecific binding molecule comprising a first binding domain that binds to the extracellular portion of dystroglycan and a second binding domain that binds laminin-2, wherein the bispecific binding molecule is a bispecific binding protein comprising one or more polypeptide chains, and wherein the bispecific binding molecule comprises two light chains comprising a structure represented by the following formula:

[0332] V L1 -L5-V L2 -L6-C L [III]

[0333] and two heavy chains comprising the structure represented by the following formula:

[0334] V H1 -L7-V H2 -L8-C H1 -Hinge-C H2 -C H3 [IV]

[0335] in:

[0336] V L1 is the first immunoglobulin light chain variable domain;

[0337] V L2 is the second immunoglobulin light chain variable domain;

[0338] V H1 is the first immunoglobulin heavy chain variable domain;

[0339] V H2 is a second immunoglobulin heavy chain variable domain;

[0340] C L is the immunoglobulin light chain constant domain;

[0341] C H1 Immunoglobulin C H1 heavy chain constant domain;

[0342] C H2 Immunoglobulin C H2 heavy chain constant domain;

[0343] C H3 Immunoglobulin C H3 heavy chain constant domain;

[0344] The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and

[0345] L5, L6, L7, and L8 are amino acid linkers;

[0346] Where V H1 and V L1 Domain formation V H1 / V L1 Combining pairs, and where V H2 and V L2 Domain formation V H2 / V L2 Combined pair.

[0347] 110. The bispecific binding molecule of item 109, wherein L5, L6, L7 and L8 are each 0 to 50 amino acid residues in length.

[0348] 111. A bispecific binding molecule according to item 109 or 110, wherein the length of L5, L6, L7 and L8 is each 0 to 25 amino acid residues.

[0349] 112. The bispecific binding molecule of any one of items 109-111, wherein L5, L6, L7 and L8 are each 0 to 14 amino acid residues in length.

[0350] 113. The bispecific binding molecule of any one of items 109-112, wherein the L5 and L7 linkers comprise the amino acid sequence GGGGSGGGGS (SEQ ID NO: 294), and wherein the L6 and L8 linkers are each 0 amino acid residues in length.

[0351] 114. The bispecific binding molecule according to any one of items 109-113, wherein one or both of the two variable domains of the polypeptide of Formula III and / or Formula IV are human, humanized or mouse variable domains.

[0352] 115. The bispecific binding molecule of any one of items 95-114, wherein V H1 / V L1 The binding pair binds to the extracellular portion of dystroglycan, and wherein V H2 / V L2 The binding pair binds to laminin-2.

[0353] 116. A bispecific binding molecule according to item 115, wherein V H1 / V L1 The binding pair binds to the extracellular portion of human dystroglycan.

[0354] 117. The bispecific binding molecule of item 116, wherein V H1 / V L1 The binding pair has an equilibrium dissociation constant (K) of less than about 1 μM. D ) binds to the extracellular portion of human dystroglycan.

[0355] 118. The bispecific binding molecule according to any one of items 115-117, wherein V H1 / V L1 The binding pair binds to the extracellular portion of human and mouse dystroglycan.

[0356] 119. The bispecific binding molecule according to any one of items 115-118, wherein V H1 / V L1 Binding to beta-dystroglycan.

[0357] 120. The bispecific binding molecule of item 119, wherein V H1 / V L1 The binding pair binds to a polypeptide comprising the sequence SIVVEWTNN TLPLEPCPKE QIIGLSRRIA DENGKPRPAF SNALEPDFKA LSIAVTGSGS CRHLQFIPVAPPSPGSSAAP ATEVPDRDPE KSSEDD (SEQ ID NO: 290).

[0358] 121. The bispecific binding molecule of item 119 or 120, wherein V H1 / V L1 The binding pair binds to a polypeptide comprising the sequence SIVVEWT NNTLPLEPCP KEQIAGLSRR IAEDDGKPRP AFSNALEPDF KATSITVTGS GSCRHLQFIPVVPPRRVPSE APPTEVPDRD PEKSSEDDV (SEQ ID NO: 291).

[0359] 122. A bispecific binding molecule according to any one of items 115-118, wherein V H1 / V L1 Binding to α-dystroglycan.

[0360] 123. A bispecific binding molecule according to any one of items 115-122, wherein V H2 / V L2 The binding pair binds to human laminin-2.

[0361] 124. A bispecific binding molecule according to item 123, wherein V H2 / V L2 The binding pair has an equilibrium dissociation constant (K) of less than about 1 μM. D ) binds to human laminin-2.

[0362] 125. The bispecific binding molecule of any one of items 115-124, wherein V H2 / V L2 The binding pair binds both mouse and human laminin-2.

[0363] 126. A bispecific binding molecule according to any one of items 115-125, wherein V H2 / V L2 The binding pair binds to a polypeptide comprising the laminin G-like (LG) domain 4 of laminin-2, the laminin G-like (LG) domain 5 of laminin-2, or both.

[0364] 127. The bispecific binding molecule of item 126, wherein V H2 / V L2 The binding pair binds to a polypeptide comprising the laminin G-like (LG) domain 4 and the laminin G-like (LG) domain 5 of laminin-2.

[0365] 128. A bispecific binding molecule according to item 126, wherein V H2 / V L2The binding pair contains the sequence VQPQPV PTPAFPFPAP TMVHGPCVAE SEPALLTGSK QFGLSRNSHI AIAFDDTKVK NRLTIELEVRTEAESGLLFY MARINHADFA TVQLRNGFPY FSYDLGSGDT STMIPTKIND GQWHKIKIVRVKQEGILYVDDASSQTISPK KADILDVVGI LYVGGLPINY TTRRIGPVTY SLDGCVRNLH MEQAPVDLDQ PTSSFHVGTCFANAESGTYF DGTGFAKAVG GFKVGLDLLV EFEFRTTRPT GVLLGVSSQK MDGMGIEMID EKLMFHVDNGAGRFTAIYDA GIPGHMCNGQ WHKVTAKKIK NRLELVVDGN QVDAQSPNSA STSADTNDPV FVGGFPGGLNQFGLTTNIRF RGCIRSLKLT KGTGKPLEVN A polypeptide of FAKALELRGV QPVSCPTT (SEQ ID NO: 300).

[0366] 129. The bispecific binding molecule according to item 127 or according to item 128, wherein V H2 / V L2 The binding pair contains the sequence Q PEPVPTPAFP TPTPVLTHGP CAAESEPALL IGSKQFGLSR NSHIAIAFDD TKVKNRLTIELEVRTEAESG LLFYMARINH ADFATVQLRN GLPYFSYDLG SGDTHTMIPT KINDGQWHKI KIMRSKQEGILYVDGASNRT ISPKKADILD VVGMLYVGGL PINYTTRRIG PVTYSIDGCV RNLHMAEAPA DLEQPTSSFHVGTCFANAQR GTYFDGTGFA KAVGGFKVGL DLLVEFEFRT TTTTGVLLGI SSQKMDGMGI EMIDEKLMFHVDNGAGRFTA VYDAGVPGHL CDGQWHKVTA NKIKHRIELT VDGNQVEAQS PNPASTSADT NDPVFVGGFPDDLKQFGLTT SIPFRGCIRS LKLTKGTGKP A polypeptide of LEVNFAKALE LRGVQPVSCP AN (SEQ ID NO: 301).

[0367] 130. The bispecific binding molecule of item 126, wherein V H2 / V L2 The binding pair binds to a polypeptide comprising the laminin G-like (LG) domain 5 of laminin-2.

[0368] 131. A bispecific binding molecule according to item 130, wherein V H2 / V L2 The binding pair binds to a polypeptide comprising the sequence ANAESGTYF DGTGFAKAVG GFKVGLDLLV EFEFRTTRPT GVLLGVSSQK MDGMGIEMID EKLMFHVDNGAGRFTAIYDA GIPGHMCNGQ WHKVTAKKIK NRLELVVDGN QVDAQSPNSA STSADTNDPV FVGGFPGGLNQFGLTTNIRF RGCIRSLKLT KGTGKPLEVN FAKALELRGV QPVSCPTT (SEQ ID NO: 292).

[0369] 132. The bispecific binding molecule of item 130 or 131, wherein V H2 / V L2 The binding pair binds to a polypeptide comprising the sequence ANAQR GTYFDGTGFA KAVGGFKVGL DLLVEFEFRT TTTTGVLLGI SSQKMDGMGI EMIDEKLMFHVDNGAGRFTA VYDAGVPGHL CDGQWHKVTA NKIKHRIELT VDGNQVEAQS PNPASTSADT NDPVFVGGFPDDLKQFGLTT SIPFRGCIRS LKLTKGTGKP LEVNFAKALE LRGVQPVSCP AN (SEQ ID NO: 293).

[0370] 133. A bispecific binding molecule according to item 115, wherein V H1 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-17, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-27; and / or wherein V L1The domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-37, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-42, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-50.

[0371] 134. A bispecific binding molecule according to item 133, wherein V H1 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 170, 172, 174, 176, 178, 180, 182, 184, 186 and 188.

[0372] 135. The bispecific binding molecule of item 133 or 134, wherein V L1 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 171, 173, 175, 177, 179, 181, 183, 185, 187 and 189.

[0373] 136. A bispecific binding molecule according to item 133, wherein V H1 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 230, 232, 234, 236, 238, 240, 242, 244, 246 and 248.

[0374] 137. The bispecific binding molecule of item 133 or 136, wherein V L1 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 231, 233, 235, 237, 239, 241, 243, 245, 247 and 249.

[0375] 138. The bispecific binding molecule according to any one of items 115 and 133-137, wherein V H2 The domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-55 and 81-95, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-60 and 96-110, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-65 and 111-125; and / or wherein V L2The domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-70 and 126-140, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 71-75 and 141-154, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-80 and 155-169.

[0376] 139. The bispecific binding molecule of item 138, wherein V H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228.

[0377] 140. The bispecific binding molecule of item 138 or 139, wherein V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227 and 229.

[0378] 141. A bispecific binding molecule according to item 138, wherein V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286 and 288.

[0379] 142. The bispecific binding molecule of item 138 or 141, wherein V L2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287 and 289.

[0380] 143. A bispecific binding molecule according to any one of items 95-114, wherein V H1 / V L1 Binding pair binds to laminin-2, and wherein V H2 / V L2 The binding pair binds to the extracellular portion of dystroglycan.

[0381] 144. The bispecific binding molecule of item 143, wherein V H2 / V L2 The binding pair binds to the extracellular portion of human dystroglycan.

[0382] 145. The bispecific binding molecule of item 144, wherein V H2 / V L2 The binding pair has an equilibrium dissociation constant (K) of less than about 1 μM. D ) binds to the extracellular portion of human dystroglycan.

[0383] 146. A bispecific binding molecule according to any one of items 143-145, wherein V H2 / V L2 The binding pair binds to the extracellular portion of human and mouse dystroglycan.

[0384] 147. The bispecific binding molecule of any one of items 143-146, wherein V H2 / V L2 Binding to beta-dystroglycan.

[0385] 148. A bispecific binding molecule according to item 147, wherein V H2 / V L2 The binding pair binds to a polypeptide comprising the sequence SIVVEWTNN TLPLEPCPKE QIIGLSRRIA DENGKPRPAF SNALEPDFKA LSIAVTGSGS CRHLQFIPVAPPSPGSSAAP ATEVPDRDPE KSSEDD (SEQ ID NO: 290).

[0386] 149. The bispecific binding molecule according to item 147 or according to item 148, wherein V H2 / V L2 The binding pair binds to a polypeptide comprising the sequence SIVVEWT NNTLPLEPCP KEQIAGLSRR IAEDDGKPRP AFSNALEPDF KATSITVTGSGSCRHLQFIP VVPPRRVPSE APPTEVPDRD PEKSSEDDV (SEQ ID NO: 291).

[0387] 150. The bispecific binding molecule of any one of items 143-146, wherein V H2 / V L2 Binding to α-dystroglycan.

[0388] 151. A bispecific binding molecule according to any one of items 143-150, wherein V H1 / V L1 The binding pair binds to human laminin-2.

[0389] 152. A bispecific binding molecule according to item 151, wherein V H1 / V L1 The binding pair has an equilibrium dissociation constant (K) of less than about 1 μM. D ) binds to human laminin-2.

[0390] 153. A bispecific binding molecule according to any one of items 143-152, wherein V H1 / V L1 The binding pair binds both mouse and human laminin-2.

[0391] 154. A bispecific binding molecule according to any one of items 143-153, wherein V H1 / V L1 The binding pair binds to a polypeptide comprising the laminin G-like (LG) domain 4 of laminin-2, the laminin G-like (LG) domain 5 of laminin-2, or both.

[0392] 155. A bispecific binding molecule according to item 154, wherein V H1 / V L1 The binding pair binds to a polypeptide comprising the laminin G-like (LG) domain 4 and the laminin G-like (LG) domain 5 of laminin-2.

[0393] 156. A bispecific binding molecule according to item 155, wherein V H1 / V L1The binding pair contains the sequence VQPQPV PTPAFPFPAP TMVHGPCVAE SEPALLTGSK QFGLSRNSHI AIAFDDTKVK NRLTIELEVRTEAESGLLFY MARINHADFA TVQLRNGFPY FSYDLGSGDT STMIPTKIND GQWHKIKIVR VKQEGILYVDDASSQTISPK KADILDVVGI LYVGGLPINY TTRRIGPVTY SLDGCVRNLH MEQAPVDLDQ PTSSFHVGTCFANAESGTYF DGTGFAKAVG GFKVGLDLLV EFEFRTTRPT GVLLGVSSQK MDGMGIEMID EKLMFHVDNGAGRFTAIYDA GIPGHMCNGQ WHKVTAKKIK NRLELVVDGN QVDAQSPNSA STSADTNDPV FVGGFPGGLNQFGLTTNIRF RGCIRSLKLT KGTGKPLEVN A polypeptide of FAKALELRGV QPVSCPTT (SEQ ID NO: 300).

[0394] 157. The bispecific binding molecule of item 155 or 156, wherein V H1 / V L1 The binding pair contains the sequence Q PEPVPTPAFP TPTPVLTHGP CAAESEPALL IGSKQFGLSR NSHIAIAFDD TKVKNRLTIELEVRTEAESG LLFYMARINH ADFATVQLRN GLPYFSYDLG SGDTHTMIPT KINDGQWHKIKIMRSKQEGILYVDGASNRT ISPKKADILD VVGMLYVGGL PINYTTRRIG PVTYSIDGCV RNLHMAEPADLEQPTSSFHVGTCFANAQR GTYFDGTGFAKAVGGFKVGL DLLVEFEFRT TTTTGVLLGI SSQKMDGMGI EMIDEKLMFHVDNGAGRFTA VYDAGVPGHL CDGQWHKVTANKIKHRIELT VDGNQVEAQS PNPASTSADT NDPVFVGGFPDDLKQFGLTT SIPFRGCIRS LKLTKGTGKP LEVNFAKALE A polypeptide of LRGVQPVSCP AN (SEQ ID NO: 301).

[0395] 158. A bispecific binding molecule according to item 154, wherein V H1 / V L1 The binding pair binds to a polypeptide comprising the laminin G-like (LG) domain 5 of laminin-2.

[0396] 159. A bispecific binding molecule according to item 158, wherein V H1 / V L1 The binding pair binds to a polypeptide comprising the sequence ANAESGTYF DGTGFAKAVG GFKVGLDLLV EFEFRTTRPT GVLLGVSSQK MDGMGIEMID EKLMFHVDNGAGRFTAIYDA GIPGHMCNGQ WHKVTAKKIK NRLELVVDGN QVDAQSPNSA STSADTNDPV FVGGFPGGLNQFGLTTNIRF RGCIRSLKLT KGTGKPLEVN FAKALELRGV QPVSCPTT (SEQ ID NO: 292).

[0397] 160. The bispecific binding molecule of item 158 or 159, wherein V H1 / V L1 The binding pair binds to a polypeptide comprising the sequence ANAQR GTYFDGTGFAKAVGGFKVGL DLLVEFEFRT TTTTGVLLGI SSQKMDGMGI EMIDEKLMFHVDNGAGRFTA VYDAGVPGHL CDGQWHKVTANKIKHRIELT VDGNQVEAQS PNPASTSADT NDPVFVGGFPDDLKQFGLTT SIPFRGCIRS LKLTKGTGKP LEVNFAKALE LRGVQPVSCP AN (SEQ ID NO: 293).

[0398] 161. A bispecific binding molecule according to item 143, wherein V H2 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-17, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-27; and / or wherein V L2The domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-37, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-42, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-50.

[0399] 162. A bispecific binding molecule according to item 161, wherein V H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 170, 172, 174, 176, 178, 180, 182, 184, 186 and 188.

[0400] 163. The bispecific binding molecule of item 161 or 162, wherein V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 171, 173, 175, 177, 179, 181, 183, 185, 187 and 189.

[0401] 164. A bispecific binding molecule according to item 161, wherein V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 230, 232, 234, 236, 238, 240, 242, 244, 246 and 248.

[0402] 165. The bispecific binding molecule of item 161 or 164, wherein V L2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 231, 233, 235, 237, 239, 241, 243, 245, 247 and 249.

[0403] 166. A bispecific binding molecule according to any one of items 143 and 161-165, wherein V H1 The domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-55 and 81-95, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-60 and 96-110, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-65 and 111-125; and / or wherein V L1The domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-70 and 126-140, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 71-75 and 141-154, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-80 and 155-169.

[0404] 167. A bispecific binding molecule according to item 166, wherein V H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228.

[0405] 168. The bispecific binding molecule of item 166 or 167, wherein V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227 and 229.

[0406] 169. A bispecific binding molecule according to item 166, wherein V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286 and 288.

[0407] 170. The bispecific binding molecule of item 166 or 169, wherein V L2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287 and 289.

[0408] 171. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a bispecific binding molecule according to any one of items 95-170.

[0409] 172. An expression vector comprising the nucleic acid molecule according to item 171.

[0410] 173. An isolated host cell comprising the nucleic acid molecule according to item 171.

[0411] 174. An isolated host cell comprising the expression vector of item 172.

[0412] 175. A vector system comprising one or more vectors encoding the first, second, third and fourth polypeptide chains of the bispecific binding molecule of item 95.

[0413] 176. A vector system comprising one or more vectors encoding two light chains and two heavy chains of the bispecific binding molecule according to item 109.

[0414] 177. An isolated host cell comprising the vector system according to item 175 or 176.

[0415] 178. A method of producing a bispecific binding molecule, the method comprising:

[0416] a) culturing the host cell according to any one of items 173, 174 and 177 under conditions such that said host cell expresses said bispecific binding molecule; and

[0417] b) isolating the bispecific binding molecule from the host cell.

[0418] 179. A method for treating or preventing alpha-dystroglycanopathy in an individual, said method comprising administering to said individual the bispecific binding molecule according to any one of items 95-170.

[0419] 180. A method for providing a linkage between laminin-2 and the extracellular portion of dystroglycan in an individual, said method comprising administering to said individual a bispecific binding molecule according to any one of items 95-170.

[0420] 181. The method of claim 179 or claim 180, wherein the individual has reduced expression of alpha-dystroglycan.

[0421] 182. A method according to item 179 or according to item 180, wherein the alpha-dystroglycan expressed in the individual has impaired or abnormal O-glycosylation.

[0422] 183. The method of claim 179 or 180, wherein the individual has an enzyme selected from the group consisting of dystroglycan (DAG1), protein O-mannosyltransferase-1 (POMT1), protein O-mannosyltransferase-2 (POMT2), protein O-linked mannose β1,2-N-acetylglucosaminyltransferase subunit 1 (POMGNT1), protein O-linked mannose β1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), xylosyl and glucuronyltransferase 1 (LARGE1), xylosyl and glucuronyltransferase 2 (LARGE2), phosphodelmannosyltransferase Mutations in genes of a group consisting of dolichol phosphomannosyltransferase subunit 1 (DPM1), dolichol phosphomannosyltransferase subunit 2 (DPM2), dolichol phosphomannosyltransferase subunit 3 (DPM3), Fukutin, Fukutin-related protein (FKRP), isoprenoid synthase domain-containing protein (ISPD), protein O-mannokinase (POMK), β-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2), β-1,4-glucuronosyltransferase 1 (B4GAT1), dolichol kinase (DOLK), transmembrane protein 5 (TMEM5), and GDP-mannose pyrophosphorylase B (GMPPB).

[0423] 184. A method according to any one of items 179-183, wherein the bispecific binding molecule is administered by intravenous infusion.

[0424] 185. A method according to any one of items 179-183, wherein the bispecific binding molecule is administered by intramuscular, intraperitoneal or subcutaneous injection.

[0425] 186. A method according to any one of items 179-185, wherein the individual is a human.

[0426] 187. A pharmaceutical composition comprising the bispecific binding molecule according to any one of items 95-170 and a pharmaceutically acceptable carrier.

[0427] 188. A kit for use in treating or preventing alpha-dystroglycanopathy in an individual comprising the bispecific binding molecule according to any one of items 95-170 and instructions.

[0428] 189. The kit of claim 188, wherein the individual has reduced expression of alpha-dystroglycan.

[0429] 190. The kit of item 188, wherein the alpha-dystroglycan expressed in the individual has impaired or abnormal O-glycosylation.

[0430] 191. The kit of claim 188, wherein the individual has an enzyme selected from the group consisting of dystroglycan (DAG1), protein O-mannosyltransferase-1 (POMT1), protein O-mannosyltransferase-2 (POMT2), protein O-linked mannose beta 1,2-N-acetylglucosaminyltransferase subunit 1 (POMGNT1), protein O-linked mannose beta 1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), xylosyl and glucuronosyltransferase 1 (LARGE1), xylosyl and glucuronosyltransferase 2 (LARGE2), phosphodelphinol mannosyltransferase subunit 1 (POMGNT1), protein O-linked mannose beta 1,4-N-acetylglucosaminyltransferase subunit 2 (POMGNT2), Mutations in genes of a group consisting of dolichol kinase (DOLK), transmembrane protein 5 (TMEM5), phosphodolyl mannosyltransferase subunit 1 (DPM1), phosphodolyl mannosyltransferase subunit 2 (DPM2), phosphodolyl mannosyltransferase subunit 3 (DPM3), Fukutin, Fukutin-related protein (FKRP), isoprenoid synthase domain-containing protein (ISPD), protein O-mannokinase (POMK), β-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2), β-1,4-glucuronosyltransferase 1 (B4GAT1), dolichol kinase (DOLK), transmembrane protein 5 (TMEM5), and GDP-mannose pyrophosphorylase B (GMPPB) were detected.

[0431] 192. The kit of any one of items 188-191, wherein the individual is a human. BRIEF DESCRIPTION OF THE DRAWINGS

[0432] Figure 1A and 1B Normal protein interactions and functions of the dystrophin-associated glycoprotein complex are shown. O-linked glycans in the mucin-like domain of α-dystroglycan serve as receptors for several ligands, including laminin-2 in muscle. Figure 1A A dystrophin-associated glycoprotein complex is shown, with normal O-glycosylation of dystroglycan. Figure 1B Laminin-2 in the basement membrane is shown interacting with O-glycosylated α-dystroglycan. β-dystroglycan interacts with dystrophin, which in turn binds to filamentous actin in the cell membrane.

[0433] Figure 1C The etiology of α-dystroglycanopathy is revealed. In the absence of O-linked glycosylation on α-dystroglycan, the binding of laminin-2 to α-dystroglycan is lost, leading to detachment of the basement membrane from the sarcolemma of the muscle and resulting in membrane damage and muscular dystrophy during exercise.

[0434] Figure 1D and 1E The present invention shows a strategy for treating α-dystroglycan disease using multispecific or bispecific antibodies. The bispecific and multispecific antibodies specifically recognize and bind laminin-2 with one or more arms and specifically recognize and bind α-dystroglycan with one or more other arms. Figure 1D ) or β-dystroglycan ( Figure 1E ), thereby restoring the connection between laminin-2 and dystroglycan in order to treat α-dystroglycanopathy.

[0435] Figure 2A A sequence alignment of the human and mouse laminin globular (LG)-4 / 5 domains is shown. The protein sequences of human and mouse LG-5 share significant homology, with 88% identity. Boxed sequences from the α-2 subunit of human and mouse laminin-2 were used for protein expression and antibody generation. SEQ ID NOs: 305 (top) and 300 (bottom) are shown. Figure 2B A sequence alignment of the extracellular domains of human and mouse β-dystroglycan (DG) is shown. The protein sequences of the human and mouse β-DG extracellular domains are homologs with 88.4% identity. Boxed sequences in human and mouse β-DG were used for protein expression and antibody generation. SEQ ID NOs: 303 (top) and 304 (bottom) are shown.

[0436] Figure 3A and 3B Shows the relationship with people ( Figure 3A ) and mice ( Figure 3B ) Surface plasmon resonance (Biacore; GE Healthcare) kinetic data of LG-4 / 5 binding to an anti-laminin-2 antibody derived from hybridoma clone C21.

[0437] Figure 3C Shown is fluorescence-activated cell sorting (FACS) analysis of anti-laminin-2 antibodies derived from hybridoma clone C21 binding to human and mouse LG-4 / 5 expressed on HEK293 cells.

[0438] Figure 3D Shown are dot blots of varying amounts of recombinant human laminin-2, murine LG-5 (mLG5), human LG-5 (hLG5), and human LG-4 / 5 (hLG4 / LG5) spotted onto nitrocellulose and probed with an anti-laminin-2 antibody derived from hybridoma clone C21. The amount of laminin-2 in C2C12 cell lysates was below the limit of detection.

[0439] Figure 3E and3F Shows the relationship with people ( Figure 3F ) and mice ( Figure 3G ) Surface plasmon resonance (Biacore; GE Healthcare) kinetic data of LG-4 / 5 binding to an anti-laminin-2 antibody derived from hybridoma clone C3.

[0440] Figure 3G Shown is fluorescence-activated cell sorting (FACS) analysis of anti-laminin-2 antibodies derived from hybridoma clone C3 binding to human and mouse LG-4 / 5 expressed on HEK293 cells.

[0441] Figure 3H Shown are dot blots of varying amounts of recombinant human laminin-2 (Hu 211), murine LG-5 (mLG5), human LG-5 (hLG5), and human LG-4 / 5 (hLG4 / LG5) spotted onto nitrocellulose and probed with an anti-laminin-2 antibody derived from hybridoma clone C3. The amount of laminin-2 in C2C12 cell lysates was below the limit of detection.

[0442] Figure 3I and 3J Shows the relationship with people ( Figure 3I ) and mice ( Figure 3J ) Surface plasmon resonance (Biacore; GE Healthcare) kinetic data of β-DG binding to an anti-β-DG antibody derived from hybridoma clone AS30.

[0443] Figure 3K Shown are dot blots of varying amounts of recombinant murine β-DG ECD (mβDG), human β-DG ECD (HuβDG), or recombinant dystroglycan (rhDG) spotted on nitrocellulose and probed with anti-β-DG antibodies derived from hybridoma clone AS30. βDG levels in C2C12 cell lysates and tibialis anterior muscle cell lysates (TA lysates) were below the limit of detection. Fabryase (agalsidase beta, Genzyme) was used as a negative control.

[0444] Figure 3LShown is a Western blot of samples generated by immunoprecipitation of β-DG from C2C12 cell lysates using an anti-β-DG antibody derived from hybridoma clone AS30. The first lane shows a positive control, the second lane shows an immunoprecipitated sample probed with an anti-β-DG antibody derived from phage display clone B06 (which has low affinity for βDG and therefore minimal pull-down of βDG and α-DG), and the third lane shows an immunoprecipitated sample probed with a high-affinity anti-β-DG antibody derived from hybridoma clone AS30 (in which abundant βDG and α-DG were immunoprecipitated).

[0445] Figure 3M and 3N Shows the relationship with people ( Figure 3M ) and mice ( Figure 3N ) Surface plasmon resonance (Biacore; GE Healthcare) kinetic data of β-DG binding to an anti-β-DG antibody derived from hybridoma clone AS19.

[0446] Figure 3O Dot blots showing different amounts of recombinant mouse β-DG ECD, human β-DG ECD, or recombinant dystroglycan spotted on nitrocellulose and probed with anti-β-DG antibodies derived from hybridoma clone AS19. C2C12 cell lysate, tibialis anterior muscle cell lysate (TA lysate). Fabryase (agalsidase beta, Genzyme) was used as a negative control.

[0447] Figure 3P Shown is a Western blot of samples generated by immunoprecipitation of β-DG from C2C12 cell lysates using an anti-β-DG antibody derived from hybridoma clone AS19. The first lane shows a positive control, the second lane shows an immunoprecipitated sample probed with an anti-β-DG antibody derived from phage display clone B06 (which has low affinity for βDG and therefore minimal pull-down of βDG and α-DG), and the third lane shows an immunoprecipitated sample probed with an anti-β-DG antibody derived from hybridoma clone AS19.

[0448] Figure 4A and 4B Shown are unfixed frozen sections of human and mouse muscle tissue, which were stained with a protein derived from the hybridoma clone C21 ( Figure 4A ) and C3( Figure 4B ) were stained with an anti-laminin-2 antibody and then detected with a fluorescently labeled anti-mouse IgG secondary antibody. However, the secondary antibody did not reveal any staining (not shown).

[0449] Figure 4C and4D Shown are unfixed frozen sections of human and mouse muscle tissue, which were stained with a protein derived from the hybridoma clone AS30 ( Figure 4C ) and AS19( Figure 4D ) were stained with an anti-β-DG antibody and then detected with a fluorescently labeled anti-mouse IgG secondary antibody. However, the secondary antibody alone did not reveal any staining (not shown).

[0450] Figure 5A Shown is a schematic design of a tetravalent bispecific tandem IgG format antibody (TBTI antibody) specific for β-DG and laminin-2 according to some embodiments.

[0451] Figure 5B Shown is a schematic design of a crossover dual variable domain IgG format (CODV) bispecific antibody specific for β-DG and laminin-2 according to some embodiments.

[0452] Figure 6A and 6B Targeting human LG-4 / 5 and human β-DG ( Figure 6A ) or against mouse LG-4 / 5 and mouse β-DG ( Figure 6B Sequential surface plasmon resonance (Biacore; GE Healthcare) binding analysis data of parental monoclonal antibodies (AS19, C3, and C21) and bispecific antibodies (T1T2, C5C6, and T5T6).

[0453] Figure 7 Results of a double-layer sandwich ELISA showing simultaneous binding of LG-4 / 5 and β-DG to bispecific antibodies are shown. Binding of the parental monoclonal antibodies (AS19, C3, and C21) with or without the addition of β-DG was measured, as well as the bispecific antibodies (T1T2, C5C6, or T5T6). Only the bispecific antibodies T1T2, T5T6, and C5C6 showed significant simultaneous binding to LG-4 / 5 and β-DG.

[0454] Figure 8A and 8B Wild-type mouse muscle tissue ( Figure 8A ) or LARGE myd-3J / GrsrJ Mouse muscle tissue ( Figure 8B ) were stained with parental monoclonal antibodies (AS19, C3, and C21) or bispecific antibodies (T1T2, C5C6, or T5T6) and detected with a fluorescently labeled anti-mouse IgG secondary antibody.

[0455] Figure 8CThe bispecific antibody was injected intramuscularly into LARGE myd-3J / GrsrJ The tibialis anterior (TA) muscles of mice were injected with Evans blue dye (EB) on day 5 to track muscle fiber damage. The mice underwent forced treadmill exercise and were sacrificed on day 6.

[0456] Figure 8D Shown are the average numbers of Evans blue positive (i.e. damaged) myofibers treated with the bispecific antibody T1T2 versus a mixture of parental monoclonal antibodies (AS19 and C3). Less damage was seen with the bispecific antibody treatment than with the control parental antibody treatment.

[0457] Figure 8E LARGE cells treated with the bispecific antibody T1T2 or a mixture of parental monoclonal antibodies (AS19 and C3) were shown to myd-3J / GrsrJ Stained muscle tissue of mice. Evans blue dye staining (arrows) is much more pronounced in tissue treated with the parental monoclonal antibodies compared to the bispecific antibody T1T2. Staining using a fluorescent secondary antibody is shown for the bispecific antibody T1T2 or a mixture of parental monoclonal antibodies (AS19 and C3).

[0458] Figure 8F The pharmacokinetics and biodistribution of the bispecific antibody T1T2 after systemic delivery (by tail vein injection or intraperitoneal administration) and the parental antibody derived from hybridoma clones AS19 or C3 are shown. The bispecific antibody was still detectable in the blood 4 days after administration.

[0459] Figures 9A to 9C Wild-type mice (downward-pointing triangles), LARGE mice treated with control monoclonal parental antibody are shown. myd-3J / GrsrJ LARGE in mice (upward-pointing triangles) and bispecific antibody therapy myd-3J / GrsrJ Behavioral testing of mice (squares). Figure 9A Shown with untreated LARGE myd-3J / GrsrJ Compared to mice treated with bispecific antibodies, the myd-3J / GrsrJ The mice showed improvements in grip strength tests. Figure 9B Shown with untreated LARGE myd-3J / GrsrJ Compared to mice treated with bispecific antibodies, the myd-3J / GrsrJ The mice showed improvement in the wire hanging test. Figure 9C Shown with untreated LARGE myd-3J / GrsrJ Compared to mice treated with bispecific antibodies, the myd-3J / GrsrJ The mice showed improvements in a running time test.

[0460] Figure 9D Shown with untreated LARGE myd-3J / GrsrJ Compared to mice treated with bispecific antibodies, the myd -3J / GrsrJ The mice had reduced creatine kinase levels, indicating less muscle damage.

[0461] Figure 10 The results show that the LARGE myd-3J / GrsrJ The average number of Evans blue positive (i.e. damaged) muscle fibers in the tissues of mice. Wild-type untreated mice (Group 3WT) were used as controls. myd-3J / GrsrJ In mice treated with the bispecific antibody T1T2, less damage was seen than with the control parental antibody.

[0462] Figure 11 Shown are the LARGE expression levels 4 days after injection of bispecific antibody T1T2, parental monoclonal antibodies AS19 or C3, or PBS as a negative control. myd-3J / GrsrJ Immunofluorescence staining of mouse tissues. Slides were washed and mounted using Vectashield mounting medium with DAPI (Vector Labs). IV: intravenous injection; IP: intraperitoneal injection.

[0463] Figure 12A The overall structure of AS30 Fab bound to the antigen human β-DG is shown, with the antigen shown between the heavy and light chains. Figure 12B A close-up view of the interaction between the CDRs of AS30 Fab and the antigen β-DG is shown. The residues involved in the interaction are shown as sticks; the arrows in the CDRs indicate the direction from the N-terminus to the C-terminus.

[0464] Figure 12C The overall structure of C21 Fab bound to the antigen human laminin-2 LG-5 domain is shown, with the antigen shown between the heavy and light chains. Figure 12D A close-up view of the interaction between the CDRs of C21 Fab and the antigen laminin-2 LG-5 domain is shown. The residues involved in the interaction are shown as sticks; the arrows in the CDRs indicate the direction from the N-terminus to the C-terminus.

[0465] Figure 13 Shown is a schematic diagram of a trivalent binding protein (triAb) comprising four polypeptide chains forming three antigen binding sites for binding laminin-2 or β-DG, according to some embodiments.

[0466] Figure 14A and 14B Shown are the results of a double-binding sandwich ELISA assay testing the binding of triAb to human LG4 / 5 or β-DG. Figure 14A In the experiment, biotinylated N'Avi-HPC4-human LG4 / 5 was used to coat the plate and detect the binding to human β-DG. Figure 14B In the assay, plates were coated with human β-DG-HPC4-Avi-C' and binding to human LG4 / 5 was detected.

[0467] Figure 14C The sequential binding of triAb 3407, 3437, or 3439 to human LG4 / 5 and then to human β-DG is shown. In contrast, the monovalent anti-LG4 / 5 antibodies C3_Hu11, C21_Hu11, C21_Hu21, and C3_Hu10 bound only to LG4 / 5, while the monovalent anti-β-DG antibody AS30_Hu6 bound only to β-DG, and the negative control triAb showed no binding.

[0468] Figure 15 The effect of treatment with triAb 3407, 3437, or 3439 on LARGE myd-3J / GrsrJ Effects on muscle function in mice. Administration of the indicated triAbs was compared to administration of saline or a negative control triAb. Performance of wild-type mice in the assay was also measured.

[0469] Figure 16 The effects of treatment with triAb 3407, 3437, or 3439 on LARGE myd -3J / GrsrJ Effects on muscle function in mice. Administration of the indicated triAbs was compared to administration of saline or a negative control triAb. Performance of wild-type mice in the assay was also measured.

[0470] Figure 17 The effect of treatment with triAb 3407, 3437, or 3439 on LARGE myd-3J / GrsrJ Effects on muscle function in mice. Administration of the indicated triAbs was compared to administration of saline or a negative control triAb. Performance of wild-type mice in the assay was also measured. Detailed Description of the Invention

[0471] The present disclosure provides multispecific and bispecific binding molecules comprising a first binding domain that binds to the extracellular portion of dystrophin and a second binding domain that binds to laminin-2. In some embodiments, the binding molecule is bispecific and comprises a first binding domain that binds to the extracellular portion of dystrophin and a second binding domain that binds to laminin-2. In some embodiments, the binding molecule is multispecific and comprises a first binding domain that binds to the extracellular portion of dystrophin, a second binding domain that binds to laminin-2, and one or more additional binding domains that bind to one or more additional targets. The present disclosure provides a variety of configurations of multispecific / bispecific binding molecules that are capable of simultaneously binding to dystrophin and laminin-2 and improving the symptoms of α-dystrophin disease in an in vivo model system.

[0472] The following description sets forth exemplary methods, parameters, etc. However, it should be recognized that such description is not intended to limit the scope of the present disclosure, but is instead provided as a description of exemplary embodiments.

[0473] definition

[0474] Unless otherwise indicated, as used in accordance with this disclosure, the following terms shall be understood to have the following meanings: Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0475] As used herein, the term "antigen" or "target antigen" or "antigen target" refers to a molecule or portion of a molecule that can be bound by a binding protein and which can also be used to raise antibodies in an animal that can bind to an epitope of the antigen. A target antigen may have one or more epitopes. For each target antigen recognized by a binding protein, the binding protein is capable of competing with an intact antibody that recognizes the target antigen. Exemplary target antigens described herein include dystroglycan (e.g., an extracellular portion thereof) and laminin-2.

[0476] The term "epitope" includes any determinant, such as a polypeptide determinant, that is capable of specific binding to an immunoglobulin or T-cell receptor. In certain embodiments, epitope determinants include chemically active surface groups of molecules, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and in certain embodiments, may have specific three-dimensional structural characteristics and / or specific charge characteristics. An epitope is a region of an antigen that is bound by an antibody or binding protein. In certain embodiments, a binding protein is considered to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and / or macromolecules. In some embodiments, an epitope is considered to specifically bind an antigen when the equilibrium dissociation constant is ≤10 -6 M, for example, when the equilibrium dissociation constant is ≤10 -9M, and for example when the dissociation constant is ≤10 -10 When M, the binding protein is considered to specifically bind the antigen.

[0477] For example, the dissociation constant (K) of a binding protein can be determined by surface plasmon resonance. D Typically, surface plasmon resonance analysis uses a BIAcore system (Pharmacia Biosensor; Piscataway, NJ) to measure the real-time binding interaction between a ligand (target antigen on a biosensor matrix) and an analyte (binding protein in solution) by surface plasmon resonance (SPR). Surface plasmon analysis can also be performed by immobilizing the analyte (binding protein on a biosensor matrix) and presenting the ligand (target antigen). As used herein, the term "K D ” refers to the dissociation constant of the interaction between a specific binding protein and its target antigen.

[0478] As used herein, the term "specifically binds" refers to a binding protein or antigen-binding fragment thereof with a specific binding affinity of at least about 1 x 10 -6 M, 1x 10 -7 M, 1x 10 -8 M, 1x 10 -9 M, 1x 10 -10 M, 1x 10 -11 M, 1x 10 -12 M, or larger K D The ability to bind to an antigen containing the epitope and / or to bind to the epitope with an affinity at least two times greater than its affinity for a nonspecific antigen.

[0479] As used herein, the term "binding protein" refers to a non-naturally occurring (or recombinant or engineered) molecule that specifically binds to at least one target antigen.

[0480] The term "monospecific binding protein" refers to a binding protein that specifically binds to one antigenic target.

[0481] The term "monovalent binding protein" refers to a binding protein with one antigen binding site.

[0482] The term "bispecific binding protein" refers to a binding protein that specifically binds to two different antigenic targets. Bispecific or bifunctional antibodies are generally artificial hybrid antibodies with two different heavy chain / light chain pairs and two different binding sites or epitopes. Bispecific antibodies can be produced by a variety of methods, including but not limited to fusion of hybridomas or linking of F(ab') fragments.

[0483] The term "bivalent binding protein" refers to a binding protein having two binding sites or domains.

[0484] As used herein, term " polynucleotide " refers to a single-stranded or double-stranded nucleic acid polymer with a length of at least 10 nucleotides. In certain embodiments, the nucleotides constituting the polynucleotides can be modified forms of ribonucleotides or deoxyribonucleotides or any class of nucleotides. Such modifications include base modifications such as bromouridine, ribose modifications such as arabinoside and 2', 3'-dideoxyribose, and internucleotide connections modified such as phosphorothioate, phosphorodithioate, selenophosphate, diselenphosphate, anilinothioate (phosphoroanilothioate), anilinophosphate (phoshoraniladate) and phosphoramidate. Term " polynucleotide " specifically includes single-stranded and double-stranded forms of DNA.

[0485] An "isolated polynucleotide" is a polynucleotide of genomic, cDNA, or synthetic origin, or some combination thereof, that: (1) is not associated with all or part of a polynucleotide in which the isolated polynucleotide occurs in nature, (2) is linked to a polynucleotide to which the isolated polynucleotide is not linked in nature, or (3) does not occur in nature as part of a larger sequence.

[0486] An "isolated polypeptide" is one that (1) is free of at least some other polypeptides with which it is normally found, (2) is substantially free of other polypeptides from the same source, e.g., from the same species, (3) is expressed by cells from a different species, (4) is separated from at least about 50% of the polynucleotides, lipids, carbohydrates, or other substances with which it is associated in nature, (5) is not associated (by covalent or non-covalent interactions) with portions of a polypeptide to which the "isolated polypeptide" is associated in nature, (6) is operably associated (by covalent or non-covalent interactions) with a polypeptide to which it is not associated in nature, or (7) does not occur in nature. Such an isolated polypeptide can be encoded by genomic DNA, cDNA, mRNA, or other RNA of a synthetic origin, or any combination thereof. In some embodiments, an isolated polypeptide is substantially free of polypeptides or other contaminants found in its natural environment that would interfere with its use (therapeutic, diagnostic, prophylactic, research, or otherwise).

[0487] Naturally occurring antibodies generally comprise tetramers. Each such tetramer is generally composed of two identical pairs of polypeptide chains, each pair having one full-length "light chain" (typically having a molecular weight of about 25 kDa) and one full-length "heavy chain" (typically having a molecular weight of about 50-70 kDa). The terms "heavy chain" and "light chain" as used herein refer to any immunoglobulin polypeptide having a variable domain sequence sufficient to confer specificity for a target antigen. The amino terminal portion of each light and heavy chain typically comprises a variable domain of about 100 to 110 or more amino acids that is typically responsible for antigen recognition. The carboxyl terminal portion of each chain typically defines the constant domains that are responsible for effector function. Thus, in naturally occurring antibodies, a full-length heavy chain immunoglobulin polypeptide comprises one variable domain (V H ) and three constant domains (C H1 、C H2 and C H3 ), where V H The domain is located at the amino terminus of the polypeptide and the C H3 The variable domain is located at the carboxyl terminus, and the full-length light chain immunoglobulin polypeptide includes a variable domain (V L ) and a constant domain (C L ), where V L The domain is located at the amino terminus of the polypeptide and the C L The domain is located at the carboxyl terminus.

[0488] Human light chains are generally classified as kappa and lambda light chains, and human heavy chains are generally classified as μ, δ, γ, α, or ε, and the isotype of the antibody is defined as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses, including but not limited to IgG1, IgG2, IgG3, and IgG4. IgM has subclasses, including but not limited to IgM1 and IgM2. Similarly, IgA is further divided into subclasses, including but not limited to IgA1 and IgA2. Within the full-length light and heavy chains, the variable domains and constant domains are generally connected by a "J" region of about 12 or more amino acids, wherein the heavy chain also includes a "D" region of about 10 or more amino acids. See, for example, Fundamental Immunology (Paul, W., ed., Raven Press, 2nd edition, 1989), which is incorporated herein by reference for all purposes. The variable region of each light chain / heavy chain pair generally forms an antigen binding site. The variable domains of naturally occurring antibodies typically display the same general structure of relatively conservative framework regions (FRs) connected by three hypervariable regions (also referred to as complementary determining regions or CDRs). The CDRs from each pair of two chains are typically aligned by the framework regions, which can enable them to bind to specific epitopes. From amino-terminal to carboxyl-terminal, the light chain variable domain and the heavy chain variable domain typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0489] The term "CDR set" refers to the group of three CDRs present in a single variable region capable of binding an antigen. The exact boundaries of these CDRs are defined differently according to different systems. The system described by Kabat (Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) provides not only an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries that define the three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia and Lesk, 1987, J. Mol. Biol. 196:901-17; Chothia et al., 1989, Nature 342:877-83) found that certain subportions within the Kabat CDRs adopt nearly identical peptide backbone conformations despite having enormous diversity at the amino acid sequence level. These subportions are designated L1, L2, and L3 or H1, H2, and H3, where "L" and "H" denote the light and heavy chain regions, respectively. These regions may be referred to as Chothia CDRs, which have similarities to the Kabat CDRs. Boundaries of overlapping CDRs. Other boundaries defining CDRs that overlap with Kabat CDRs have been described by Padlan, 1995, FASEB J. 9: 133-39; MacCallum, 1996, J. Mol. Biol. 262(5): 732-45; and Lefranc, 2003, Dev. Comp. Immunol. 27: 55-77. Still other definitions of CDR boundaries may not strictly follow one of the systems herein, but still overlap with Kabat CDRs, but they may be shortened or lengthened based on predictions or experimental findings that particular residues or groups of residues, or even entire CDRs, do not significantly affect antigen binding. Although certain embodiments use CDRs defined by Kabat or Chothia, the methods used herein can utilize CDRs defined according to any of these systems. The use of amino acid sequences to identify predicted CDRs is well known in the art, for example, as cited in Martin, AC "Protein sequence and structure analysis of antibody variable domains," In Antibody Engineering, Vol. 2. Kontermann R., Dübel S., eds. Springer-Verlag, Berlin, pp. 33–51 (2010).The amino acid sequence of heavy chain and / or light chain variable domain can also be checked by other conventional methods to identify the sequence of CDR, which method is for example determined by comparing with the known amino acid sequences of other heavy chain and light chain variable regions. The numbered sequences can be aligned by visual inspection, or aligned by using an alignment program such as one of the CLUSTAL program suites, as described in Thompson, 1994, Nucleic Acids Res. 22: 4673-80. Molecular modeling is routinely used to correctly depict framework and CDR regions, thereby correcting sequence-based allocation.

[0490] The term "Fc" as used herein refers to a molecule comprising a non-antigen binding fragment sequence produced by antibody digestion or produced by other means, and is either a monomer or a polymer form, and can contain a hinge region. In some embodiments, the original immunoglobulin source of natural Fc is human-derived and can be any immunoglobulin, such as IgG1 and IgG2. Fc molecules are composed of monomeric polypeptides that can be connected into dimer or multimeric form by covalent (i.e., disulfide bond) and non-covalent binding. Depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgGA2), the number of intermolecular disulfide bonds between the monomer subunits of natural Fc molecules is 1 to 4. An example of Fc is a disulfide bonded dimer produced by papain digestion of IgG. The term "Fc" as used herein is general for monomer, dimer, and multimeric form.

[0491] F(ab) fragments usually contain a light chain and a heavy chain V H and C H1 domain, wherein the V H -C H1 The heavy chain portion cannot form disulfide bonds with another heavy chain polypeptide. As used herein, a F(ab) fragment may also include a light chain containing two variable domains separated by an amino acid linker, and a light chain containing two variable domains separated by an amino acid linker and a C H1 A heavy chain with two variable domains separated by a domain.

[0492] The F(ab') fragment usually consists of a light chain and a portion of a heavy chain containing the more constant region (C H1 and C H2 domains), allowing for the formation of an interchain disulfide bond between the two heavy chains to form a F(ab')2 molecule.

[0493] A "recombinant" molecule is a molecule that has been prepared, expressed, produced, or isolated by recombinant means.

[0494] One embodiment of the present disclosure provides the biological and immunological specific binding proteins for one and three target antigens.Another embodiment of the present disclosure provides the nucleic acid molecules comprising the nucleotide sequence encoding the polypeptide chain forming such binding proteins.Another embodiment of the present disclosure provides an expression vector comprising the nucleic acid molecules comprising the nucleotide sequence encoding the polypeptide chain forming such binding proteins.Another embodiment of the present disclosure provides the host cell expressing such binding proteins (that is, comprising the nucleic acid molecules or vector encoding the polypeptide chain forming such binding proteins).

[0495] As used herein, the term "interchangeability" refers to the interchangeability of variable domains within a binding protein format, and wherein folding and ultimate binding affinity are preserved. "Fully interchangeable" refers to the ability to exchange V domains in a polypeptide chain of Formula I or a polypeptide chain of Formula II. H1 and V H2 The order of the domains is thus swapped L1 and V L2 The ability to modify the order of the domains (i.e., to reverse the order) while maintaining full functionality of the binding protein, as evidenced by retention of binding affinity. H and V L Refers only to the position of a domain on a particular protein chain in its final form. For example, V H1 and V H2 Can be derived from V in parent antibody L1 and V L2 domain and is placed in the V H1 and V H2 Position. Similarly, V L1 and V L2 Can be derived from V in parent antibody H1 and V H2 domain and is placed in the V H1 and V H2 position. Therefore, V H and V L The names refer to the current position, not the original position in the parent antibody. H and V L The domains are thus "exchangeable".

[0496] An "isolated" binding molecule or protein is one that has been identified and separated and / or recovered from a component of its natural environment. Contaminating components of its natural environment are substances that would interfere with the diagnostic or therapeutic use of the binding protein and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, the binding molecule or protein will be purified: (1) to greater than 95% by weight of the antibody as determined by the Lowry Method, and in some embodiments greater than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to a degree of homogeneity by SDS-PAGE performed under reducing or non-reducing conditions using Coomassie Brilliant Blue or silver stain. An isolated binding molecule or protein includes the molecule / protein in situ within recombinant cells since at least one component of the natural environment will not be present.

[0497] As used herein, the term "substantially pure" or "substantially purified" refers to a compound or species that is present as a major species (i.e., on a molar basis, it is more abundant than any other individual species in the composition). In some embodiments, a substantially purified portion is a composition wherein the species comprises at least about 50% (on a molar basis) of all macromolecular species present. In other embodiments, a substantially pure composition will comprise greater than about 80%, 85%, 90%, 95%, or 99% of all macromolecular species present in the composition. In still other embodiments, the species is purified to basic homogeneity (contaminant species cannot be detected in the composition by conventional detection methods), wherein the composition consists essentially of a single macromolecular species.

[0498] As used herein, the term "vector" refers to any molecule (e.g., nucleic acid, plasmid or virus) for transferring coding information to a host cell. The term "vector" includes nucleic acid molecules that can transport another nucleic acid connected thereto. One type of vector is a "plasmid," which refers to a circular double-stranded DNA molecule into which another DNA segment can be inserted. Another type of vector is a viral vector, in which another DNA segment can be inserted into the viral genome. Certain vectors (e.g., bacterial vectors and additional mammalian vectors with bacterial replication origins) can replicate autonomously in the host cell into which they are introduced. Other vectors (e.g., non-additional mammalian vectors) are integrated into the genome of the host cell after being introduced into the host cell, thereby replicating together with the host genome. In addition, certain vectors can guide the expression of genes operably connected thereto. Such vectors are referred to herein as "recombinant expression vectors" (or simply as "expression vectors"). Generally speaking, the expression vectors used in recombinant DNA technology are often in the form of plasmids. The terms "plasmid" and "vector" are used interchangeably herein because plasmids are the most commonly used vector forms. However, the disclosure is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), that serve equivalent functions.

[0499] As used herein, the phrase "recombinant host cell" (or "host cell") refers to a cell into which a recombinant expression vector has been introduced. Recombinant host cell or host cell is expected to mean not only a specific subject cell, but also the offspring of such a cell. Due to mutation or environmental influences, certain modifications may occur in subsequent generations, and in fact such offspring may be different from the parent cell, but such cells are still included in the scope of the term "host cell" used in this article. Various host cell expression systems can be used for expressing the binding protein, including bacteria, yeast, baculovirus and mammalian expression systems (and phage display expression systems). The example of a suitable bacterial expression vector is pUC19. In order to recombinantly express the binding protein, the host cell is transformed or transfected with one or more recombinant expression vectors carrying the DNA fragments of the polypeptide chain encoding the binding protein so that the polypeptide chain is expressed in the host cell and secreted into the culture medium for cultivating the host cell, from which the binding protein can be recovered.

[0500] As used herein, the term "conversion" refers to the change of cellular genetic characteristics, and the cell has been transformed when it is modified to contain new DNA. For example, when the cell undergoes genetic modification from its native state, the cell is transformed. After conversion, the transforming DNA can be physically integrated into the cell chromosome and recombined with the DNA of the cell, or can be maintained for a short period of time as an additional element and not replicated, or can be replicated independently as a plasmid. When DNA is replicated along with cell division, it is believed that the cell has been stably transformed. As used herein, the term "transfection" refers to the uptake of external or exogenous DNA by the cell, and when exogenous DNA has been introduced into the cell membrane, the cell has been "transfected." Many transfection techniques are well known in the art. Such technology can be used for introducing one or more exogenous DNA molecules into suitable host cells.

[0501] As used herein and as applied to an object, the term "naturally occurring" refers to the fact that the object can be found in nature but has not been manipulated by humans. For example, a polynucleotide or polypeptide present in an organism (including a virus) that can be isolated from a source in nature but has not been intentionally modified by humans is naturally occurring. Similarly, as used herein, "non-naturally occurring" refers to an object that is not found in nature or has been structurally modified or synthesized by humans.

[0502] As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. Stereoisomers of the twenty conventional amino acids (e.g., D-amino acids); non-natural amino acids and analogs, such as α-, α-disubstituted amino acids, N-alkyl amino acids, lactic acid and other unconventional amino acids can also be suitable components of the binding protein polypeptide chain. Examples of unconventional amino acids include: 4-hydroxyproline, γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ-N-methylarginine and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In accordance with standard usage and convention, in the polypeptide symbols used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl terminal direction.

[0503] Naturally occurring residues can be divided into several categories based on common side chain properties:

[0504] (1) Hydrophobic: Met, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Pro;

[0505] (2) Polar hydrophilic: Arg, Asn, Asp, Gln, Glu, His, Lys, Ser, Thr;

[0506] (3) Aliphatic: Ala, Gly, Ile, Leu, Val, Pro;

[0507] (4) Aliphatic hydrophobic: Ala, Ile, Leu, Val, Pro;

[0508] (5) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

[0509] (6) Acidic: Asp, Glu;

[0510] (7) Basic: His, Lys, Arg;

[0511] (8) Residues that affect chain orientation: Gly, Pro;

[0512] (9) Aromatic: His, Trp, Tyr, Phe; and

[0513] (10) Aromatic hydrophobic: Phe, Trp, Tyr.

[0514] Conservative amino acid substitutions may involve exchanging a member of one of these classes with another member of the same class. Non-conservative substitutions may involve exchanging a member of one of these classes with a member of another class.

[0515] The skilled artisan will be able to determine suitable variants of the binding protein polypeptide chain using well-known techniques. For example, one skilled in the art can identify appropriate regions of the polypeptide chain that can be altered without destroying the activity by targeting regions that are thought to be unimportant for activity. Alternatively, one skilled in the art can identify residues and portions of the molecule that are conserved among similar polypeptides. Additionally, conservative amino acid substitutions can be made even in regions that may be important for biological activity or structure without destroying the biological activity or adversely affecting the structure of the polypeptide.

[0516] As used herein, the term "patient" (the terms "individual" and "subject" are used interchangeably herein) includes human and animal (e.g., mammals, including but not limited to dogs, cats and other domestic pets; horses, cows, goats, rabbits, buffalo and other livestock; and research animals, such as non-human primates, mice, etc.) subjects.

[0517] In some embodiments, the terms "treatment" or "treat" as used herein refer to therapeutic management, such as reducing or alleviating the severity or presence of one or more symptoms.

[0518] In other embodiments, the term "prevention" as used herein may refer to prophylactic or preventative measures, such as preventing or delaying the onset of one or more symptoms, such as in an individual at risk for developing a pathological condition described herein.

[0519] As used herein, the term "pharmaceutical composition" or "therapeutic composition" refers to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient.

[0520] As used herein, the term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" refers to one or more formulation materials suitable for achieving or enhancing the delivery of a binding protein.

[0521] The terms "effective amount" and "therapeutically effective amount," when used in reference to a pharmaceutical composition comprising one or more binding proteins, refer to an amount or dosage sufficient to produce the desired therapeutic result. More specifically, a therapeutically effective amount is an amount of a binding protein sufficient to inhibit one or more clinically defined pathological processes associated with the condition being treated for a period of time. The effective amount can vary depending on the specific binding protein used and also depends on various factors and conditions associated with the patient being treated and the severity of the condition. For example, if the binding protein is to be administered in vivo, factors such as the patient's age, weight, and health, as well as dose-response curves and toxicity data obtained in preclinical animal work, will be among those factors to be considered. Determination of the effective amount or therapeutically effective amount of a given pharmaceutical composition is well within the capabilities of those skilled in the art.

[0522] One embodiment of the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a binding molecule.

[0523] Binding molecules

[0524] Certain aspects of the present disclosure relate to multispecific binding molecules comprising one or more binding domains that bind to the extracellular portion of dystroglycan and one or more binding domains that bind to laminin-2. In some embodiments, the multispecific binding molecule is a multispecific binding protein comprising one or more polypeptide chains. In some embodiments, the multispecific binding molecule is a bivalent or tetravalent bispecific binding molecule comprising two or four antigen binding sites. In some embodiments, the multispecific binding molecule is a trivalent multispecific binding molecule comprising three antigen binding sites. The terms "binding domain" and "binding site" are used interchangeably herein.

[0525] Various forms and configurations of multispecific binding proteins are known in the art and are suitable for use as described herein. A description of exemplary and non-limiting forms is provided below. Any form described in International Publication No. WO2017 / 180913 and its optional features can be used in the binding proteins described herein (e.g., multispecific binding proteins).

[0526] Multispecific trivalent binding protein

[0527] In some embodiments, the binding protein is a multispecific binding protein. In some embodiments, the multispecific binding protein is a trivalent binding protein comprising three antigen binding sites and co-targeting two or more target antigens. In some embodiments, the binding protein (e.g., a multispecific binding protein) comprises four polypeptide chains, wherein the first polypeptide chain comprises a structure represented by the following formula:

[0528] V L2 -L1-V L1 -L2-C L [I]

[0529] And the second polypeptide chain comprises a structure represented by the following formula:

[0530] V H1 -L3-V H2 -L4-C H1 -Hinge-C H2 -C H3 [II]

[0531] And the third polypeptide chain comprises a structure represented by the following formula:

[0532] V H3 -C H1 -Hinge-C H2 -C H3 [III]

[0533] And the fourth polypeptide chain comprises a structure represented by the following formula:

[0534] V L3 -C L [IV]

[0535] in:

[0536] V L1 is the first immunoglobulin light chain variable domain;

[0537] V L2 is the second immunoglobulin light chain variable domain;

[0538] V L3 is the third immunoglobulin light chain variable domain;

[0539] V H1 is the first immunoglobulin heavy chain variable domain;

[0540] V H2 is a second immunoglobulin heavy chain variable domain;

[0541] V H3 is the third immunoglobulin heavy chain variable domain;

[0542] C L is the immunoglobulin light chain constant domain;

[0543] C H1 Immunoglobulin C H1 heavy chain constant domain;

[0544] C H2 Immunoglobulin C H2 heavy chain constant domain;

[0545] C H3 Immunoglobulin C H3 heavy chain constant domain;

[0546] The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and

[0547] L1, L2, L3 and L4 are amino acid linkers.

[0548] In some embodiments, the polypeptide of Formula I and the polypeptide of Formula II form a crossover light chain-heavy chain pair. H1 and V L1 Forming antigen binding site, V H2 and V L2 Form an antigen binding site, and V H3 and V L3 Forming antigen binding sites, a total of three antigen binding sites. In some embodiments, the three antigen binding sites include at least one antigen binding site that binds to the extracellular portion of dystroglycan and at least one antigen binding site that binds to laminin-2 (e.g., one antigen binding site that binds to the extracellular portion of dystroglycan and two antigen binding sites that bind to laminin-2, or two antigen binding sites that bind to the extracellular portion of dystroglycan and one antigen binding site that binds to laminin-2).

[0549] In some embodiments, the two antigen binding sites that bind laminin-2 bind to different epitopes of laminin-2. In some embodiments, the two antigen binding sites that bind laminin-2 bind to the same epitope or overlapping epitopes of laminin-2. In some embodiments, V H1 and V L1 Forms the first antigen binding site for laminin-2, V H2 and V L2 Forms a second antigen binding site that binds laminin-2, and V H3 and V L3 Forms a third antigen binding site that binds to the extracellular portion of dystroglycan.

[0550] In some embodiments, the two antigen binding sites that bind to the extracellular portion of dystroglycan bind to different epitopes of the extracellular portion of dystroglycan. In some embodiments, the two antigen binding sites that bind to the extracellular portion of dystroglycan bind to the same epitope or overlapping epitopes of the extracellular portion of dystroglycan. In some embodiments, V H1 and V L1 Forms the first antigen binding site that binds to the extracellular portion of dystroglycan, V H2 and V L2 Forms a second antigen binding site that binds to the extracellular portion of dystroglycan, and V H3 and V L3 Forms a third antigen binding site that binds laminin-2.

[0551] Any of the antigen binding sites described herein can be used in a binding protein (e.g., a multispecific binding protein) described herein, including, but not limited to, a binding protein comprising a polypeptide according to Formula I, II, III, and / or IV described above.

[0552] In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises: a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence GFTFTDSV (SEQ ID NO: 316), a CDR-H2 comprising the sequence IYPGSGNF (SEQ ID NO: 318), and a CDR-H3 comprising the sequence AMRRSS (SEQ ID NO: 320); and a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence QTIVHSNSKTY (SEQ ID NO: 332), a CDR-L2 comprising the sequence KVS (SEQ ID NO: 334), and a CDR-L3 comprising the sequence FQGSHVPLT (SEQ ID NO: 336). In some embodiments, the VH and VL domains form an antigen binding site that binds to the extracellular portion of dystroglycan (e.g., VL). H1 and V L1 、V H2 and V L2 or V H3 and V L3 In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises 1, 2, 3, 4, 5, or 6 CDR sequences of antibody AS30SS_Hu6 or AS30SS_Hu9 shown in Table A2.

[0553] In some embodiments, the VH and / or VL domains are humanized. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 314 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 330. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 346 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 362. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises the VH and / or VL domain sequences of antibodies AS30SS_Hu6 or AS30SS_Hu9 shown in Table D2. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a VH domain encoded by the polynucleotide sequence of SEQ ID NO: 306 and / or a VL domain encoded by the polynucleotide sequence of SEQ ID NO: 322. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a VH domain encoded by the polynucleotide sequence of SEQ ID NO: 338 and / or a VL domain encoded by the polynucleotide sequence of SEQ ID NO: 354.

[0554] In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises: a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence GFTFSSYT (SEQ ID NO: 380), a CDR-H2 comprising the sequence ISSSGSNT (SEQ ID NO: 382), and a CDR-H3 comprising the sequence ARFDYGSSLDS (SEQ ID NO: 384); and a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence QSISNN (SEQ ID NO: 396), a CDR-L2 comprising the sequence YAS (SEQ ID NO: 398), and a CDR-L3 comprising the sequence QQSKSWPRT (SEQ ID NO: 400). In some embodiments, the VH and VL domains form an antigen binding site that binds laminin-2 (e.g., VL). H1 and V L1 、V H2 and V L2 , or V H3 and V L3 In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises 1, 2, 3, 4, 5, or 6 CDR sequences of antibody C3_Hu10 shown in Table A2.

[0555] In some embodiments, the VH and / or VL domains are humanized. In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 378 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 394. In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise the VH and / or VL domain sequences of the antibody C3_Hu10 shown in Table D2. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a VH domain encoded by the polynucleotide sequence of SEQ ID NO: 370 and / or a VL domain encoded by the polynucleotide sequence of SEQ ID NO: 386.

[0556] In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises: a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence GFTFSSYT (SEQ ID NO: 380), a CDR-H2 comprising the sequence ISSSGSNT (SEQ ID NO: 382), and a CDR-H3 comprising the sequence ARFDYGSSLDS (SEQ ID NO: 384); and a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence QSIGNN (SEQ ID NO: 428), a CDR-L2 comprising the sequence YAS (SEQ ID NO: 398), and a CDR-L3 comprising the sequence QQSKSWPRT (SEQ ID NO: 400). In some embodiments, the VH and VL domains form an antigen binding site that binds laminin-2 (e.g., VL). H1 and V L1 、V H2 and V L2 or V H3 and V L3 In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises 1, 2, 3, 4, 5, or 6 CDR sequences of antibody C3_Hu11 shown in Table A2.

[0557] In some embodiments, the VH and / or VL domains are humanized. In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 410 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 426. In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise the VH and / or VL domain sequences of the antibody C3_Hu11 shown in Table D2. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a VH domain encoded by the polynucleotide sequence of SEQ ID NO:402 and / or a VL domain encoded by the polynucleotide sequence of SEQ ID NO:418.

[0558] In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises: a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence GFTFSSYT (SEQ ID NO: 444), a CDR-H2 comprising the sequence ISSSGSNT (SEQ ID NO: 446), and a CDR-H3 comprising the sequence ARFDYGSSLDS (SEQ ID NO: 448); and a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence QSISNY (SEQ ID NO: 460), a CDR-L2 comprising the sequence YAS (SEQ ID NO: 462), and a CDR-L3 comprising the sequence QQSKSWPRT (SEQ ID NO: 464). In some embodiments, the VH and VL domains form an antigen binding site that binds laminin-2 (e.g., VL). H1 and V L1 、V H2 and V L2 or V H3 and V L3 In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises 1, 2, 3, 4, 5, or 6 CDR sequences of antibody C21_Hu11 shown in Table A2.

[0559] In some embodiments, the VH and / or VL domains are humanized. In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 442 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 458. In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise the VH and / or VL domain sequences of antibody C21_Hu11 shown in Table D2. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a VH domain encoded by the polynucleotide sequence of SEQ ID NO: 434 and / or a VL domain encoded by the polynucleotide sequence of SEQ ID NO: 450.

[0560] In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises: a heavy chain variable domain (VH) comprising a CDR-H1 comprising the sequence GFTFSSYT (SEQ ID NO: 444), a CDR-H2 comprising the sequence ISSSGDNT (SEQ ID NO: 478), and a CDR-H3 comprising the sequence ARFDYGSSLDS (SEQ ID NO: 448); and a light chain variable domain (VL) comprising a CDR-L1 comprising the sequence QSISNY (SEQ ID NO: 460), a CDR-L2 comprising the sequence YAS (SEQ ID NO: 462), and a CDR-L3 comprising the sequence QQSKSWPRT (SEQ ID NO: 464). In some embodiments, the VH and VL domains form an antigen binding site that binds laminin-2 (e.g., VL). H1 and V L1 、V H2 and V L2 , or V H3 and V L3 In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises 1, 2, 3, 4, 5, or 6 CDR sequences of antibody C21_Hu21 shown in Table A2.

[0561] In some embodiments, the VH and / or VL domains are humanized. In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 474 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 490. In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise the VH and / or VL domain sequences of the antibody C21_Hu21 shown in Table D2. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a VH domain encoded by the polynucleotide sequence of SEQ ID NO: 466 and / or a VL domain encoded by the polynucleotide sequence of SEQ ID NO: 482.

[0562] In some embodiments, V H1comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Containing the sequence SEQ ID NO: 378, V L1 Containing the sequence SEQ ID NO: 394; V H2 Containing the sequence SEQ ID NO: 378, V L2 comprising the sequence SEQ ID NO: 394; and V H3 Containing the sequence SEQ ID NO: 314, V L3 comprising the sequence of SEQ ID NO: 330. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises: a first polypeptide chain comprising the sequence of SEQ ID NO: 500, a second polypeptide chain comprising the sequence of SEQ ID NO: 498, a third polypeptide chain comprising the sequence of SEQ ID NO: 499, and a fourth polypeptide chain comprising the sequence of SEQ ID NO: 501. In some embodiments, the binding protein comprises 1, 2, 3, or 4 polypeptide chains of triAb 3407, e.g., as shown in Table 12 or 14.

[0563] In some embodiments, V H1comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 446, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Containing the sequence SEQ ID NO: 378, V L1 Containing the sequence SEQ ID NO: 394; V H2 Containing the sequence SEQ ID NO:442, V L2 comprising the sequence SEQ ID NO: 458; and V H3 Containing the sequence SEQ ID NO: 314, V L3 comprising the sequence of SEQ ID NO: 330. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a first polypeptide chain comprising the sequence of SEQ ID NO: 504, a second polypeptide chain comprising the sequence of SEQ ID NO: 502, a third polypeptide chain comprising the sequence of SEQ ID NO: 503, and a fourth polypeptide chain comprising the sequence of SEQ ID NO: 505. In some embodiments, the binding protein comprises 1, 2, 3, or 4 polypeptide chains of triAb 3423, e.g., as shown in Table 12 or 14.

[0564] In some embodiments, V H1comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 478, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Contains the sequence SEQ ID NO:410, V L1 Containing the sequence SEQ ID NO:426; V H2 Containing the sequence SEQ ID NO: 474, V L2 comprising the sequence SEQ ID NO: 490; and V H3 Containing the sequence SEQ ID NO: 314, V L3 comprising the sequence of SEQ ID NO: 330. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a first polypeptide chain comprising the sequence of SEQ ID NO: 508, a second polypeptide chain comprising the sequence of SEQ ID NO: 506, a third polypeptide chain comprising the sequence of SEQ ID NO: 507, and a fourth polypeptide chain comprising the sequence of SEQ ID NO: 509. In some embodiments, the binding protein comprises 1, 2, 3, or 4 polypeptide chains of triAb 3429, e.g., as shown in Tables 12 or 14.

[0565] In some embodiments, V H1comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 446, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 428, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Containing the sequence SEQ ID NO:442, V L1 Containing the sequence SEQ ID NO: 458; V H2 Contains the sequence SEQ ID NO:410, V L2 comprising the sequence SEQ ID NO: 426; and V H3 Contains the sequence SEQ ID NO: 314, and V L3 comprising the sequence of SEQ ID NO: 330. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a first polypeptide chain comprising the sequence of SEQ ID NO: 512, a second polypeptide chain comprising the sequence of SEQ ID NO: 510, a third polypeptide chain comprising the sequence of SEQ ID NO: 511, and a fourth polypeptide chain comprising the sequence of SEQ ID NO: 513. In some embodiments, the binding protein comprises 1, 2, 3, or 4 polypeptide chains of triAb 3437, e.g., as shown in Tables 12 or 14.

[0566] In some embodiments, V H1comprising a CDR-H1 comprising the sequence of SEQ ID NO: 444, a CDR-H2 comprising the sequence of SEQ ID NO: 478, and a CDR-H3 comprising the sequence of SEQ ID NO: 448, and V L1 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 460, a CDR-L2 comprising the sequence of SEQ ID NO: 462, and a CDR-L3 comprising the sequence of SEQ ID NO: 464; V H2 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 380, a CDR-H2 comprising the sequence of SEQ ID NO: 382, ​​and a CDR-H3 comprising the sequence of SEQ ID NO: 384, and V L2 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 396, a CDR-L2 comprising the sequence of SEQ ID NO: 398, and a CDR-L3 comprising the sequence of SEQ ID NO: 400; and V H3 comprising a CDR-H1 comprising the sequence of SEQ ID NO: 316, a CDR-H2 comprising the sequence of SEQ ID NO: 318, and a CDR-H3 comprising the sequence of SEQ ID NO: 320, and V L3 comprising a CDR-L1 comprising the sequence of SEQ ID NO: 332, a CDR-L2 comprising the sequence of SEQ ID NO: 334, and a CDR-L3 comprising the sequence of SEQ ID NO: 336. In some embodiments, V H1 Containing the sequence SEQ ID NO: 474, V L1 Containing the sequence SEQ ID NO: 490; V H2 Containing the sequence SEQ ID NO: 378, V L2 comprising the sequence SEQ ID NO: 394; and V H3 Containing the sequence SEQ ID NO: 314, V L3 comprising the sequence of SEQ ID NO: 330. In some embodiments, a binding protein (e.g., a multispecific binding protein) of the present disclosure comprises a first polypeptide chain comprising the sequence of SEQ ID NO: 516, a second polypeptide chain comprising the sequence of SEQ ID NO: 514, a third polypeptide chain comprising the sequence of SEQ ID NO: 515, and a fourth polypeptide chain comprising the sequence of SEQ ID NO: 517. In some embodiments, the binding protein comprises 1, 2, 3, or 4 polypeptide chains of triAb 3439, e.g., as shown in Tables 12 or 14.

[0567] Bispecific binding proteins

[0568] In some embodiments, the binding protein is a bispecific binding protein. In some embodiments, the bispecific binding protein is a bivalent binding protein comprising two antigen binding sites and co-targeting two target antigens. In some embodiments, the bispecific binding protein is a tetravalent binding protein comprising four antigen binding sites and co-targeting two target antigens.

[0569] In some embodiments, the bispecific binding molecule comprises a first binding domain that binds to the extracellular portion of dystroglycan and a second binding domain that binds laminin-2, wherein the first binding domain comprises a first immunoglobulin heavy chain variable domain (V H1 ) and the first immunoglobulin light chain variable domain (V L1 ), wherein the second binding domain comprises a second immunoglobulin heavy chain variable domain (V H2) and a second immunoglobulin light chain variable domain (V L2 In some embodiments, the bispecific binding molecule is a bispecific binding protein, such as a bispecific antibody.

[0570] In some embodiments, the bispecific binding molecule comprises four polypeptide chains that form four antigen binding sites, wherein two of the polypeptide chains comprise a structure represented by the following formula:

[0571] V L1 -L1-V L2 -L2-C L [I]

[0572] And the two polypeptide chains contain the structure represented by the following formula:

[0573] V H2 -L3-V H1 -L4-C H1 -Hinge-C H2 -C H3 [II]

[0574] in:

[0575] V L1 is the first immunoglobulin light chain variable domain;

[0576] V L2 is the second immunoglobulin light chain variable domain;

[0577] V H1 is the first immunoglobulin heavy chain variable domain;

[0578] V H2 is a second immunoglobulin heavy chain variable domain;

[0579] C Lis the immunoglobulin light chain constant domain;

[0580] C H1 Immunoglobulin C H1 heavy chain constant domain;

[0581] C H2 Immunoglobulin C H2 heavy chain constant domain;

[0582] C H3 Immunoglobulin C H3 heavy chain constant domain;

[0583] The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and

[0584] L1, L2, L3, and L4 are amino acid linkers;

[0585] Where V H1 and V L1 Domain formation V H1 / V L1 Combining pairs, and where V H2 and V L2 Domain formation V H2 / V L2 Combined pair.

[0586] In some embodiments, Formula I and Formula II describe the arrangement of domains within each polypeptide chain in order from N-terminus to C-terminus. In some embodiments, one or more polypeptide chains may comprise additional one or more sequences, for example, at the N-terminus or C-terminus.

[0587] For exemplary descriptions of this format, see, for example, International Publication No. WO 2012 / 135345, US Patent No. 9,221,917, and European Patent No. EP 2 691 416 Bl.

[0588] In some embodiments, the bispecific binding molecule comprises two polypeptide chains according to Formula II comprising the sequence SEQ ID NO: 530 and two polypeptide chains according to Formula I comprising the sequence SEQ ID NO: 531. In some embodiments, the bispecific binding molecule comprises two polypeptide chains according to Formula II comprising the sequence SEQ ID NO: 532 and two polypeptide chains according to Formula I comprising the sequence SEQ ID NO: 533. In some embodiments, the binding protein comprises two polypeptide chains as shown in Tables I3 or I4 for AS30_Hu9xC3_Hu11 CODV or AS30_Hu9xC21_Hu21 CODV. In some embodiments, the binding protein comprises a variable domain comprising 1, 2, 3, 4, 5, or 6 CDR sequences as shown in Table A2. In some embodiments, the binding protein comprises 1, 2, 3, or 4 variable domains as shown in Tables D2, I3, or I4.

[0589] In some embodiments, V H1 / V L1 Binds to the extracellular portion of dystroglycan, and V H2 / V L2 In other embodiments, V H2 / V L2 Binds to the extracellular portion of dystroglycan, and V H1 / V L1 The binding pair binds to laminin-2.

[0590] In some embodiments of any of the multispecific and / or bispecific binding molecules described above, the polypeptide of Formula I and the polypeptide of Formula II form a crossover light chain-heavy chain pair. H1 and V L1 Domains intersect to form V H1 / V L1 In some embodiments, V H2 and V L2 Domains intersect to form V H2 / V L2Binding pair. In some embodiments, the term linker as used herein in the above form refers to one or more amino acid residues inserted between immunoglobulin domains, thereby providing sufficient mobility for the domains of the light chain and heavy chain to fold into a cross-double variable region immunoglobulin. Linkers are inserted at the transition between variable domains or between variable domains and constant domains at the sequence level. The transition between domains can be identified because the approximate size of immunoglobulin domains is well understood. As demonstrated by experimental data, or as can be assumed by modeling or secondary structure prediction techniques, the precise position of the domain transition can be determined by locating peptide segments that do not form secondary structural elements such as β-sheets or α-helices. Linkers L1, L2, L3, and L4 are independent, but they may have the same sequence and / or length in some cases.

[0591] In some embodiments, the linkers of the present disclosure comprise the sequence DKTHT (SEQ ID NO: 534). In some embodiments, L1 and L2 comprise the sequence DKTHT (SEQ ID NO: 534). In some embodiments, L3 and L4 comprise the sequence DKTHT (SEQ ID NO: 534). In some embodiments, L1, L2, L3, and L4 comprise the sequence DKTHT (SEQ ID NO: 534). Any linker and linker combination described in International Publication No. WO2017 / 180913 can be used in the binding proteins described herein (e.g., multispecific binding proteins).

[0592] In some embodiments, L1, L2, L3 and L4 are each 0 to 50 amino acid residues in length, 0 to 40 amino acid residues in length, 0 to 30 amino acid residues in length, 0 to 25 amino acid residues in length, 0 to 20 amino acid residues in length, 0 to 18 amino acid residues in length, 0 to 16 amino acid residues in length, or 0 to 14 amino acid residues in length. In some embodiments, the length of the linkers L1, L2, L3 and L4 ranges from no amino acids (length = 0) to about 100 amino acids, or less than 100, 50, 40, 30, 20 or 15 amino acids or less. The linker length can also be 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid. L1, L2, L3 and L4 in a binding protein can all have the same amino acid sequence or can all have different amino acid sequences.

[0593] In certain embodiments, L1 is 5 amino acid residues in length, L2 is 5 amino acid residues in length, L3 is 5 amino acid residues in length, and L4 is 5 amino acid residues in length. In certain embodiments, L1 is 14 amino acid residues in length, L2 is 2 amino acid residues in length, L3 is 14 amino acid residues in length, and L4 is 2 amino acid residues in length. In some embodiments, L1 and L3 each comprise the sequence EPKSDKTHTSPPSP (SEQ ID NO: 296), and / or L2 and L4 each comprise the sequence GG. In certain embodiments, L1 is 7 amino acid residues in length, L2 is 5 amino acid residues in length, L3 is 1 amino acid residue in length, and L4 is 2 amino acid residues in length. In some embodiments, L1 comprises the sequence GQPKAAP (SEQ ID NO: 297), L2 comprises the sequence TKGPS (SEQ ID NO: 298), L3 comprises a serine residue (e.g., sequence S), and L4 comprises the sequence RT. In certain embodiments, L1 is 10 amino acid residues in length, L2 is 10 amino acid residues in length, L3 is 0 amino acid residues in length, and L4 is 0 amino acid residues in length. In some embodiments, L1 and L2 each comprise the sequence GGSGSSGSGG (SEQ ID NO: 299).

[0594] In some embodiments, one or both of the two variable domains of the polypeptide of Formula I and / or Formula II are human, humanized, or mouse variable domains.

[0595] In some embodiments, the bispecific binding molecule comprises two light chains comprising a structure represented by the following formula:

[0596] V L1 -L5-V L2 -L6-C L [III]

[0597] and two heavy chains comprising the structure represented by the following formula:

[0598] V H1 -L7-V H2 -L8-C H1 -Hinge-C H2 -C H3 [IV]

[0599] in:

[0600] V L1 is the first immunoglobulin light chain variable domain;

[0601] V L2 is the second immunoglobulin light chain variable domain;

[0602] V H1 is the first immunoglobulin heavy chain variable domain;

[0603] V H2 is a second immunoglobulin heavy chain variable domain;

[0604] C L is the immunoglobulin light chain constant domain;

[0605] C H1 Immunoglobulin C H1 heavy chain constant domain;

[0606] C H2 Immunoglobulin C H2 heavy chain constant domain;

[0607] C H3 Immunoglobulin C H3 heavy chain constant domain;

[0608] The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and

[0609] L5, L6, L7, and L8 are amino acid linkers;

[0610] Where V H1 and V L1 Domain formation V H1 / V L1 Combining pairs, and where V H2 and V L2 Domain formation V H2 / V L2 Combined pair.

[0611] In some embodiments, Formula III and Formula IV describe the arrangement of domains within each polypeptide chain in order from N-terminus to C-terminus. In some embodiments, one or more of these polypeptide chains may contain additional one or more sequences, for example, at the N-terminus or C-terminus.

[0612] For an exemplary description of this form, see, for example, US PG Publication No. US20130209469.

[0613] In some embodiments, the bispecific binding molecule comprises two heavy chains comprising the sequence of SEQ ID NO: 522 and two light chains comprising the sequence of SEQ ID NO: 523. In some embodiments, the bispecific binding molecule comprises two heavy chains comprising the sequence of SEQ ID NO: 528 and two light chains comprising the sequence of SEQ ID NO: 529. In some embodiments, the binding protein comprises two polypeptide chains as shown in Tables I3 or I4 for AS30_Hu6xC3_Hu10 or AS30_Hu6xC21_Hu11. In some embodiments, the binding protein comprises a variable domain comprising one, two, three, four, five, or six of the CDR sequences shown in Table A2. In some embodiments, the binding protein comprises one, two, three, or four of the variable domains shown in Tables D2, I3, or I4.

[0614] In some embodiments, V H1 / V L1 Binds to the extracellular portion of dystroglycan, and V H2 / V L2 In other embodiments, V H2 / V L2 Binds to the extracellular portion of dystroglycan, and V H1 / V L1 The binding pair binds to laminin-2.

[0615] In some embodiments, one or both of the two variable domains of the polypeptide of Formula III and / or Formula IV are human, humanized, or mouse variable domains.

[0616] connector

[0617] In some embodiments, L5, L6, L7 and L8 are each 0 to 50 amino acid residues in length, 0 to 40 amino acid residues in length, 0 to 30 amino acid residues in length, 0 to 25 amino acid residues in length, 0 to 20 amino acid residues in length, 0 to 18 amino acid residues in length, 0 to 16 amino acid residues in length, or 0 to 14 amino acid residues in length. In some embodiments, the length of the linkers L5, L6, L7 and L8 ranges from no amino acids (length = 0) to about 100 amino acids, or less than 100, 50, 40, 30, 20 or 15 amino acids or less. The linker length can also be 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid. L5, L6, L7 and L8 in a binding protein can all have the same amino acid sequence or can all have different amino acid sequences.

[0618] In some embodiments, the linkers of the present disclosure comprise the sequence DKTHT (SEQ ID NO: 534). In some embodiments, L1 and L2 comprise the sequence DKTHT (SEQ ID NO: 534). In some embodiments, L3 and L4 comprise the sequence DKTHT (SEQ ID NO: 534). In some embodiments, L1, L2, L3, and L4 comprise the sequence DKTHT (SEQ ID NO: 534). Any linker and linker combination described in International Publication No. WO2017 / 180913 can be used in the binding proteins described herein (e.g., multispecific binding proteins).

[0619] In some embodiments, L1, L2, L3 and L4 are each 0 to 50 amino acid residues in length, 0 to 40 amino acid residues in length, 0 to 30 amino acid residues in length, 0 to 25 amino acid residues in length, 0 to 20 amino acid residues in length, 0 to 18 amino acid residues in length, 0 to 16 amino acid residues in length, or 0 to 14 amino acid residues in length. In some embodiments, the length of the linkers L1, L2, L3 and L4 ranges from no amino acids (length = 0) to about 100 amino acids, or less than 100, 50, 40, 30, 20 or 15 amino acids or less. The linker length can also be 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid. L1, L2, L3 and L4 in a binding protein can all have the same amino acid sequence or can all have different amino acid sequences.

[0620] In certain embodiments, L1 is 5 amino acid residues in length, L2 is 5 amino acid residues in length, L3 is 5 amino acid residues in length, and L4 is 5 amino acid residues in length. In certain embodiments, L1 is 14 amino acid residues in length, L2 is 2 amino acid residues in length, L3 is 14 amino acid residues in length, and L4 is 2 amino acid residues in length. In some embodiments, L1 and L3 each comprise the sequence EPKSDKTHTSPPSP (SEQ ID NO: 296), and / or L2 and L4 each comprise the sequence GG. In certain embodiments, L1 is 7 amino acid residues in length, L2 is 5 amino acid residues in length, L3 is 1 amino acid residue in length, and L4 is 2 amino acid residues in length. In some embodiments, L1 comprises the sequence GQPKAAP (SEQ ID NO: 297), L2 comprises the sequence TKGPS (SEQ ID NO: 298), L3 comprises a serine residue (e.g., sequence S), and L4 comprises the sequence RT. In certain embodiments, L1 is 10 amino acid residues in length, L2 is 10 amino acid residues in length, L3 is 0 amino acid residues in length, and L4 is 0 amino acid residues in length. In some embodiments, L1 and L2 each comprise the sequence GGSGSSGSGG (SEQ ID NO: 299).

[0621] In certain embodiments, the L5 and L7 linkers comprise the amino acid sequence GGGGSGGGGS (SEQ ID NO: 294), and / or the L6 and L8 linkers are each 0 amino acid residues in length.

[0622] The examples listed above (e.g., for L1, L2, L3, L4, L5, L6, L7, or L8) are not intended to limit the scope of the present disclosure in any way, and linkers comprising randomly selected amino acids selected from valine, leucine, isoleucine, serine, threonine, lysine, arginine, histidine, aspartic acid, glutamic acid, asparagine, glutamine, glycine, and proline are suitable for use in binding proteins.

[0623] The identity of the amino acid residue in the joint and sequence can depend on the type of secondary structure element that needs to realize in the joint and change.For example, glycine, serine and alanine are used for flexible joints.If need more rigid extended joint, some combinations of glycine, proline, threonine and serine are useful so.Any amino acid residue can be considered as the joint in combination with other amino acid residues, so that according to the property of expectation, bigger peptide joint is built when needed.

[0624] Constant / Fc region

[0625] In some embodiments, the binding proteins of the present disclosure (e.g., multispecific binding proteins) comprise a "knob" mutation on the second polypeptide chain and a "hole" mutation on the third polypeptide chain. In some embodiments, the binding proteins of the present disclosure comprise a "knob" mutation on the third polypeptide chain and a "hole" mutation on the second polypeptide chain. In some embodiments, the "knob" mutation is included in a substitution at a position corresponding to position 354 and / or 366 of human IgG1 or IgG4 according to the EU index. In some embodiments, the amino acid substitution is S354C, T366W, T366Y, S354C and T366W, or S354C and T366Y. In some embodiments, the "knob" mutation is included in a substitution at a position corresponding to position 354 and 366 of human IgG1 or IgG4 according to the EU index. In some embodiments, the amino acid substitution is S354C and T366W. In some embodiments, the "hole" mutation is included in a substitution at a position corresponding to position 407 of human IgG1 or IgG4 according to the EU index and optionally 349, 366 and / or 368. In some embodiments, the amino acid substitution is Y407V or Y407T and optionally Y349C, T366S and / or L368A. In some embodiments, the "hole" mutation comprises substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to the EU index. In some embodiments, the amino acid substitution is Y349C, T366S, L368A, and Y407V.

[0626] In some embodiments, the C of the second polypeptide chain H3 The domain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to the EU index (e.g., S354C and T366W); and C of the third polypeptide chain H3 The domain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to the EU index (e.g., Y349C, T366S, L368A, and Y407V). H3 The domain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to the EU index (e.g., Y349C, T366S, L368A, and Y407V); and C of the third polypeptide chain H3 The domain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to the EU index (eg, S354C and T366W).

[0627] In some embodiments, the binding protein of the present disclosure (e.g., multispecific binding protein) comprises one or more mutations to improve purification, for example, by adjusting the affinity for purification reagents. For example, it is known that if one of the two Fc regions of the heterodimer form contains a mutation that reduces or eliminates binding to protein A, the heterodimer binding protein can selectively leave their homodimer form and be purified, because the heterodimer form has a moderate affinity for protein A-based purification compared to any homodimer form and can be selectively eluted from protein A by, for example, using different pH values ​​(see, for example, Smith, EJ et al. (2015) Sci. Rep. 5: 17943). In some embodiments, the first and / or second Fc region is a human IgG1 Fc region. In some embodiments, the first and / or second Fc region is a human IgG4 Fc region. In some embodiments, the mutation is included in a substitution at a position corresponding to position 435 and 436 of human IgG1 or IgG4 according to the EU index, wherein the amino acid substitution is H435R and Y436F. In some embodiments, the C of the second and third polypeptide chains H3 The domain is human IgG1 or IgG4 C H3 domain, and only one C H3 The domain comprises amino acid substitutions at positions corresponding to positions 435 and 436 of human IgG1 or IgG4 according to the EU index (eg, H435R and Y436F). In some embodiments, the binding proteins of the present disclosure comprise knob and hole mutations and one or more mutations that improve purification.

[0628] In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise one or more mutations that increase half-life, such as in vivo half-life. In some embodiments, the binding proteins comprise one or more mutations described in U.S. Patent No. 7,083,784. For example, in some embodiments, the C of the second and third polypeptide chains is H2 The domain is human IgG1 or IgG4 C H2 A domain comprising a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256, numbered according to the EU index.

[0629] In some embodiments, the binding proteins (e.g., multispecific binding proteins) of the present disclosure comprise one or more mutations that result in an Fc region with altered glycosylation and / or reduced effector function. In some embodiments, the binding proteins comprise one or more mutations described in U.S. Patent No. 9,790,268. For example, in some embodiments, the C of the second and third polypeptide chains is H2 The domain is human IgG1 or IgG4 C H2A domain comprising an asparagine residue at position 297, an asparagine residue at position 298, an alanine residue at position 299, and a serine or threonine residue at position 300, numbered according to the EU index.

[0630] Another bispecific binding protein platform considered for use herein is described in US PG Publication No. US2013 / 0039913 and Labrijn, AF et al., (2013) Proc.Natl.Acad.Sci.110:5145-5150. In this method, each binding domain is produced in a homodimer form and then assembled in vitro to form a heterodimer bispecific binding protein. This method uses specific mutations (for example, in antibody CH3 domains) to promote Fab arm exchange, thereby producing a heterodimer binding protein that is more stable than any homodimer form. In some embodiments, according to the EU index described in Kabat et al., these mutations occur in, for example, positions 366, 368, 370, 399, 405, 407 and / or 409. Specific mutations are described in more detail in US PG Publication No. US2013 / 0039913 and Labrijn, AF et al., (2013) Proc. Natl. Acad. Sci. 110:5145-5150.

[0631] Additional bispecific binding protein platforms contemplated for use herein are briefly described below. One strategy proposed by Carter et al. (Ridgway et al., 1996, Protein Eng. 9(7):617-21; Carter, 2011, J. Immunol. Methods 248(1-2):7-15) utilizes the C H3 A set of "knob-into-hole" mutations in the Fc domains generate Fc heterodimers. These mutations result in a conserved hydrophobic core C H3 Alterations in the stacking complementarity of residues between the domain interfaces, thereby favoring the formation of heterodimers over homodimers, have resulted in good heterodimer expression from mammalian cell culture. Although this strategy resulted in higher heterodimer yields, homodimers were not completely suppressed (Merchant et al., 1998, Nat. Biotechnol. 16(7): 677-81).

[0632] In order to increase the yield of binding protein, in some embodiments, the C H3domains, a technique described in detail in several examples, such as International Publication No. WO 96 / 027011, Ridgway et al., 1996, Protein Eng. 9: 617-21; and Merchant et al., 1998, Nat. Biotechnol. 16: 677-81. Specifically, the two C H3 domains, thereby increasing the interaction surface of the two C H3 Heterodimerization of the two heavy chains of the domain. H3 Each of the domains can be a "knob" and the other a "hole." The introduction of disulfide bridges further stabilizes the heterodimer (Merchant et al., 1998; Atwell et al., 1997, J. Mol. Biol. 270:26-35) and increases yield. In certain embodiments, the knob is located on the CH3 domain of one polypeptide chain. In other embodiments, the knob is located on the first pair of polypeptides with a cross orientation. In still other embodiments, the CH3 domain is located on the first pair of polypeptides with a cross orientation. In still other embodiments, the CH3 domain is located on the first pair of polypeptides with a cross orientation. In yet ... H3 The domain does not contain a protuberance within the cavity.

[0633] In some embodiments, the binding proteins of the present disclosure comprise a "knob" mutation on one polypeptide chain and a "hole" mutation on another polypeptide chain. In some embodiments, the "knob" mutation comprises a substitution at positions corresponding to positions 354 and 366 of human IgG1 according to the EU index. In some embodiments, the amino acid substitutions are S354C and T366W. In some embodiments, the "hole" mutation comprises a substitution at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 according to the EU index. In some embodiments, the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

[0634] In some embodiments, the binding proteins of the present disclosure comprise one or more mutations that improve serum half-life (see, e.g., Hinton, PR et al., (2006) J. Immunol. 176(1):346-56). In some embodiments, the mutations comprise substitutions at positions corresponding to positions 428 and 434 of human IgG1 according to the EU index, wherein the amino acid substitutions are M428L and N434S. In some embodiments, the binding proteins of the present disclosure comprise knob and hole mutations and one or more mutations that improve serum half-life.

[0635] Another bispecific binding protein platform contemplated for use herein is the heterodimeric bivalent antibody Fc-containing format described in WO2011131746. Any antigen binding site described herein can be combined in this heterodimeric bispecific format. In some embodiments, the multispecific (e.g., bispecific) binding protein of the present disclosure comprises: a first heavy chain variable (VH) domain and a first C H3 a first antibody heavy chain comprising a first Fc region of an immunoglobulin having a first Fc region, and a first antibody light chain comprising a first light chain variable (VL) domain, wherein the first VH and VL domains form a first antigen binding domain that binds to the extracellular portion of dystroglycan, and a first antibody light chain comprising a second heavy chain variable (VH) domain and a second C H3 In some embodiments, the first and second C H3 The sequences of the regions are different, and the first and second C H3 The heterodimeric interaction between the first and second C H3 In some embodiments, the first homodimeric protein has an amino acid other than Lys, Leu or Met at position 409, the second homodimeric protein has an amino acid substitution at a position selected from 366, 368, 370, 399, 405 and 407, and / or the first and second C H3 The sequence of the region makes C H3 The dissociation constant of the homodimeric interaction of each region is between 0.01 and 10 micromolar. In some embodiments, the first antibody heavy chain comprises the sequence of SEQ ID NO: 518, the second antibody heavy chain comprises the sequence of SEQ ID NO: 519, the first antibody light chain comprises the sequence of SEQ ID NO: 520, and the second antibody light chain comprises the sequence of SEQ ID NO: 521. In some embodiments, the binding protein comprises two antibody light chains and two antibody heavy chains shown for the AS30_Hu6xC3_Hu10 duobody in Table 13.

[0636] Another bispecific binding protein platform contemplated for use herein is the "DuetMab" design (Mazor, Y. et al., (2015) MAbs 7:377-389). In short, the above-mentioned "knob-into-hole" approach is combined with replacing the native disulfide bonds in one of the CH1-CL interfaces with engineered disulfide bonds to improve the efficiency of pairing of homologous heavy and light chains. In some embodiments, according to Kabat numbering, the heavy chain of one binding domain has an F126C mutation, and the homologous light chain of the binding domain has an S121C mutation. For example, in some embodiments, the multispecific (e.g., bispecific) binding protein of the present disclosure comprises a first antibody heavy chain comprising the sequence SEQ ID NO: 524, a second antibody heavy chain comprising the sequence SEQ ID NO: 525, a first antibody light chain comprising the sequence SEQ ID NO: 526, and a second antibody light chain comprising the sequence SEQ ID NO: 527. In some embodiments, the binding protein comprises two antibody light chains and two antibody heavy chains shown for AS30_Hu6xC21_Hu11 duetmab in Table 13.

[0637] Gunasekaran et al. explored the effect of C H3 The feasibility of maintaining the integrity of the hydrophobic core while driving the formation of Fc heterodimers by charge complementarity at the domain interface (Gunasekaran et al., 2010, J. Biol. Chem. 285(25):19637-46). Utilizing an electrostatic steering mechanism, these constructs have been shown to effectively promote the formation of Fc heterodimers with minimal homodimer contamination by mutating two pairs of peripherally positioned charged residues. In contrast to the protuberance-into-cavity design, homodimerization is uniformly inhibited, but not completely avoided, due to the nature of the electrostatic repulsion mechanism.

[0638] Davis et al. described the use of human IgG and IgA C H3 This is an antibody engineering method that converts Fc homodimers into heterodimers by interdigitating the β-strands of the Fc domains without introducing additional interchain disulfide bonds (Davis et al., 2010, Protein Eng. Des. Sel. 23(4):195-202). The SEEDbody (Sb) fusion protein was expressed in mammalian cells to produce Sb heterodimers in high yields, which were easily purified to eliminate minor byproducts.

[0639] US Patent Application Publication No. US2010 / 331527A1 describes a C-based H3 A bispecific antibody with a heterodimerization domain, in which one heavy chain has a C H3 Mutations H95R and Y96F were introduced into the domain. These amino acid substitutions are derived from the CH3 domains and will heterodimerize with the IgG1 backbone. The common light chain that readily pairs with each heavy chain is based on the C H3 The desired heterodimer can be purified from this mixture because its binding properties to protein A differ from those of the parent antibody: the IgG3-derived C H3 The IgG1 domain does not bind to Protein A, whereas IgG1 does bind to Protein A. Thus, the heterodimer binds to Protein A but elutes at a higher pH than pure IgG1 homodimers, making it possible to selectively purify the bispecific heterodimer.

[0640] U.S. Patent No. 7,612,181 describes a dual variable domain IgG (DVD-IgG) bispecific antibody based on the dual Fv format described in U.S. Patent No. 5,989,830. Similar bispecific formats are also described in U.S. Patent Application Publication No. US2010 / 0226923A1. The constant domains are added to the corresponding chains (C H1 -Fc is added to the heavy chain, and kappa or lambda constant domains are added to the light chain) to produce functional bispecific antibodies without any additional modifications (i.e., obviously, constant domains are added to enhance stability). Some antibodies expressed in DVD-Ig / TBTI format show position effects on the second (or innermost) antigen binding site (Fv2). Depending on the sequence and properties of the antigen recognized by the Fv2 site, such antibody domains show reduced affinity for their antigen (i.e., loss of on-rate compared to the parent antibody). One possible explanation for this observation is that V L1 and V L2 The linker in between protrudes into the CDR regions of Fv2, making Fv2 somewhat inaccessible to larger antigens.

[0641] The second configuration of bispecific antibody fragments described in U.S. Patent No. 5,989,830 is a cross-over double-headed (CODH) structure in which the variable domains expressed on both chains have the following orientation:

[0642] For the light chain V L1 -Connector-V L2 ,and

[0643] For the heavy chain V H2 -Connector-V H1 .

[0644] CDR, VH and VL domain sequences

[0645] Described below are exemplary CDR, VH domain, and VL domain sequences that can be used in any number, combination, or configuration in any multispecific or bispecific binding protein of the disclosure.

[0646] In some embodiments of any of the forms described herein, the V H1 / V L1 The binding pair binds to the extracellular portion of dystroglycan, and the V H2 / V L2 The binding pair binds to laminin-2.

[0647] In some embodiments, V H1 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-17, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-27; and / or wherein V L1 The domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-37, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-42, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-50. In some embodiments of any of the forms described herein, V H1 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 170, 172, 174, 176, 178, 180, 182, 184, 186, and 188. In some embodiments, V L1 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 171, 173, 175, 177, 179, 181, 183, 185, 187, and 189. In some embodiments, V H1 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 230, 232, 234, 236, 238, 240, 242, 244, 246, and 248. In some embodiments, the V L1 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 231, 233, 235, 237, 239, 241, 243, 245, 247 and 249.

[0648] In some embodiments of any of the forms described herein, the V H1 / V L1 The binding pair binds to the extracellular portion of dystroglycan, and the V H2 / VL2 The binding pair binds to laminin-2 (e.g., laminin G-like (LG) domain 5 or LG-5). In some embodiments of any of the forms described herein, V H2 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-55, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-60, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-65; and / or wherein V L2 The V domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-70, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 71-75, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-80. H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 190, 192, 194, 196, and 198. In some embodiments, V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 191, 193, 195, 197, and 199. In some embodiments, V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 250, 252, 254, 256, and 258. In some embodiments, V L2 The domain is encoded by a nucleic acid sequence selected from SEQ ID NO: 251, 253, 255, 257 and 259.

[0649] In some embodiments of any of the forms described herein, the V H1 / V L1 The binding pair binds to the extracellular portion of dystroglycan, and the V H2 / V L2 The binding pair binds to laminin-2 (e.g., laminin G-like (LG) domains 4 and / or 5, or LG-4 / 5). In some embodiments of any of the forms described herein, V H2 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 81-95, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 96-110, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 111-125; and / or wherein V L2The V domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 126-140, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38 and SEQ ID NOs: 141-154, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 155-169. H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228. In some embodiments, V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, and 229. In some embodiments, V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, and 288. In some embodiments, V L2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287 and 289.

[0650] In some embodiments of any of the forms described herein, the V H2 / V L2 The binding pair binds to the extracellular portion of dystroglycan, and the V H1 / V L1 Binding to laminin-2. In some embodiments of any of the forms described herein, V H2 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-8, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-17, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 18-27; and / or wherein V L2 The domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-37, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-42, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-50. In some embodiments of any of the forms described herein, V H2The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 170, 172, 174, 176, 178, 180, 182, 184, 186, and 188. In some embodiments, V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 171, 173, 175, 177, 179, 181, 183, 185, 187, and 189. In some embodiments, V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 230, 232, 234, 236, 238, 240, 242, 244, 246, and 248. In some embodiments, the V L2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 231, 233, 235, 237, 239, 241, 243, 245, 247 and 249.

[0651] In some embodiments of any of the forms described herein, the V H2 / V L2 The binding pair binds to the extracellular portion of dystroglycan, and the V H1 / V L1 The binding pair binds to laminin-2 (e.g., laminin G-like (LG) domain 5 or LG-5). In some embodiments of any of the forms described herein, V H2 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-55, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-60, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-65; and / or wherein V L2 The V domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-70, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 71-75, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76-80. H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 190, 192, 194, 196, and 198. In some embodiments, V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 191, 193, 195, 197, and 199. In some embodiments, V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 250, 252, 254, 256, and 258. In some embodiments, V L2The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 251, 253, 255, 257 and 259.

[0652] In some embodiments of any of the forms described herein, the V H2 / V L2 The binding pair binds to the extracellular portion of dystroglycan, and the V H1 / V L1 The binding pair binds to laminin-2 (e.g., laminin G-like (LG) domains 4 and / or 5 or LG-4 / 5). In some embodiments of any of the forms described herein, V H2 The structural domain comprises a CDR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 81-95, a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 96-110, and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 111-125; and / or wherein V L2 The V domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 126-140, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 38 and SEQ ID NOs: 141-154, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 155-169. H2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, and 228. In some embodiments, V L2 The domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, and 229. In some embodiments, V H2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 280, 282, 284, 286, and 288. In some embodiments, V L2 The domain is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287 and 289.

[0653] Exemplary CDR sequences suitable for use in the binding proteins of the present disclosure are provided in Tables AC below. Exemplary VH and VL sequences (polypeptides and nucleic acids) suitable for use in the binding proteins of the present disclosure are provided in Table DI below. In some embodiments, the bispecific binding proteins of the present disclosure comprise a binding domain that binds to the extracellular portion of dystroglycan, wherein the binding domain comprises a VH domain and / or a VL domain, the VH domain comprising at least one, at least two, at least three, at least four, at least five, or six CDR sequences of an antibody shown in Table A below, and the VL domain comprising at least one, at least two, at least three, at least four, at least five, or six CDR sequences of an antibody shown in Table A below. In some embodiments, the bispecific binding protein of the present disclosure comprises a binding domain that binds laminin-2, wherein the binding domain comprises a VH domain comprising at least 1, at least 2, at least 3, at least 4, at least 5, or 6 CDR sequences of an antibody shown in Table B or Table C below and / or a VL domain comprising at least 1, at least 2, at least 3, at least 4, at least 5, or 6 CDR sequences of an antibody shown in Table B or Table C below. In some embodiments, the bispecific binding proteins of the present disclosure comprise a binding domain that binds to the extracellular portion of dystroglycan, wherein the binding domain comprises a VH domain comprising a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VH sequence shown in Table D below and / or a VL domain comprising a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VL sequence shown in Table D below. In some embodiments, the bispecific binding proteins of the present disclosure comprise a binding domain that binds laminin-2, wherein the binding domain comprises a VH domain comprising a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a VH sequence shown in Table E or Table F below and / or a VL domain comprising a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a VL sequence shown in Table E or Table F below.In some embodiments, the bispecific binding proteins of the present disclosure comprise a binding domain that binds to the extracellular portion of dystroglycan, wherein the binding domain comprises a VH domain comprising a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a VH sequence encoded by the polynucleotide sequence shown in Table G below and / or a VL domain comprising a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a VL sequence encoded by the polynucleotide sequence shown in Table G below. In some embodiments, the bispecific binding proteins of the present disclosure comprise a binding domain that binds laminin-2, wherein the binding domain comprises a VH domain comprising a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a VH sequence encoded by the polynucleotide sequence shown in Table H or Table I below and / or a VL domain comprising a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a VL sequence encoded by the polynucleotide sequence shown in Table H or Table I below.

[0654] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 9, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 18; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 28, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 38, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 43. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 170 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 171. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 230 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 231.

[0655] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 19; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 29, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 38, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 43. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 172 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 173. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 232 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 233.

[0656] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 2, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 11, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 20; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 30, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 39, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 44. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 174 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 175. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 234 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 235.

[0657] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 3, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 21; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 31, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 40, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 45. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 176 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 177. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 236 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 237.

[0658] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 22; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 32, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 41, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 46. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 178 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 179. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 238 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 239.

[0659] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 23; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 33, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 41, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 46. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 180 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 181. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 240 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 241.

[0660] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 5, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 24; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 34, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 42, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 47. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 182 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 183. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 242 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 243.

[0661] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 6, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 15, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 25; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 35, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 40, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 48. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 184 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 185. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 244 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 245.

[0662] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 7, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 26; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 40, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 49. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 186 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 187. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 246 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 247.

[0663] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 8, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 17, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 27; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 37, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 40, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 50. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 188 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 189. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 248 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 249.

[0664] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 51, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 56, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 61; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 66, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 71, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 76. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 190 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 191. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 250 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 251.

[0665] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 52, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 57, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 62; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 67, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 72, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 192 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 193. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 252 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 253.

[0666] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 53, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 58, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 63; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 68, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 73, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 78. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 194 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 195. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 254 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 255.

[0667] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 54, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 59, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 64; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 69, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 74, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 79. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 196 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 197. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 256 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 257.

[0668] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 55, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 60, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 65; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 70, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 75, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 80. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 198 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 199. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 258 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 259.

[0669] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 81, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 96, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 111; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 126, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 141, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 155. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 200 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 201. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 260 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 261.

[0670] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 82, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 97, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 112; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 127, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 142, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 156. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 202 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 203. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 262 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 263.

[0671] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 83, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 98, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 113; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 128, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 143, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 157. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 204 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 205. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 264 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 265.

[0672] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 84, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 99, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 114; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 129, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 144, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 158. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 206 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 207. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 266 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 267.

[0673] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 85, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 100, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 115; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 130, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 145, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 159. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 208 and / or a VL domain sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 209. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 268 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 269.

[0674] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 86, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 101, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 116; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 131, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 146, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 160. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 210 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 211. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 270 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 271.

[0675] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 87, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 102, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 117; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 132, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 147, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 161. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 212 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 213. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 272 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 273.

[0676] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 88, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 103, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 118; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 133, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 148, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 162. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 214 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 215. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 274 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 275.

[0677] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 89, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 104, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 119; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 134, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 149, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 163. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 216 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 217. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 276 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 277.

[0678] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 90, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 105, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 120; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 135, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 150, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 164. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 218 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 219. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 278 and / or a VL domain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 279.

[0679] In some embodiments, the bispecific binding proteins of the present disclosure comprise (a) a VH domain comprising (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 91, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 106, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 121; and / or (b) a VL domain comprising (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 136, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 151, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 165. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 220 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 221. In some embodiments, the bispecific binding proteins of the present disclosure comprise a VH domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VH domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 280 and / or a VL domain sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the VL domain sequence encoded by the polynucleotide sequence of SEQ ID NO: 281. [06...

Claims

1. A multispecific binding molecule comprising at least one first binding domain that binds to the extracellular portion of dystroglycan and at least one second binding domain that binds to laminin-2.

2. The multispecific binding molecule according to claim 1, wherein the multispecific binding molecule is a multispecific binding protein comprising one or more polypeptide chains.

3. The multispecific binding molecule according to claim 2, wherein the binding protein comprises four polypeptide chains, wherein the first polypeptide chain comprises a structure represented by the following formula: V L2 -L1-V L1 -L2-C L [I] And the second polypeptide chain comprises a structure represented by the following formula: V H1 -L3-V H2 -L4-C H1 -Hinge-C H2 -C H3 [II] And the third polypeptide chain comprises a structure represented by the following formula: V H3 -C H1 -Hinge-C H2 -C H3 [III] And the fourth polypeptide chain comprises a structure represented by the following formula: V L3 -C L [IV] in: V L1 is the first immunoglobulin light chain variable domain; V L2 is a second immunoglobulin light chain variable domain; V L3 is the third immunoglobulin light chain variable domain; V H1 is the first immunoglobulin heavy chain variable domain; V H2 is a second immunoglobulin heavy chain variable domain; V H3 is the third immunoglobulin heavy chain variable domain; C L is the immunoglobulin light chain constant domain; C H1 Immunoglobulin C H1 heavy chain constant domain; C H2 Immunoglobulin C H2 heavy chain constant domain; C H3 Immunoglobulin C H3 heavy chain constant domain; The hinge is connected to C H1 and C H2 an immunoglobulin hinge region of a domain; and L1, L2, L3 and L4 are amino acid linkers; wherein the polypeptide of Formula I and the polypeptide of Formula II form a crossover light chain-heavy chain pair; and Where V H1 and V L1 Form an antigen binding site, where V H2 and V L2 forms an antigen binding site, and wherein V H3 and V L3 Antigen binding sites are formed, three antigen binding sites in total, and wherein the three antigen binding sites comprise at least one antigen binding site that binds to the extracellular portion of dystroglycan and at least one antigen binding site that binds to laminin-2.

4. A multispecific binding molecule according to claim 3, comprising one antigen binding site that binds to the extracellular part of dystroglycan and two antigen binding sites that bind to laminin-2.

5. The multispecific binding molecule according to claim 4, wherein the two laminin-2 binding antigen binding sites bind to different epitopes of laminin-2.

6. The multispecific binding molecule according to claim 4, wherein the two laminin-2 binding antigen binding sites bind to the same epitope of laminin-2.

7. The multispecific binding molecule according to any one of claims 4 to 6, wherein V H1 and V L1 Forms the first antigen binding site for laminin-2, V H2 and V L2 Forms a second antigen binding site that binds laminin-2, and V H3 and V L3 A third antigen binding site is formed that binds the extracellular portion of dystroglycan.

8. The multispecific binding molecule according to claim 3, comprising two antigen binding sites that bind to the extracellular part of dystroglycan and one antigen binding site that binds to laminin-2.

9. The multispecific binding molecule according to claim 8, wherein the two antigen binding sites that bind to the extracellular portion of dystroglycan bind to different epitopes of the extracellular portion of dystroglycan.

10. The multispecific binding molecule according to claim 8, wherein the two antigen binding sites that bind to the extracellular portion of dystroglycan bind to the same epitope of the extracellular portion of dystroglycan.

Citation Information

Cited By

  • Preschool child personalized learning path planning method and system of online education system

    CN119648494A

  • Method and System for Planning Personalized Learning Paths for Preschool Children in an Online Education System

    CN119648494B